The place to be!
for more research
networking
education
special interest groups
exhibitors &
programs for junior members

4th Biennial North American Epilepsy Congress

66th Annual Meeting
Program Book
SUPERNUS HAS BEEN DEVELOPING ADVANCED DRUG DELIVERY SYSTEMS FOR MORE THAN 20 YEARS

OUR PROVEN EXTENDED RELEASE TECHNOLOGIES INCLUDE:

**Microtrol®**: Multiparticulate Platform
Employs multiparticulates filled into capsules or compressed into tablets to deliver customized-release profiles, including immediate, extended, pulsed, and delayed

Benefits may include:
- More convenient or less frequent dosing
- Improved side effect profile for compounds with a narrow therapeutic window
- Enhanced patient compliance
- Sprinkle option for ease of administration

**Solutrol®**: Matrix Delivery Platform
An innovative platform that enables delivery of poorly soluble, highly water-soluble, and pH-dependent compounds in a reproducible and complete manner

Benefits may include:
- Tablet presentation for challenging compounds
- More convenient or less frequent dosing
- Improved patient compliance

SUPERNUS TECHNOLOGIES HAVE BEEN USED TO DEVELOP SEVERAL ADVANCED THERAPIES, INCLUDING:

- **Adderall XR®** (mixed salts of a single-entity amphetamine product) Extended-Release Capsules
- **Carbatrol®** (carbamazepine) Extended-Release Capsules
- **Intuniv®** (guanfacine) Extended-Release Tablets
- **Oracea®** (doxycycline, USP) Capsules
- **Sanctura XR®** (trospium chloride extended release tablets)


For more information visit www.supernus.com

Microtrol and Solutrol are registered trademarks of Supernus Pharmaceuticals, Inc. Adderall XR, Carbatrol, and Intuniv are registered trademarks of and marketed by Shire LLC. Oracea is a registered trademark of Galderma Laboratories, LP. Sanctura XR is a registered trademark of Allergan, Inc.

©2012 Supernus Pharmaceuticals, Inc. All rights reserved. SPN.2012-0005
Welcome to San Diego, and the 4th Biennial North American Epilepsy Congress. We are proud to host this meeting in conjunction with our 66th Annual Meeting. Within these pages you will find a broad schedule of programs, exhibits, social events, and networking opportunities that invite your participation. It has been an exciting year, and the annual meeting brings together so much of the accomplishments of our members!

The year 2012 has seen our impact as a Society on clinical practice parameters, advocacy efforts and the Institute of Medicine Report on Epilepsy, increased activity in translational epilepsy research, clinical trials, and medical education. You will find these well represented in our symposia and course offerings, as well as career development sessions. In addition to the scheduled program events, there are several other aspects of our offerings I’d like to highlight below:

**Sessions to Advance and Maintain Professional Competence** – Your AES Annual Meeting and Scientific Program Committees have organized quality educational sessions targeted to the wide interests and professional needs of our annual meeting attendees. With the need for MD licensed and certified clinicians to follow Maintenance of Certification (MOC), and with the advent of the Subspecialty Certification exam in Epilepsy (administered by the American Board of Neurology and Psychiatry), the American Epilepsy Society is moving forward in service to its members. Starting with the 2011 Annual Meeting AES has identified ABPN Core Competencies and secured ABPN review for each Symposium. AES is also building a Learning Management System called AES Epilepsy Institute, including ABPN authorized Part II Self-Assessment exams for CME credit, starting with questions related to the Epilepsy Specialist and Fundamentals Symposia.

**Epilepsy Specialist Symposium** – This year’s discussion focuses on care of patients with new onset or difficult to control seizures, diagnosis and treatment of a first seizure, approaches to pre-surgical evaluation, patient selection, and the how, when and with which patients to broach the topic of SUDEP.

**Translational Epilepsy Research Symposium** – This is the second year that we have introduced a program that explicitly covers the interface between basic research and early human trials in therapeutics and diagnostics development. This is aimed at increasing the dialogue between researchers and clinicians to accelerate discovery development for epilepsy.

**Fundamentals Symposium** – A discussion of newer antiepileptic drugs and generics, their pharmacology and mechanisms of action, clinical pharmacokinetics, and drug interactions, plus the efficacy and adverse effects of newer AEDs in approved indications and alternative uses in epilepsy syndromes and status.

**Six Skills Workshops** – First introduced at last year’s annual meeting, these limited-attendance, smaller, more-focused intensives are doubled in number this year to accommodate the high interest expressed in these sessions. The workshops take place on Tuesday.

**Program for Junior Members** – Block arrow symbol “▶” indicates programs of particular interest to junior members.

**Poster Walking Tours** – Enhanced learning opportunities during present time at Poster Sessions 1, 2 and 3 can be enjoyed by joining one of the now-traditional poster walking tours led by AES leadership.

**Social Networking Groups** – The popular social networking time is extended by another hour this year — Sunday 8:00 p.m. – 10:00 p.m. — giving SIG, Investigators’ Workshop and symposium participants a greater opportunity to meet and continue discussions.

**Epilepsy Fellows Program** – Some 85 neurology trainees in approved epilepsy fellowships attend this meeting at AES’s invitation to pair with mentors for career guidance and support. The program is made possible by grants from Eisai, Inc., Lundbeck, and UCB, Inc.

**Spanish Translation** – Spanish translation is available during the Annual Course on Sunday and the North American Commission Symposium on Tuesday. Also of interest to our Spanish-speaking attendees is the Spanish Symposium on Friday.

**Virtual Tote Bag** – AES’s 66th Annual Meeting takes our commitment to protecting the environment seriously. Therefore, we are providing virtualTotebag, a new “green” solution that connects you to all important meeting information. Attendees can easily use virtualTotebag to access, store and share exhibitor and session material. See page 10 for more information.

Thank you for joining us here in sunny California! Please enjoy the meeting.

Frances E. Jensen, M.D.
President, American Epilepsy Society
JOIN OUR CAST OF CHARACTERS!

WALK FOR AES RESEARCH & TRAINING

RAISE FUNDS FOR EPILEPSY RESEARCH & TRAINING
THE NATIONAL WALK FOR EPILEPSY
WASHINGTON, DC - APRIL 20, 2013

Walk with your colleagues, join Mike Privitera, Nathan Fountain, Dennis Spencer, Jack Pellock, Jaideep Kapur, Patty Shafer and many others for the 2013 National Walk for Epilepsy.

All funds raised by AES Teams Support AES’ Research and Training efforts – even virtual teams can participate! Teams can support any AES fund – Spencer, Lennox and Lombroso, Dreifuss, Penry, Goldberg-Kaufman. Raise the most money and win the AES trophy!

Sign up or get more information today! Contact Kathy Hucks at 860-586-7505 x512 or khucks@aesnet.org.
### Table of Contents

#### Meeting Information

**FRIDAY**
- AES Epilepsy Specialist Symposium: 19
- Advances in the Management of Epilepsy and the Epilepsy Clinic: 19
- Annual Fundamentals of Epilepsy: 19
- Professional Development in AES: 20
- Special Interest Group Meetings: 20
- Spanish Symposium: 21
- Hoyer Lecture: 21
- Special Interest Group Meetings: 21
- Hot Topics Symposium: 23
- Fellows Recognition Gathering: 24

**SATURDAY**
- Special Interest Group Meetings: 25
- Presidential Symposium: 25
- Professionals in Epilepsy Care Symposium: 26
- Clinical and Basic Science Keynotes: 26
- Translational Research Symposium: 27
- Special Interest Group Meetings: 27
- Investigators’ Workshops: 28
- Antiepileptic Therapy Symposium: 28
- Poster Session 1: 30

**SUNDAY**
- Annual Course: 41
- Investigators’ Workshops: 42
- ABPN Town Hall on MOC: 44
- Mentoring Session for Junior Investigators: 44
- Special Interest Group Meetings: 44
- Social Networking Groups: 44
- Poster Session 2: 45

**MONDAY**
- Patient Education for Clinicians: 55
- Special Interest Group Meetings: 55
- Merritt-Putnam Symposium: 57
- Lennox and Lombroso Lecture: 57
- Investigators’ Workshop: 57
- Special Interest Group Meetings: 58
- Pediatric Epilepsy Highlights Session: 58
- Platform Sessions: 59
- Pediatric State of the Art Symposium: 59
- Poster Session 3: 61

**TUESDAY**
- Special Interest Group Meetings: 71
- Scientific Symposium: 71
- North American Commission Symposium: 72
- Skills Workshops: 73
“Which potential AED drug interactions should I be most concerned about?”

“Do patients with hepatic impairment necessitate a dose adjustment with their AED?”

VISIT US AT AES
BOOTH #614 DEC 1 – DEC 3

JOIN THE CONVERSATION ON CURRENT PRACTICES WITH EPILEPSY THOUGHT LEADERS

Meet our special guest, Dr. Barry Gidal
Dr. Gidal will share his expertise on AEDs in adult patients with epilepsy.

Take the AED/Mechanism of Action Challenge
Play our interactive touch screen game. See if you can get the high score.

Visit us at www.epilog.us
Learn how EPILOG can keep you connected to the latest scientific data and expert insights on epilepsy.
Our dedication to discovering and developing innovative therapies for CNS disorders now extends to epilepsy.

Sunovion—a new presence in epilepsy research.

Visit Booth 637 at AES 2012
CONVENTION CENTER — Complimentary Wireless Zone

SOCIAL MEDIA LOUNGE
Convention Center - Room 2 Upper Level
Ground Floor Lobby A-H
outside the exhibit halls and Tides Restaurant

<table>
<thead>
<tr>
<th>AES Hotels</th>
<th>Wi-Fi in Hotel</th>
<th>Guest Room Availability and Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>San Diego Marriott Marquis and Marina</td>
<td>Complimentary Wi-Fi available: Marina Kitchen Restaurant and the bar/lounge area</td>
<td>$12.95 for every 24 hour period, includes Wi-Fi and phone calls. (plus tax)</td>
</tr>
<tr>
<td></td>
<td>Starbucks The Exchange Foyer The Main Lobby The Tequila Bar and Grille</td>
<td></td>
</tr>
<tr>
<td>Manchester Grand Hyatt San Diego</td>
<td>Purchase per day in guest room for access in public areas of the hotel</td>
<td>$9.95 per guest room (plus tax, per day)</td>
</tr>
<tr>
<td>Hilton San Diego Bayfront</td>
<td>Complimentary in lobby and Starbucks</td>
<td>$13.95 for Standard $19.95 for High-speed (plus tax, per day)</td>
</tr>
<tr>
<td>Residence Inn San Diego Downtown Gaslamp</td>
<td>Complimentary Wi-Fi available in all public areas</td>
<td>Complimentary Wi-Fi in all of the sleeping room suites</td>
</tr>
</tbody>
</table>

5 Ways to Enhance Your AES Annual Meeting Experience with Social Media

1) Join in the conversation – use the Twitter hashtag #AESMTG12, AES LinkedIn group or the AES Facebook page to follow annual meeting activities, speakers, events and conversations.

2) “Attend” more than one session at a time – seeing posts from various sessions throughout the AES meeting will allow you to eavesdrop on more than one session at a time.

3) Find New Friends – use social media to connect with people online and at the Annual Meeting – find people with similar interests and set times to connect with them.

4) Expand your notes – think about social media as a way to collect your notes and share thoughts about the sessions with others.

5) Maintain connections – maintain connections virtually with those you meet at the Annual Meeting.

NEW THIS YEAR – AES has added a social media lounge for those who want to learn more about social media and how to join the conversation. Please visit us in room 2 on the Upper Level of the Convention Center. We’ll look forward to connecting with you there or in cyberspace.

Open during press room hours (see page 108)
is proud to recognize the following supporters of the 2012 Annual Meeting.

<table>
<thead>
<tr>
<th>Level</th>
<th>Support Range</th>
<th>Companies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leader Level</td>
<td>$250,000 – $499,999</td>
<td>UCB, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eisai, Inc.</td>
</tr>
<tr>
<td>Partner Level</td>
<td>$100,000 – $249,999</td>
<td>Lundbeck</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sunovion Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Supporter Level</td>
<td>$50,000 – $99,999</td>
<td>Supernus Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Contributor Level</td>
<td>$25,000 – $49,999</td>
<td>Questcor Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nikon Kohden America, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Upsher-Smith</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cyberonics, Inc.</td>
</tr>
<tr>
<td>Advocate Level</td>
<td>$10,000 – $24,999</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Novartis Pharmaceuticals Corporation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Elekta</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medtronic, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Electrical Geodesics, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Grass Technologies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cadwell Laboratories</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Care Fusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Compumedics Limited</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Natus Medical</td>
</tr>
<tr>
<td>Patron Level</td>
<td>$5,000 – $9,999</td>
<td>Visualase</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ad Tech Medical Instrument Corp.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neuropace</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ILAE/IBE Congress</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rhythm Link</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Blackrock Microsystems</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Epilepsy Foundation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neurolynx, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PMT Corporation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ripple LLC</td>
</tr>
</tbody>
</table>

Listing is in order of support level
FRIDAY November 30

6:30 a.m. - 6:00 p.m.  Registration
Convention Center – Ballroom 6 Lobby,
Upper Level

8:30 a.m. - 11:30 a.m.  ▶ Epilepsy Specialist Symposium:
Algorithms in the Diagnosis and Treatment of
Epilepsy
Convention Center – Room 5, Upper Level

12:30 p.m. - 3:00 p.m.  ▶ Annual Fundamentals of Epilepsy Symposium:
Optimal Use of the Newest AEDs and Generics
Convention Center – Ballroom 6A, Upper Level

1:30 p.m. - 3:00 p.m.  ▶ Professional Development in AES:
A Program for Junior Members and Those in Transition
Convention Center – Room 3, Upper Level

1:30 p.m. - 3:00 p.m.  ▶ Special Interest Group Meetings
See page 20

3:30 p.m. - 6:00 p.m.  Spanish Symposium:
Extratemporal Epilepsies
Convention Center – Room 5, Upper Level

SCHEDULE-AT-A-GLANCE

SATURDAY December 1

6:30 a.m. - 6:00 p.m.  Registration
Convention Center – Ballroom 6 Lobby,
Upper Level

6:30 a.m. - 7:00 a.m.  Continental Breakfast
Convention Center – Upper Level

7:00 a.m. - 8:30 a.m.  ▶ Special Interest Group Meetings
See page 25

8:30 a.m. - 11:30 a.m.  ▶ Presidential Symposium:
IOM Report 2012: Epilepsy Across the Spectrum: Promoting Health and Understanding
Convention Center – Ballroom 6C, Upper Level

11:45 a.m. - 6:00 p.m.  ▶ Poster Session 1
Convention Center – Hall B, Ground Level
Exhibit Hall B
(Lunch: 11:45 a.m. - 12:45 p.m.)
(Reception: 4:30 p.m. - 6:00 p.m.)

3:30 p.m. - 6:00 p.m.  Spanish Symposium:
Extratemporal Epilepsies
Convention Center – Room 5, Upper Level

SUNDAY December 2

7:30 a.m. - 6:00 p.m.  Registration
Convention Center – Ballroom 6, Lobby

8:00 a.m. - 5:00 p.m.  Scientific Exhibits
See page 29

8:00 a.m. - 6:00 p.m.  ▶ Poster Session 2
Coffee Available
Convention Center – Hall B, Ground Level

8:45 a.m. - 5:15 p.m.  ▶ Annual Course: Managing Common Complex Symptomatic Epilepsies:
Tumors and Trauma
(Spanish translation available)
Convention Center – Ballroom 6C, Upper Level

8:45 a.m. - 5:15 p.m.  ▶ Investigators’ Workshops
IW Posters / Boxed Lunch: Noon - 2:00 p.m.
See page 42

10:00 a.m. - 4:00 p.m.  Exhibit Hall – Lunch: Noon - 1:00 p.m.
Convention Center – Hall B, Ground Level

5:15 p.m. - 6:15 p.m.  ABPN Town Hall on MOC Requirements
Convention Center – Room 7, Upper Level

3:00 p.m. - 3:30 p.m.  Coffee Break
Convention Center – Hall B, Ground Level

6:00 p.m. - 7:30 p.m.  ▶ Mentoring Session for Junior Investigators
Marriott – Laguna, South Tower, Level 1

7:30 p.m. - 9:00 p.m.  ▶ Special Interest Group Meetings
See page 44

8:00 p.m. - 10:00 p.m.  Social Networking Groups
Marriott, Oceanside, South Tower, Level 1
SCHEDULE-AT-A-GLANCE

Monday December 3

7:30 a.m. - 6:00 p.m.  Registration
Convention Center – Ballroom 6 Lobby, Upper Level

6:30 a.m. - 7:00 a.m.  Continental Breakfast
Convention Center – Upper Level

7:00 a.m. - 8:30 a.m.  Patient Education for Clinicians
Convention Center – Room 7, Upper Level

7:00 a.m. - 8:30 a.m.  ▶ Special Interest Group Meetings
See page 71

8:00 a.m. - 3:00 p.m.  ▶ Poster Session 3
Continental Breakfast
Convention Center – Hall B, Ground Level

8:00 a.m. - 11:00 a.m.  Scientific Exhibits
See page 73

9:00 a.m. - 10:30 a.m.  ▶ Special Interest Group Meetings
See page 55

9:00 a.m. - Noon  ▶ Merritt-Putnam Symposium:
From Molecules to Cells, Networks and Seizures: How Does a Gene Cause Epilepsy?
Convention Center – Ballroom 6C, Upper Level

SCHEDULE-AT-A-GLANCE

Tuesday December 4

8:30 a.m. - 12:30 p.m.  Registration
Convention Center – Ballroom 6 Lobby, Upper Level

6:30 a.m. - 7:00 a.m.  Continental Breakfast
Convention Center – Upper Level

7:00 a.m. - 8:30 a.m.  ▶ Special Interest Group Meetings
See page 71

8:30 a.m. - 10:00 a.m.  North American Commission Symposium:
Epilepsy Classification: Hot Controversies in 2012
(Spanish translation available)
Convention Center – Ballroom 6A, Upper Level

9:00 a.m. - Noon  ▶ Merritt-Putnam Symposium:
From Molecules to Cells, Networks and Seizures: How Does a Gene Cause Epilepsy?
Convention Center – Ballroom 6C, Upper Level

Please plan to attend
Investigators’ Workshop Keynote Speakers
Epilepsy Research Recognition Awardees

Saturday, December 1
2:00 p.m. – 2:30 p.m.
Ballroom 6C, Upper Level

Award for Basic Science
Richard Miles, Ph.D.

Award for Clinical Science
Renzo Guerrini, M.D.

See page 14 for award information

Programs listed with this symbol ▶ are recommended for junior attendees
AES is pleased to announce that Nihon Kohden and Neuralynx are participating in the 2012 AES Annual Benefit Auction this year. These companies have contributed equipment and/or software to be auctioned off, and the winning bids will be announced at the meeting.

Nihon Kohden and Neuralynx are contributing 100% of their proceeds to the Lennox and Lombroso Trust for Research & Training, and the Susan S. Spencer Fund for Education and Research.

Proceeds from the auction of its new 1200A Diagnostic and Monitoring Solution (includes cart, camera and microphone) will be presented by Nihon Kohden America, Inc. to the American Epilepsy Society in support of the Lennox and Lombroso Trust and the new Susan S. Spencer Research Fund. The Children’s Hospital of Orange County will be recognized as the highest tender of $27,684. A check presentation ceremony will take place at noon, December 1 in Exhibit Booth #231.

**Auction Item: Complete Neuralynx Atlas Human Single Unit Recording System**

NEURALYNX will accept bids on a 60 Day Trial. Neuralynx will honor the top 5 highest bids.

- **Worth:** $85,000
- **Minimum Bid:** $500
- **Contact:** Scott Smith at 406.404.1017 or email scotts@neuralynx.com

We thank Nihon Kohden and Neuralynx for their donations, and you for bidding on these items. If you know of other companies that would be interested in participating in the AES Annual Benefit Auction, or if you have questions, contact Sue Cipriani at scipriani@aesnet.org.
Poster Walking Tours
Convention Center – Hall B, Ground Level

This program is designed for students, residents, fellows, and junior faculty to meet with AES mentors and visit interesting, compelling, or novel posters discussing their perspectives on how the presented data is meaningful. Poster walking tours will be held on the days noted below and cover the topics displayed on that day. Mentors and participants will meet at the Poster Information table near the front of the Poster Hall. The tours will depart each day during the authors’ present times noted below. Approximately six posters will be discussed in each category. These posters have been pre-selected by the mentors. Selections are for educational purposes only and are not based on merit. Poster Sessions and authors’ present times are noted below:

**Saturday, December 1**
Poster Session 1
Authors Present: 11:45 a.m. – 1:45 p.m.

**Sunday, December 2**
Poster Session 2
Authors Present: Noon – 2:00 p.m.

**Monday, December 3**
Poster Session 3
Authors Present: Noon – 2:00 p.m.

New for this year, there are daily prize drawings and a Grand Prize Drawing on Monday in the Exhibit Hall.

### Prize Drawing Schedule:

**SATURDAY, DECEMBER 1**
Prize Drawing – 5:00 p.m. - Epilepsy Resource Center

**SUNDAY, DECEMBER 2**
Prize Drawing – 3:15 p.m. - Epilepsy Resource Center

**MONDAY, DECEMBER 3**
Prize Drawing & Grand Prize Drawing – 2:45 p.m. - Epilepsy Resource Center

In your AES Annual Meeting bag as well as the Virtual Tote Bag, you will find a Passport brochure. To be included in the drawing to win a variety of great prizes, visit the booths of participating exhibitors to get your Passport validated. The more exhibitors you visit, the better the prize.

Please complete your contact information and drop the passport in the raffle drum located in the Epilepsy Resource Center. Participants must be present to win. See your Passport for a list of participating exhibitors.
Poster Walking Tours begin at the Poster Information table

Questions? Please visit the Poster Information table in front of the poster area.
### Saturday, December 1

**Poster Session 1**: 11:45 a.m. – 6:00 p.m. – Convention Center, Hall B, Ground Level (see pages 30-39)
Authors Present: 11:45 a.m. – 1:45 p.m. (1.001 – 1.351)
Poster Walking Tours: 11:45 a.m. – 1:45 p.m. (see page 11 for further details)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Room Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Translational Research</td>
<td>1.001 – 1.047</td>
</tr>
<tr>
<td>Professionals in Epilepsy Care</td>
<td>1.048 – 1.059</td>
</tr>
<tr>
<td>Neurophysiology</td>
<td>1.060 – 1.109</td>
</tr>
<tr>
<td>Clinical Epilepsy</td>
<td>1.110 – 1.167</td>
</tr>
<tr>
<td>Neuroimaging</td>
<td>1.168 – 1.199</td>
</tr>
<tr>
<td>Comorbidity</td>
<td>1.200 – 1.222</td>
</tr>
<tr>
<td>Antiepileptic Drugs</td>
<td>1.223 – 1.241</td>
</tr>
<tr>
<td>Non-AED / Non-Surgical Treatments</td>
<td>1.242 – 1.266</td>
</tr>
<tr>
<td>Surgery</td>
<td>1.267 – 1.291</td>
</tr>
<tr>
<td>Behavior / Neuropsychology / Language</td>
<td>1.292 – 1.311</td>
</tr>
<tr>
<td>Genetics</td>
<td>1.312 – 1.322</td>
</tr>
<tr>
<td>Neuropathology of Epilepsy</td>
<td>1.323 – 1.331</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>1.332 – 1.339</td>
</tr>
<tr>
<td>Public Health</td>
<td>1.340 – 1.348</td>
</tr>
<tr>
<td>History of Epilepsy</td>
<td>1.349 – 1.351</td>
</tr>
</tbody>
</table>

---

### Sunday, December 2

**Poster Session 2**: 8:00 a.m. – 6:00 p.m. – Convention Center, Hall B, Ground Floor (see pages 45-54)
Authors Present: Noon – 2:00 p.m. (2.001 – 2.353)
Poster Walking Tours: Noon – 2:00 p.m. (see page 11 for further details)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Room Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Translational Research</td>
<td>2.001 – 2.048</td>
</tr>
<tr>
<td>Neurophysiology</td>
<td>2.049 – 2.091</td>
</tr>
<tr>
<td>Clinical Epilepsy</td>
<td>2.092 – 2.143</td>
</tr>
<tr>
<td>Neuroimaging</td>
<td>2.144 – 2.184</td>
</tr>
<tr>
<td>Comorbidity</td>
<td>2.185 – 2.197</td>
</tr>
<tr>
<td>Antiepileptic Drugs</td>
<td>2.198 – 2.237</td>
</tr>
<tr>
<td>Surgery</td>
<td>2.238 – 2.278</td>
</tr>
<tr>
<td>Behavior / Neuropsychology / Language</td>
<td>2.279 – 2.310</td>
</tr>
<tr>
<td>Genetics</td>
<td>2.311 – 2.320</td>
</tr>
<tr>
<td>Health Services</td>
<td>2.321 – 2.337</td>
</tr>
<tr>
<td>Practice Resources</td>
<td>2.338 – 2.345</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>2.346 – 2.353</td>
</tr>
</tbody>
</table>

**Investigators’ Workshop Lunch Poster Session**
Noon – 2:00 p.m.
Convention Center – Ballroom 6A, Upper Level (see pages 42-43)

---

### Monday, December 3

**Poster Session 3**: 8:00 a.m. – 3:00 p.m. – Convention Center, Hall B, Ground Floor (see pages 61-69)
Authors Present: Noon – 2:00 p.m. (3.001 – 3.358)
Poster Walking Tours: Noon – 2:00 p.m. (see page 11 for further details)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Room Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Translational Research</td>
<td>3.001 – 3.074</td>
</tr>
<tr>
<td>Neurophysiology</td>
<td>3.075 – 3.118</td>
</tr>
<tr>
<td>Clinical Epilepsy</td>
<td>3.119 – 3.174</td>
</tr>
<tr>
<td>Neuroimaging</td>
<td>3.175 – 3.206</td>
</tr>
<tr>
<td>Antiepileptic Drugs</td>
<td>3.207 – 3.265</td>
</tr>
<tr>
<td>Surgery</td>
<td>3.266 – 3.291</td>
</tr>
<tr>
<td>Behavior / Neuropsychology / Language</td>
<td>3.292 – 3.311</td>
</tr>
<tr>
<td>Genetics</td>
<td>3.312 – 3.326</td>
</tr>
<tr>
<td>Neuropathology of Epilepsy</td>
<td>3.327 – 3.349</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>3.350 – 3.358</td>
</tr>
</tbody>
</table>
Richard Miles, Ph.D., directs the group, Cortex and Epilepsy at the Institute for the Brain and Spinal Cord, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris. He received his doctorate in physiology from the University of Bristol, England, and completed postdoctoral training in neuroscience at the University of Texas, Galveston. Dr. Miles pursued research in cell neurobiology at the Institut Pasteur, Paris, beginning in 1989, following academic research and teaching positions in the U.S. He is a recipient of the French Academy of Science’s Prix du l’Etat Award.

Dr. Miles has made a number of seminal contributions to the understanding of hippocampal electrophysiology using in vitro and in situ neuronal recording techniques chiefly focused on CA3 synaptic circuits. With his collaborators he demonstrated differences between somatic and dendritic inhibition, providing remarkable insight into cortical wiring. His work suggesting that GABAergic activity could be excitatory in epileptic human tissue engendered a new field in epilepsy research. In addition to ongoing studies of resected human epileptic brain tissue from pharmaco-resistant patients with temporal lobe epilepsy, Dr. Miles’s recent work is focused on genetic and acquired animal models of epilepsy.

Dr. Miles’s important discoveries have been published in Science, Nature, and in leading journals in neuroscience and physiology. He is co-author with Roger D. Traub, M.D., of Neuronal Networks of the Hippocampus, a major classic work in the field. He has also served on the editorial boards of the Journal of Physiology, the European Community DGXII, Neurosciences Grants Committee, the Wellcome Trust Neurosciences and Mental Health Committee, and currently serves as an advisor to the French Foundation for Epilepsy Research.

Renzo Guerrini, M.D., is Director and Professor of Pediatric Neurology and Psychiatry, Department of Neuroscience, University of Florence Anna Meyer Children’s Hospital. He received his medical degree from the University of Perugia where he also completed postgraduate training in neurology. He then completed postgraduate studies in child neurophysiology and research at the University of Aix-Marseille, France, and in child neurology and psychiatry at the University of Pisa, Italy.

Through highly original pioneering scientific study Dr. Guerrini has contributed significantly to the clinical semiology, genetics, neurophysiology, and imaging of childhood epilepsies. Besides running a clinical service, he has established a diagnostic laboratory where he has collected and performed DNA sequencing on large patient cohorts. Dr. Guerrini’s rare expertise in combining the study of genetic patterns and MRI patterns has enabled him to make major contributions in describing subtypes of malformations in their specific clinical and genetic features, including double cortex syndrome, periventricular nodular heterotopias, polymicrogyrias, Dravet Syndrome, and other encephalopathies. As a result, Dr. Guerrini has served on a number of committees that have helped define the radiographic features of epileptic disorders. He is currently coordinating a major European research effort to improve diagnosis, prevention and treatment of children with difficult-to-treat epilepsy.

Dr. Guerrini has trained many neurologists in genetic techniques and clinical imaging. He has edited ten books, written 286 peer-reviewed papers, and served as an invited speaker at more than 350 meetings worldwide. His active service to the international epilepsy community also includes 12 academic and organizational scientific committee memberships and reviewer appointments in Europe, the U.S. and Japan. He is an appointed ILAE/BEA Ambassador for Epilepsy.

A $10,000 award is provided by the Lennox and Lombroso Trust Fund

William G. Lennox Award
Monday, December 3 – 9:00 a.m.
Convention Center – Ballroom 6C, Upper Level
(Immediately preceding the Merritt-Putnam Symposium)

David C. Taylor, M.D., Hon. F.R.C.P.C.H.
Professor David C. Taylor is the retired Foundation Chair in Child and Adolescent Psychiatry, and lately Head of the Department of Psychiatry and Behavioural Sciences, at the University of Manchester UK. Following his M.Phil. in Psychiatry in 1964, he researched for Murray Falconer, following-up, usually in their homes, 100 patients operated on for TLE from 5 to 25 years post-op with a 100-item schedule. Correlation analysis revealed important effects of side, sex, and lesion type. “Focal Dysplasia” was noted as an anomaly in the routine Pathology reports. Publications of the work won the Gowers Memorial Prize of the British Epilepsy Association (1967). In 1967 he moved to Oxford University and The Park Hospital for Children, which became the first National Centre for Children with Epilepsy. Sex differences in the effects of cerebral lesions were widespread and shown to be related to the more rapid development of females (Gender Differences their Ontogeny and Significance 1971). In 1980 he was invited to Manchester where he worked with paediatric neurologists and undertook sessions at the David Lewis Centre for Epilepsy. In 1990 he retired but continued to work sessionally at the Department of Neurology at Great Ormond St. Hospital and in Dublin monitoring the candidates for epilepsy surgery until 2003.
Daniel H. Lowenstein, M.D.

Daniel H. Lowenstein, M.D. is Vice-Chairman and Professor of Neurology, Director of the UCSF Epilepsy Center, Director of Physician-Scientist Education and Training, and Associate Dean of Clinical and Translational Science at UCSF.

Dr. Lowenstein graduated from the University of Colorado with a degree in mathematics, and received his M.D. at Harvard Medical School. He then did his residency in neurology at UCSF and a two-year molecular biology fellowship in Stanley Prusiner’s laboratory, and went on to become the Robert B. and Ellinor Aird Professor of Neurology and established the Epilepsy Research Laboratory at UCSF. After serving as Dean for Medical Education at Harvard from 2000-2002, he returned to the Bay Area to renew his academic work at UCSF.

Dr. Lowenstein is a clinician-scientist who has studied both basic science and clinical aspects of epilepsy. Dr. Lowenstein’s laboratory studies have examined the fundamental basis of neuronal network remodeling that occurs during epileptogenesis, with a particular focus on the parallels between injury-induced remodeling and the molecular and cellular mechanisms underlying normal brain development. His clinical research includes studies on the management and treatment of patients with status epilepticus, and he was the principal investigator for two prospective, multicenter clinical trials sponsored by the NIH examining the potential benefits of active treatment for patients with status epilepticus in the prehospital setting. In the last ten years, he has been a principal organizer of large-scale, international efforts to study the complex genetics of epilepsy. These include the “Epilepsy Phenome/Genome Project” and “Epi4K: Gene Discovery in 4,000 Genomes,” both of which are funded by NIH.

Dr. Lowenstein has been actively involved in advancing the cause of epilepsy at the national and international level, and has held numerous leadership roles in professional organizations and foundations, including serving as President of the AES in 2003-04.

He has served in a wide range of capacities for the AES including two terms on the Board of Directors; Living Well II Task Force Chair; Neurobehavioral Fellows Program Chair; Annual Course Committee; Annual Meeting Committee; Corporate Advisory Committee; Epilepsy Currents Contributing Editor; Nominating Committee; PEC Education; PEC Steering Committee; Practice Committee; QOL Survey Group; Research Initiative Fund Committee (twice); Research Recognition Awards; Scientific Program Committee (twice); Vision 2020; Neuropsychology Focus Group; and he was the 2005 Lennox Lecturer. He also served two terms on the Epilepsy Foundation Board of Directors and was Chair of the Professional Advisory Board (PAB), and Chair of the Research Committee of the BOD where he oversaw development of the special research initiatives, with many other assignments. He has served on the BOD and/or PAB for Epilepsy Foundation affiliates in Chicago, Memphis and Madison and has been active in ILAE neuropsychology working groups, and NINDS CDE development groups (quality of life, neuropsychology) as well as the Benchmark committees.

Dr. Hermann has served on the editorial boards of Epilepsia, Epilepsy and Behavior, Epilepsy Research, and the Journal of Epilepsy, and he is currently an associate editor of Epilepsia. He has served on grant review committees for the NIH, CDC, AES and EFA. He has maintained an active research program and has been NIH supported since 1998, currently investigating cognitive, brain, and behavioral development in children with new-onset epilepsies.
### NURSE AWARDEES

<table>
<thead>
<tr>
<th>Contact Author</th>
<th>Abstract Title</th>
<th>Poster</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lindsey L. Benefield, M.S.N.</td>
<td>Does A Seizure-Free Interval (Honeymoon Period) Occur After Abrupt Withdrawal Of AEDs In Patients With Daily Seizures?</td>
<td>2.133</td>
</tr>
<tr>
<td>Catherine L. Dezort, RN, M.S.N., CPNP</td>
<td>Evaluating The Effectiveness Of A Parent Completed Checklist Versus A Comprehensive Screening Program For Children With Epilepsy</td>
<td>2.189</td>
</tr>
<tr>
<td>Breanne Fisher, RN, M.S.N., CPNP</td>
<td>Evaluating The Yield And Referral Follow-Through Of Routine Behavioral And Psychological Screening In Epilepsy Care Settings</td>
<td>2.188</td>
</tr>
<tr>
<td>Siobhan J. Hannan, RN, RSCN, M.Sc., INP</td>
<td>Incidence Of Disabling Headache Post Hemispherectomy In Children With Rasmussen Syndrome</td>
<td>2.252</td>
</tr>
<tr>
<td>Karen Legg, M.N., NP</td>
<td>Marijuana Use In First Seizure Patients: The Halifax Adult First Seizure Clinic Experience</td>
<td>2.115</td>
</tr>
<tr>
<td>Melissa R. Osborn, RN, B.S.N.</td>
<td>Benefits Of Conversion From Immediate Release Lamotrigine To Extended Release Lamotrigine In Individuals With Drug-Resistant Epilepsy Or Adverse Effects</td>
<td>3.255</td>
</tr>
<tr>
<td>Debbie Terry, M.S., CNP</td>
<td>How Do Parents Learn About Epilepsy: Written Handouts Or Lived Experiences?</td>
<td>1.050</td>
</tr>
</tbody>
</table>

**Acknowledgment:** Nurse awards are supported by Eisai, Inc.

### GRASS AWARDEES

This award is intended to recognize and honor outstanding young investigators conducting research in basic or clinical neuroscience related to epilepsy. Awardees are selected from Young Investigators who submit an accepted abstract. The Grass Foundation and the American Epilepsy Society have combined resources to present these awards to eight deserving candidates to help support travel costs to present their research at the Annual Meeting of the American Epilepsy Society. The award is composed of a $1,000 travel stipend, a waiver of AES meeting registration fees and recognition during the Hoyer Lecture on Friday, November 30. Congratulations to the following awardees:

<table>
<thead>
<tr>
<th>Contact Author</th>
<th>Abstract Title</th>
<th>Poster / Platform #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jane B. Allendorfer, Ph.D.</td>
<td>Increased Neural Response To Stress In Temporal Lobe Epilepsy Patients Who Believe Stress Affects Their Seizure Control</td>
<td>1.184</td>
</tr>
<tr>
<td>Gemma L. Carvill, M.D.</td>
<td>Targeted Resequencing Of Known And Candidate Epilepsy Genes In 500 Patients With Epileptic Encephalopathies</td>
<td>1.312</td>
</tr>
<tr>
<td>Man Kin Choy, M.D.</td>
<td>Magnetic Resonance Imaging Within Hours Of Experimental Febrile Status Epilepticus Predicts Subsequent Epilepsy</td>
<td>3.064</td>
</tr>
<tr>
<td>Nealen Laxpati</td>
<td>Modulating The Antiepileptic Hippocampal Theta Rhythm Via Optogenetic Neuromodulation Of The Medial Septum</td>
<td>A.05</td>
</tr>
<tr>
<td>Bryan T. Leav, B.Sc. (Hons.)</td>
<td>A Mouse Model Of Early Onset Epileptic Encephalopathy Reveals A Cellular Defect And Suggests A Targeted Therapeutic Intervention</td>
<td>A.02</td>
</tr>
<tr>
<td>Kyle P. Lillis, Ph.D.</td>
<td>Functional Re-Wiring Of Hippocampal Neurons During Post-Traumatic Epileptogenesis</td>
<td>3.003</td>
</tr>
<tr>
<td>Jaime Saul, M.D.</td>
<td>Patterns Of fMRI Hippocampal Lamellar Activation Induced By Perforant Path Stimulation In The Kainic Acid Rat Model Of Epilepsy</td>
<td>3.193</td>
</tr>
<tr>
<td>Bregt Van Nieuwenhuyse</td>
<td>Hippocampal Deep Brain Stimulation Has Antiepileptogenic Potential</td>
<td>A.04</td>
</tr>
<tr>
<td>Contact Author</td>
<td>Abstract Title</td>
<td>Poster / Platform #</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Dongmei An, M.D.</td>
<td>Correlation Of EEG/fMRI BOLD Response With Postoperative Outcome In Focal Epilepsy</td>
<td>1.188</td>
</tr>
<tr>
<td>P. Bakaki, MB, ChB, M.S.</td>
<td>Defining Incident Cases Of Epilepsy In Administrative Data</td>
<td>1.334</td>
</tr>
<tr>
<td>Ana C. Coan, M.D.</td>
<td>EEG-fMRI In The Pre-Surgical Evaluation Of Temporal Lobe Epilepsy Patients</td>
<td>1.186</td>
</tr>
<tr>
<td>Chris Dulla, Ph.D.</td>
<td>Is The Loss Of Astrocytic Glutamate Reuptake In The Developing Cortex Epileptogenic?</td>
<td>3.006</td>
</tr>
<tr>
<td>Firas Fahoum, M.D., M.Sc.</td>
<td>Scalp Ripples Are Associated With Thalamic BOLD Changes</td>
<td>3.192</td>
</tr>
<tr>
<td>Kais Gadhoumi, M.S.</td>
<td>A Seizure Prediction Method For Patients With Temporal Lobe Epilepsy</td>
<td>1.105</td>
</tr>
<tr>
<td>Ravi K. Juluru, M.D.</td>
<td>Bioequivalence Studies Among Generic And Brand-Name Modified-Release Antiepileptic Drugs Supports Therapeutic Equivalence And Generic Substitution</td>
<td>1.224</td>
</tr>
<tr>
<td>Benjamin P. Kay</td>
<td>Reduced Default Mode Network Connectivity In Idiopathic Generalized Epilepsy With Uncontrolled Seizures</td>
<td>3.194</td>
</tr>
<tr>
<td>Cynthia G. Keator, M.D.</td>
<td>Evolution Of Seizures On Continuous Video EEG In Pediatric Abusive Head Trauma</td>
<td>1.061</td>
</tr>
<tr>
<td>David Keizer, B.Sc.</td>
<td>Prediction Of Ictal Propagation Using Single Pulse Electro cortical Stimulation Early Responses</td>
<td>2.070</td>
</tr>
<tr>
<td>Katsuya Kobayashi, M.D., Ph.D.</td>
<td>HFO Correlates Of Cortico-Cortical Evoked Potentials Reveal Altered Excitability In The Human Epileptic Focus</td>
<td>A.06</td>
</tr>
<tr>
<td>Pierre Mégevand, M.D., Ph.D.</td>
<td>The Accuracy Of Electric Source Imaging In Localizing Epileptic Activity Relative To The Preoperative Gold Standard Of Intracranial EEG</td>
<td>1.001</td>
</tr>
<tr>
<td>Nasir Mirza, M.D.</td>
<td>Solute Carrier Transporters In Pharmacoresistant Epilepsy: An Integrative In Silico And Ex Vivo Analysis</td>
<td>A.09</td>
</tr>
<tr>
<td>Brian D. Moseley, M.D.</td>
<td>Postictal Generalized EEG Suppression In Children: A Potential Marker Of SUDEP Risk</td>
<td>1.076</td>
</tr>
<tr>
<td>Heidi Munger-Clary, M.D., M.P.H.</td>
<td>Association Of Anxiety Symptoms With Epilepsy Type And Seizure Localization</td>
<td>1.213</td>
</tr>
<tr>
<td>Michael S. Oldham, M.D.</td>
<td>Cost Analysis Of Epilepsy Surgery In Pediatric Drug-resistant Epilepsy</td>
<td>1.277</td>
</tr>
<tr>
<td>Nicholas K. Schiltz</td>
<td>Disparities In Access To Specialized Epilepsy Care Among People With Epilepsy</td>
<td>2.331</td>
</tr>
<tr>
<td>Jacy Wagnon, M.D.</td>
<td>CELF4 Regulates A Vast Set Of mRNAs, Including Many Associated With Synaptic Function And Homeostatic Plasticity</td>
<td>3.096</td>
</tr>
<tr>
<td>Matthew P. Ward, M.D.</td>
<td>Vagal Nerve Activation Control: A New Approach To Electrical Stimulation-Based Therapy For Treatment-Resistant Temporal Lobe Epilepsy</td>
<td>1.042</td>
</tr>
<tr>
<td>Kristine E. Woodward, B.Sc.</td>
<td>Motor Reorganization In Frontal Lobe Epilepsy</td>
<td>1.190</td>
</tr>
</tbody>
</table>

**Acknowledgment:** Young Investigator Awards are supported by Eisai, Inc. and Medtronic, Inc.
2012 Special Interest Group Schedule

Friday 1:30 p.m. – 3:00 p.m.
EEG – Spotlight on Slow Waves
Epidemiology – Epilepsy Terminology
Psychiatry in Epilepsy – Interictal Dysphoric Disorder

Friday 6:30 p.m. – 8:00 p.m.
Basic Neuroscience – Juvenile Myoclonic Epilepsy
Botanicals & Alternative Therapies for Epilepsy
Ictal Semiology – Video Case Studies
Nursing – Research and Managing Well Network
SUDEF – Explaining the Unexplained

Saturday 7:00 a.m. – 8:30 a.m.
Basic Mechanisms of Epilepsy – Dendritic Dysplasticity
Critical Care Monitoring – ICU EEG Monitoring
Junior Investigator Workshop – Career Development
Pediatric Epilepsy Care-Based Discussion

Saturday 6:15 p.m. – 7:45 p.m.
Psychogenic Non-Epileptic Seizures
Sleep – Mechanisms and Consequences of Interrupted Sleep

Sunday 7:30 p.m. – 9:00 p.m.
Controversies in the Management of Women with Epilepsy
Epilepsy Surgery Failures
Neurostimulation – Neuromodulation in 2012
Private Practice Epilepsy – Collaboration
Quality & Value Indicators

Sunday 8:00 p.m. – 10:00 p.m.
Social Networking Group – continuation of SIG discussions

Monday 7:00 a.m. – 8:30 a.m.
Ketogenic Diet and Hormone / Hypothalamic Issues
Neuroimaging – Molecular Imaging
Neuropsychology – Transitory Cognitive Impairment
Novel Directions in Refractory Status Epilepticus

Monday 9:00 a.m. – 10:30 a.m.
Funding for Clinical Pharmacologic Studies in Epilepsy
Military Epileptologists – PNES in Veterans
Neonatal Seizure – Which Treatments for Which Patients?
Pregnancy Registry Outcomes

Monday 3:45 p.m. – 5:15 p.m.
Engineering and Epilepsy
Genetics – Targeted Therapies in Epilepsy
Getting Focused With MEG-EEG
Neuroendocrinology – Hormones in Epileptogenesis

Tuesday 7:00 a.m. – 8:30 a.m.
Children’s Hour – Inflammation in Epilepsy
Frontal Lobe Epilepsy
Temporal Lobe Club
Tuberous Sclerosis – Pre-surgical Epilepsy Evaluation
Tumor Induced Epilepsy

2012 AES BOARD OF DIRECTORS

PRESIDENT
Frances E. Jensen, M.D.

FIRST VICE PRESIDENT
Jacqueline A. French, M.D.

SECOND VICE PRESIDENT
Elson L. So, M.D.

TREASURER
Michael D. Privitera, M.D.

PAST PRESIDENT
John M. Pellock, M.D.

BOARD MEMBERS
Janice M. Buelow, RN, Ph.D.
William D. Gaillard, M.D.
David M. Labiner, M.D.
Page Pennell, M.D.
Steven N. Roper, M.D.
Helen Scharfman, Ph.D.

EX-OFFICIO
Gregory K. Bergey, M.D. (Epilepsy Currents)
Douglas A. Coulter, Ph.D. (Research and Training Council)
Brandy Fureman, Ph.D. (NINDS Liaison)
Robert Edward Hogan, M.D. (Council on Education)
Cesare T. Lombroso, M.D., Ph.D.
Joseph Sirven, M.D. (Epilepsy Foundation)
Dennis D. Spencer, M.D. (Development Council)
John W. Swann, Ph.D. (ILAE Liaison)
William H. Theodore, M.D. (Communications Council)
James Wheless, M.D. (Council on Clinical Activities)
8:30 a.m. – 11:30 a.m.

Epilepsy Specialist Symposium: Algorithms in the Diagnosis and Treatment of Epilepsy
(3.0 CME Credits)

Convention Center – Room 5, Upper Level

Overview
This symposium will discuss common problems encountered in caring for patients with new onset or difficult to control seizures. The topics will include:
(i) The diagnosis and treatment of a first seizure – who is at risk of recurrence, the risks and benefit balance of starting treatment, and how long to treat.
(ii) How to approach the pre-operative evaluation to localize the epileptic onset zone non-invasively and how to plan invasive recordings to localize the seizure onset zone.
(iii) Patient selection for treatment by neurostimulator devices (VNS, DBS) to palliate seizures and optimization of stimulation parameters.
(iv) Discussing SUDEP – when to have the discussion, with which patients, and how to approach the topic with patients at risk. The speakers will present the audience with algorithms that identify key decisions in the evaluation and treatment of seizures.

Learning Objectives
- Manage patients with first seizure by applying risk/benefit analysis using prediction of seizure recurrence based on presentation and ancillary tests
- Evaluate patients for epilepsy surgery, weighing the advantages / disadvantages of different approaches and understanding the rationale for selecting a specific approach
- Appropriately refer patients for implantation of and successfully treat with neurostimulator devices
- Recognize when and how to initiate discussion of SUDEP in patients who are at risk.

Target Audience
Basic and Intermediate (see page 107 for details)

Program
Chair: Fred A. Lado, M.D., Ph.D.

8:30 a.m. \ Introduction and Overview
Fred A. Lado, M.D., Ph.D.

8:45 a.m. \ First Seizure: Diagnosis, Treatment and Prognosis
Sheryl Haut, M.D.

9:15 a.m. \ Debate: Surgical Planning for Extratemporal Non-lesional Surgery?
Ashesh Mehta, M.D. and Francois Dubeau, M.D.

10:15 a.m. \ Treatment of Epilepsy with Implanted Devices: What Are Indications and Benefits?
Barbara C. Jobst, M.D.

10:45 a.m. \ Discussing SUDEP: If, When, How
Jeffrey Buchhalter, M.D., Ph.D.

11:20 a.m. \ Conclusions
Fred Lado, M.D., Ph.D.

Credit Designation
The American Epilepsy Society designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Nurses may claim up to 3.0 contact hours for this session.

Pharmacy Credit
ACPE Universal Activity Number (UAN) is 0052-9999-12-2313-L04-P and provides 3.0 contact hours.

ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Epilepsy Specialist Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Core Competencies: Medical Knowledge, Professionalism, and Practice-Based Learning and Improvement

Acknowledgment
This program is supported by an educational grant from UCB, Inc. and Cyberonics, Inc.

Separate registration required

9:00 a.m. – 4:00 p.m.

26th Annual Advances in the Management of Epilepsy and the Epilepsy Clinic
Marriott – Marina Ballroom D, Level 3

This intensive one-day conference is designed for those professionals who participate in the care of persons with epilepsy. The overall purpose is to improve services to individuals and families affected by epilepsy. The conference is presented by the Department of Neurology of Wake Forest University School of Medicine, Winston-Salem, North Carolina, through an unrestricted grant committed to the education of health professionals, in an effort to promote the comprehensive care of those with epilepsy and their families.

Registration for this program was done separately from the AES Annual Meeting and began on September 1, 2012 by Wake Forest School of Medicine.

12:30 p.m. – 3:00 p.m.

Annual Fundamentals of Epilepsy Symposium: Optimal Use of the Newest AEDs and Generics
(2.5 CME Credits)

Convention Center – Ballroom 6A, Upper Level

Overview
The Annual Fundamentals of Epilepsy Symposium will address both the newer antiepileptic medications (AEDs) and current understanding regarding use of generic medications. Presentations will address pharmacology and mechanism of action of new AEDs, their clinical pharmacokinetics and drug interactions. Efficacy and adverse effects of newer AEDs in approved indications plus alternative uses of newer AEDs in epilepsy syndromes and status epilepticus will also be reviewed. There will be discussion of current data regarding the use of generic AEDs.

Learning Objectives
- Use newer AEDs to treat patients with refractory epilepsy
- Match newest AEDs to the epileptic syndrome when appropriate
- Anticipate and recognize adverse effects related to use of newer AEDs
- Use generic medications and advocate for their use based on understanding on available scientific data.
Target Audience
Basic and Intermediate (see page 107 for details)

Program
Co-Chairs: James C. Cloyd, Pharm.D. and Michael D. Privitera, M.D.
12:30 p.m. Introduction and Overview
James C. Cloyd, Pharm.D.
12:40 p.m. Mechanism of Action of the New AEDs
Misty Smith, Ph.D.
1:05 p.m. Clinical Pharmacokinetics and Drug Interactions
Cecile Johannessen Landmark, Ph.D.
1:30 p.m. Efficacy and Adverse Effects of Newer AEDs in Approved Indications
R. Edward Faught, Jr., M.D.
1:55 p.m. The Emerging Uses of the New Antiseizure Medications in Status Epilepticus and Epilepsy
Howard Goodkin, M.D., Ph.D.
2:20 p.m. Generic AEDs: Facts and Fiction
Michael D. Privitera, M.D.
2:45 p.m. Case Presentations
All faculty
2:55 p.m. Conclusions
Michael D. Privitera, M.D.

Credit Designation
The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Nurses may claim up to 2.5 contact hours for this session.

Pharmacy Credit
ACPE Universal Activity Number (UAN) is 0052-9999-12-2317-L04-P and provides 2.5 contact hours.

ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Annual Fundamentals of Epilepsy Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Core Competencies: Medical Knowledge, Professionalism, System-Based Practice, and Practice-Based Learning and Improvement.

Acknowledgment
This program is supported by an educational grant from Eisai, Inc., Lundbeck and Sunovion Pharmaceuticals, Inc.

1:30 p.m. – 3:00 p.m.
Professional Development in AES: A Program for Junior Members and Those in Transition
Convention Center – Room 3, Upper Level

The American Epilepsy Society invites all interested meeting attendees to come to a special session on volunteer and leadership opportunities within the Society. The American Epilepsy Society has a variety of programs year-round to improve the care and treatment of patients with epilepsy. These efforts include education for basic scientists and clinicians, research grant programs, leadership and organizational activities, community outreach and advocacy. Greater participation in the Society offers members extensive career development opportunities by providing a chance to hone leadership skills, to network with other AES members and outside funding organizations, and most importantly, to make significant contributions to improve the lives of patients with epilepsy.

This session will be useful to trainees, basic scientists, clinicians and other health professionals (nurses, psychologists, Pharm.D.s) who want to know more about organizational structure or who want to become more involved. The session will provide an overview of the professional development and volunteering opportunities within the Society, followed by short presentations by members active in AES leadership. The session will end with a chance to meet with AES staff and committee leaders to learn more about available opportunities.

EEG – Spotlight on Slow Waves
Convention Center – Room 7, Upper Level
Coordinator: Hiroshi Otsubo, M.D.
Speakers: Akio Ikeda, M.D., Ph.D., Marco de Curtis, M.D., Hal Blumenfeld, M.D., Ph.D.

Slow waves represent diverse pathophysiological mechanisms in epilepsy. The spikes and high frequency oscillations (HFOs) are highlighted for epileptogenesis. However, the combination of spike and slow wave is a key element of interictal epileptic discharges. Ictal HFOs are frequently superimposed on very slow waves, called slow shift, to start seizures. Toward the end of seizures the spike and slow waves reappear to stop the seizures. This SIG EEG session’s three speakers will present mechanisms of interictal and ictal slow waves for understanding the role of epileptic slow waves.

Epidemiology – Simple, Generalized and Complex? The Words We Use to Communicate About the Central Manifestations of Epilepsy
Convention Center – Room 9, Upper Level
Coordinator: Anne T. Berg, Ph.D.
Speakers: Samden Lhatoo, M.D., FRCP, Jeffrey Buchhalter, M.D., Ph.D., Tobias Loddenkemper, M.D., Anthony Marson, M.D., Ph.D., David Thurman, M.D., M.P.H., Ana Claire Meyer

A recent report recommended major restructuring of terminology for seizures and abandoning the terms simple and complex partial in favor of describing ictal semiology instead. The impetus is to encourage precise, accurate diagnosis and, one would hope, improve treatment. This is feasible if one has the luxury of being in a monitoring unit, is essential in surgical work-ups, and is often critical in accurate recognition of rare syndromes. It is less manageable in the office setting and often impossible in epidemiological contexts. How can we develop a hierarchical, consistent lexicon that allows meaningful communication and translation across these diverse settings without losing essential detail where it is needed and without imposing it in settings where it is not available? We will have a face-off with epidemiologists and tertiary center epileptologists presenting their perspectives and lexicological needs. Videos will be used to illustrate the debacle with everyone invited to participate in a pre- and a post-self test. There will be ample time for discussion.
Psychiatry in Epilepsy – Interictal Dysphoric Disorder: Fact or Fiction
Convention Center – Room 8, Upper Level

Coordinators: Rochelle Caplan, M.D., John J. Barry, M.D.
Speakers: The SIG speakers supporting IDD will be Andres M. Kanner, M.D. and Marco Mula, M.D. and those against will be Alan B. Ettinger, M.D. and John J. Barry, M.D. David W. Dunn, M.D. will discuss its absence in pediatric epilepsy.

Interictal Dysphoric Disorder is a form of depression that has been described in people with epilepsy, but it has yet to be accepted universally. The aim of this SIG is to review the evidence for and against the presence of this condition. This debate addresses important theoretical and clinical implications of this diagnosis. From the theoretical perspective, a similar condition in migraine, and the wide range of psychiatric diagnoses in individuals with this diagnosis question the specificity of this condition and its underlying mechanisms to epilepsy. From the clinical perspective, how does this diagnosis benefit patients in terms of their treatment and long-term outcome?

This program is supported by Sunovion Pharmaceuticals, Inc.

Credit Designation
The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Nurses may claim up to 2.5 contact hours for this session.

Pharmacy Credit
ACPE Universal Activity Number (UAN) is 0052-9999-12-2315-L04-P and provides 2.5 contact hours.

ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Spanish Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Core Competencies: Medical Knowledge and Practice-Based Learning and Improvement

3:30 p.m. – 6:00 p.m.
Spanish Symposium: Extratemporal Epilepsies (2.5 CME Credits)
Convention Center – Room 5, Upper Level

Overview
The symposium will present evidence-based information concerning the scientific and clinical fundamentals of extratemporal epilepsy that are relevant for the diagnosis and management of adult and pediatric patients. The seminar will present and contrast with symptoms of temporal lobe seizures. The scientific and clinical fundamentals of extratemporal epilepsy that are relevant for the diagnosis and management of adult and pediatric patients. The criteria for determination of refractoriness will be emphasized. Presurgical evaluation and the selection of surgical or other non-pharmacologic treatments will be critically reviewed.

Learning Objectives
- Through improved diagnosis, optimize treatment and outcome of pediatric and adult extratemporal epilepsy syndromes
- By implementation of modern concepts, improve diagnosis and treatment of refractory epilepsy resulting in improved patient outcomes.

Target Audience
Basic, Intermediate (see page 107 for details)

Program
Co-Chairs: Alvaro Hernando Izquierdo Bello, M.D. and Patricio Abad, M.D.

3:30 p.m. Introduction and Overview
Alvaro Hernando Izquierdo Bello, M.D.

3:40 p.m. Extratemporal Epilepsies in Children and Adolescents
Ignacio Valencia, M.D.

4:15 p.m. Extratemporal Epilepsies in the Adult and the Elderly
José F. Téllez-Zenteno, M.D.

4:50 p.m. Surgical Treatment of Extratemporal Epilepsies: Indications, Procedure Selection, Outcome
Carlos Barzallo, M.D.

5:25 p.m. Round Table: Case Presentations and Discussion
Lilia Nuñez-Orozco, M.D. and Alyc R. Torres, M.D. (moderators)

5:50 p.m. Conclusions
Patricio E. Abad, M.D.

Credit Designation
The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Nurses may claim up to 2.5 contact hours for this session.

Pharmacy Credit
ACPE Universal Activity Number (UAN) is 0052-9999-12-2315-L04-P and provides 2.5 contact hours.

ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Spanish Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Core Competencies: Medical Knowledge and Practice-Based Learning and Improvement

4:15 p.m. – 5:45 p.m.
10th Judith Hoyer Lecture in Epilepsy
Now’s the Time: Exciting Opportunities in Epilepsy Research

Lecturer: Jaideep Kapur, M.D., Ph.D.

The 10th Judith Hoyer Lecture in Epilepsy, presented by invited lecturer Dr. Jaideep Kapur, is sponsored by the National Institute of Neurological Disorders and Stroke. Dr. Kapur’s presentation is the tenth in a series of lectures highlighting the promise of epilepsy research. This series is held in memory of Mrs. Judith Hoyer, an active member of the Board of Directors of the Epilepsy Foundation and the late wife of Representative Steny Hoyer (D-MD). Mrs. Hoyer spent her life both helping families to cope with epilepsy and promoting research into a cure and a better quality of life for those with the disorder. The purpose of the lecture is to raise awareness of epilepsy among researchers and the public and provide intellectual stimulation that will encourage continuing progress toward finding a cure for epilepsy.

This program is supported by an educational grant from Upsher-Smith Laboratories, Inc.

6:30 p.m. – 8:00 p.m.
Special Interest Group Meetings
Location listed under each session

Basic Neuroscience – Mechanisms of Juvenile Myoclonic Epilepsy: From Molecules to Networks
Convention Center – Room 8, Upper Level

Coordinators: Martin J. Gallagher, M.D., Ph.D., Michael Wong, M.D., Ph.D.
Speakers: Martin J. Gallagher, M.D., Ph.D., Antonio B. Delgado-Escueta, M.D., Ph.D., Matthias J. Koepp, M.D., Ph.D.

Juvenile Myoclonic Epilepsy (JME) is a common Idiopathic Generalized Epilepsy (IGE) syndrome that differs from the more-frequently-studied IGE syndrome, Childhood Absence Epilepsy (CAE), in several domains. Clinically, JME patients exhibit myoclonic and generalized tonic-clonic seizures as well as, occasionally, absence seizures. Moreover, JME patients experience substantially greater rates of pharmacodependence and pharmacoresistance than CAE patients. Electrographically, epileptiform discharges in JME patients occur at faster frequencies and with a different morphology than CAE
WHY JOIN THE AMERICAN EPILEPSY SOCIETY?

The American Epilepsy Society serves as a resource for its membership and the epilepsy community by providing access to data on the latest breakthroughs, technologies and methodologies in epilepsy research.

The American Epilepsy Society promotes interdisciplinary communication, scientific investigation and exchange of clinical information about epilepsy. Membership in AES opens doors to educational sessions, networking and knowledge-sharing among its members and Annual Meeting attendees.

AES MEMBERS ARE:
- Adult Neurologists
- Advanced Practice Nurses
- Basic Science Researchers
- Clinical Researchers
- Consultants
- Doctors of Osteopathic Medicine
- Doctors of Veterinary Medicine
- Emergency Room Physicians
- Epileptologists
- Fellows
- Government/Regulatory Interns
- Licensed Practical Nurses
- Non-Profit Staff
- Nutritionists
- Office Managers
- Pediatric Neurologists
- Pharmacists
- Pharmacologists
- Presidents/CEO’s in Industry
- Industry/Marketing Professionals
- Psychiatrists
- Psychologists
- Physicians Assistants
- Registered Nurses
- Residents
- Social Workers
- Students
- Technologists
- and Others

AES MEMBERS RECEIVE:
- Epilepsy Currents, the official journal of AES
- Epilepsia, the official journal of ILAE
- Reduced annual meeting registration fees
- Discounted subscriptions to scientific journals
- Listing in Find-A-Doctor online directory
- Network with members through Professional Connection
- Members-only discussion blogs
- Research funding opportunities
- Distinguished Achievement and Research Recognition Awards
- Weekly e-newsletters with relevant, timely news
- Free listing of your employment opportunities on www.AESNET.org
- and much more

www.AESNET.org
discharges. Finally, neurophysiological studies revealed that patients with JME demonstrate a particular diurnal variability of cortical excitability. These observations suggest that JME is produced by different pathophysiological mechanisms affecting different brain networks than those involved in CAE. While several animal models suggested that CAE results from disruption of thalamocortical oscillations, we still need good models of JME to understand the molecular and network mechanisms that cause this disease and to identify new targets to treat pharmacologically. This Basic Neuroscience SIG will discuss the recent developments in the identification of novel genes involved in JME, the elucidation of molecular consequences of JME mutations in vitro and in vivo, and the determination of brain regions involved in JME in human patients.

**Botanicals and Alternative Therapies for Epilepsy – Behavioral Interventions for Epilepsy**

**Convention Center – Room 10, Upper Level**

**Coordinators:** Siegward M. Elsa, M.D., Steven C. Schachter, M.D.

**Speakers:** Peter Wolf, M.D., Ph.D., Joanne Dahm, Ph.D., Donna J. Andrews, Ph.D., Rosa Michaels

This year, we plan to discuss the rationale of comprehensive behavioral interventions for improving seizure control in epilepsy patients, as described by representatives of several centers which have experience in using different methods to accomplish similar goals. Is it possible for patients to accomplish a change in attitude from a passive role, receiving external treatment to an active role of taking charge of their own epilepsy condition? Is it possible to identify early seizure warning signs or triggers for the average epilepsy patient to allow for a timely countermeasure? We hope that by comparing different approaches, critical features of behavioral interventions for seizures will become apparent in the discussion. In addition, we will consider methodological issues in the conduct of clinical trials of behavioral interventions by reviewing recently published pilot studies. For example, what are the characteristics of suitable control conditions for a study of behavioral interventions?

**Ictal Semiology**

**Convention Center – Room 7, Upper Level**

**Coordinator:** Felix Rosenow, M.D.

**Speakers:** Hans O. Lüders, M.D., Ph.D., Philippe Kahane, M.D., Ph.D., Akos C. Szabo, M.D., Felix Rosenow, M.D.

The moderator and members of the faculty will show ictal videos of epileptic patients. This will include some typical seizures as well as unusual cases. After showing the video the moderator will give the audience an opportunity to discuss the case. The discussant should describe the ictal semiology and / or epileptogenic zone. The moderator will then call on his faculty to give their opinion. At the end neurophysiological, neuroimaging or other evidence will be presented that elucidates the symptatogenic and / or epileptogenic zone.

**Nursing**

**Convention Center – Room 16, Mezzanine Level**

**Coordinators:** Madona D. Plueger, M.S.N., RN, CNNR, ACNS-BC, Georgette Smith, M.S.N., M.D.N, APRN, CPNP

**Speakers:** Shelley Stoll, M.P.H., Robert Fraser, Ph.D.

The Nursing SIG will focus the 2012 session on enhancement of nursing knowledge in the field of epilepsy regarding current practice inquiry and research. The SIG will highlight nursing awardee posters allowing author presentation and sharing of information. In addition, the Managing Well with Epilepsy Network will provide an update regarding current research projects and clinical applicability. This forum fosters the development of ongoing nursing participation and collaboration in the field.

Supported by Eisai, Inc.

**SUDEP: Explaining the Unexplained**

**Convention Center – Room 11, Upper Level**

**Coordinators:** Elizabeth J. Donner, M.D., FRCP(C), George B. Richerson, M.D., Ph.D., Lawrence J. Hirsch, M.D.

**Speakers:** Edward Glasscock, Ph.D., Rainer Surges, M.D., Anne E. Anderson, M.D., Gordon F. Buchanan, M.D., Daniel Mulkey, Ph.D.

Sudden Unexpected Death in Epilepsy (SUDEP) remains a mysterious tragedy. While the causes of death are thought to ultimately involve cardiac, autonomic or respiratory dysfunction, there is much less known about the CNS mechanisms that lead from a seizure to cardiorespiratory failure. In this session, speakers will present their own personal theories about the specific pathophysiological mechanisms involved, at the molecular, cellular and network levels within the CNS or heart, that lead from a seizure to SUDEP. An emphasis will be placed on which groups of neurons, axonal pathways, neurotransmitters, or molecules are involved, and not simply whether death is due to a cardiac or respiratory mechanism. A substantial amount of conjecture will be allowed, as long as speakers remain constrained by actual data. Following five to six short presentations, ample time will be used for a panel discussion with questions and comments from the audience.

Supported by Lundbeck

**Translational Research Programs at the NINDS and NIH**

**Convention Center – Room 9, Upper Level**

**Coordinators:** Brandy E. Fureman, Ph.D., William Benzing, Ph.D., Randall Stewart, Ph.D.

**Speakers:** William Benzing, Ph.D., Rajesh Ranganathan, Ph.D., Brian Litt, M.D., H. Steve White, Ph.D., Gregory A. Worrell, M.D., Ph.D.

NIH and NINDS speakers will provide overviews of currently available programs for funding translational research projects (including changes to the Anticonvulsant Screening Program), the application process, and review considerations. Current translational award grantees will provide experiences from the applicant point of view.

**Epilepsy: The Influence of Lifestyle and Environmental Factors**

**Convention Center – Ballroom 6A, Upper Level**

**Overview**

Exercise is a neglected area when evaluating epilepsy patients. Exercise is often considered as a disease modulating factor in other conditions, but not epilepsy. We will discuss whether cardiovascular fitness can influence the development of epilepsy and its prognosis. Stress is a negative modulator of epilepsy and the aim of this section will be to elucidate how stress can change the course of epilepsy and what can be done about it. Are there environmental or emotional factors that positively influence epilepsy, or are they all negative? Endogenous factors, such as circulating and CNS hormones, are important modulators of epileptogenesis, seizure severity and frequency. In this section hormonal factors, and how to influence them, will be discussed. The mechanism of action and disease modulating effect of neurosteroids remain an understudied area.

**Learning Objectives**

- Recommend the type of exercise that is most advantageous for patients with epilepsy and advise patients regarding the factors involved in performing exercise that can have a positive influence on epilepsy
- Counsel patients regarding different stress in life and management of stress, including those stresses that can aid in managing epilepsy
Implement therapies that can positively influence the neurosteroid environment to decrease seizure activity.

Target Audience
Basic and Intermediate (see page 107 for details)

Program
Co-Chairs: Elinor Ben-Menachem, M.D., Ph.D. and R. Edward Hogan, M.D.

6:30 p.m. Introduction and Overview
Elinor Ben-Menachem, M.D., Ph.D.

6:40 p.m. Exercise as a Neuromodulator of Cognition and Epilepsy: What Do We Know from Animal Studies?
Georg Kuhn, Ph.D.

7:00 p.m. Effects of Exercise (Cardiovascular Function) on the Development of Epilepsy in Adults
Elinor Ben-Menachem, M.D., Ph.D.

7:20 p.m. Stressors/Environmental Enhancement as a Mediator of Epileptogenesis – Animal Models
Nigel Jones, Ph.D.

7:40 p.m. Stressors/Environmental Enhancement as a Mediator of Epileptogenesis – Translational Aspects
Terence J. O’Brien, M.D.

8:00 p.m. Neurosteroids as Neuromodulators of Epileptogenesis in Animals
Istvan Mody, Ph.D.

8:25 p.m. How Neurosteroids Modulate Seizures in Children and Adults
Page B. Pennell, M.D.

8:50 p.m. Conclusions
R. Edward Hogan, M.D.

Credit Designation
The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Nurses may claim up to 2.5 contact hours for this session.

Pharmacy Credit
ACPE Universal Activity Number (UAN) is 0052-9999-12-2314-L04-P and provides 2.5 contact hours.

ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Hot Topics Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Core Competencies: Medical Knowledge, Professionalism, System-Based Practice, and Practice-Based Learning and Improvement

FRIDAY November 30, 2012

The American Epilepsy Society is pleased to announce

INNOVATION PAVILIONS

located inside the Exhibit Hall
Convention Center – Hall B

These pavilions offer companies an opportunity to provide education and training to meeting attendees in a convenient and more personal environment.

The Innovation Pavilions will be open on the following days:

Saturday, December 1: 11:45 a.m. - 6:00 p.m.
Lundbeck (B)

Sunday, December 2: 10:00 a.m. - 4:00 p.m.
Lundbeck (A, B & C)

Monday, December 3: 10:00 a.m. - 3:00 p.m.
Questcor (A)
7:00 a.m. – 8:30 a.m.

Special Interest Group Meetings
Location listed under each session
Please complete program survey – see page 11

Basic Mechanisms
Convention Center – Room 9, Upper Level
Coordinators: Howard Goodkin, M.D., Ph.D., Timothy Benke, M.D., Ph.D., Sanjay Rakhade, Ph.D., M.B.B.S.
Speakers: Nicholas P. Poolos, M.D., Ph.D., Helen E. Scharfman, Ph.D., Steve Danzer, Ph.D.

Epilepsy-induced changes in axonal and dendritic cytoarchitecture have started attracting attention again in the last few years with new studies about their role in comorbidities of epilepsy. Human pathological studies and studies in animal models of epilepsy have shown structural abnormalities in the dendrites of neurons. Several hypotheses suggest that these abnormalities may be contributing to neuronal dysfunction, epileptogenesis and cognitive / neurological dysfunction in epilepsy.

This basic mechanism SIG will be focused on updating the attendees on current knowledge about the cytoarchitecture and arborization of dendrites observed in the human subject and animal models of epilepsy. The featured talks will provide an overview of the dendritic pathologies observed in different models of epilepsy, dendritic channelopathies observed in models of epilepsy (Dr. Poolos); the structural abnormalities in mature granule cells in temporal lobe epilepsy (Dr. Danzer) and abnormalities in the ectopic granule cells in the hippocampus in pilocarpine model of epilepsy (Dr. Scharfman).

Targeted mechanisms for preventing seizure-related structural changes in dendrites may represent a novel therapeutic strategy for treating epilepsy and its complications.

Critical Care Monitoring – ICU EEG Monitoring
Convention Center – Room 8, Upper Level
Coordinators: Evan Fertig M.D., Suzette M. Laroche, M.D.
Speakers: Susan T. Herman, M.D., Suzette M. Laroche, M.D., Puneet Gupta, M.D., M.S.E., Cecil Hahn, M.D.

1) Review of the new guidelines for Critical Care EEG Monitoring developed by the ICU EEG monitoring consortium. Recommendations will be presented for equipment, personnel, review, coding, billing, etc. 2) Case presentations by expert speakers followed by audience comment and debate. Cases will highlight the utility of quantitative EEG methods and new terminology for quasi-periodic patterns developed by the ICU EEG monitoring consortium.

Junior Investigators Workshop – Opportunities for Funding and Career Development for Junior Investigators
Convention Center – Room 10
Coordinators: Andre Lagrange, M.D., Ph.D., William Stacey, M.D., Ph.D.
Speakers: Daniel Lowenstein, M.D., Jaideep Kapur, M.D., Ph.D., Randall Stewart Ph.D.

Join us for an exciting Junior Investigators Workshop on how to get funded to support your research career. This will be an interactive session in which our renowned panelists will share their pearls of wisdom. We will open the floor for discussion, so bring your questions and topics of discussion. This is sure to be a lively and informative interchange!

Pediatric Epilepsy Diagnosis and Treatment Opportunities – Case-based Discussions
Convention Center – Room 7, Upper Level
Coordinator: Elaine Wyllie, M.D.
Speakers: Ajay Gupta, M.D., Jorge Gonzalez-Martinez, M.D., Tobias Loddenkemper, M.D., Kevin Chapman, M.D., Elia Pestana-Knight, M.D., Elaine Wyllie, M.D.

Six dynamic faculty will each present an exciting case from his or her clinical experience that teaches an important clinical point and advances our field of pediatric epilepsy. Topics will be diverse and touch on controversies in EEG, seizure semiology, genetics, neurometabolism, neuroimaging, antiepileptic drug therapy, and epilepsy surgery. Audience interaction is encouraged!

Supported by Lundbeck and Questor Pharmaceuticals, Inc.

8:30 a.m. – 11:30 a.m.

(2.25 CME Credits)
Award Presentation: Research Awards
Convention Center – Ballroom 6C, Upper Level

Overview
This symposium will describe the process that led to the development of the 2012 IOM. There will be a report on the potential impact of the IOM report on both the AES community and the health care community in general. There will be a review of the major elements of the report and how it will be implemented to charge professional education, certification of epilepsy centers and specialists, and patient access to care. Actionable elements of the IOM report that will require coordinated participation of federal and nonfederal entities will be addressed. The relationship of the IOM report to the expanded NINDS and inter-institute funding programs for epilepsy research as well as how the IOM report can support the NINDS Epilepsy Benchmarks will be described. Finally, the response of patient advocacy and nongovernmental organizations will be presented, including implementation of the report recommendations and coordination with the community of professionals in epilepsy care.

Learning Objectives
- Recognize the impact of current gaps in diagnosis and treatment, as well as quality of life issues for patients with epilepsy
- Utilize information from emerging surveillance efforts to assess incidence and prevalence of epilepsy in the population across all age ranges to define clinical needs in their communities
- Understand significant areas of need for clinical, basic, and epidemiological research related to epilepsy and its comorbidities and their relationship to NINDS Epilepsy Benchmarks in order to define their research goals
- Identify and engage others devoted to provision of care in order to coordinate management of patients with epilepsy
- Manage care of patients based on established quality measures and desired improvement strategies in order to optimize patient outcomes.

Target Audience
Basic, Intermediate and Advanced (see page 107 for details)
Program
Chair: Frances E. Jensen, M.D.

8:45 a.m.  Introduction and Overview
Frances E. Jensen, M.D.

9:00 a.m.  The IOM Process and Committee Discussion
Joseph I. Sirven, M.D.

9:35 a.m.  The Context of the IOM Report: A View from HHS Leadership
Howard Koh, M.D., M.P.H.

This presentation does not provide CME credit

10:10 a.m.  What the IOM Report Means for Basic and Clinical Research
Story Landis, Ph.D.

10:45 a.m.  How the IOM Report Will Impact the Lives of Patients with Epilepsy
Susan Axelrod

11:20 a.m.  Conclusions
Frances E. Jensen, M.D.

Credit Designation
The American Epilepsy Society designates this live activity for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Nurses may claim up to 2.25 contact hours for this session.

Pharmacy Credit
ACPE Universal Activity Number (UAN) is 0052-9999-12-2316-L04-P and provides 2.25 contact hours.

ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Presidential Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Core Competencies: Medical Knowledge, Professionalism, System-Based Practice, Practice-Based Learning and Improvement

2:00 p.m. – 4:30 p.m.
Professionals in Epilepsy Care Symposium:
Current Issues in Clinical Practice:
Transitioning from Adolescent to Adult Epilepsy Care
(2.5 CME Credits)
Convention Center – Ballroom 6A, Upper Level

Overview
Clinical care guidelines for the transition of adolescents to adult epilepsy care currently are not available. Therefore, most common clinical issues associated with transition of care and practical strategies to address them are identified as an educational need for epilepsy healthcare professionals. Theoretical models, multidisciplinary and multicultural clinical experience, and current strategies for clinical practice of transition of care will be discussed. In addition, special topics in transition of care such as intellectual disability and ILAE task force activities will be presented.

Learning Objectives
• Establish procedures to support patient transition from pediatric to adult care providers
• Define specific practical issues and the role of pediatric neurologists in the transition and transfer of care within their clinical setting utilizing ILAE task force activities related to the transition of adolescents with epilepsy.

Target Audience
Basic and Intermediate (see page 107 for details)

Program
Co-Chairs: Sigita Plioplys, M.D. and Janelle Wagner, Ph.D.

2:00 p.m.  Introduction and Overview
Sigita Plioplys, M.D.

2:15 p.m.  How Can Transition Best Be Orchestrated? Models and Personal Experience
Peter R. Camfield, M.D., FRCP(C)

2:45 p.m.  Global Issues in the Transition of Adolescents with Epilepsy – A Child Neurologist’s Perspective
Jaime Carrizosa, M.D.

3:15 p.m.  Challenges in Transitioning Adolescents with Intellectual Disabilities and Epilepsy
Rebecca Schultz, Ph.D., RN, CPNP

3:45 p.m.  Adolescent Epilepsy Transition and the Role of Nursing
Laura Jurasek, FNP, M.N.

4:15 p.m.  Conclusions
Janelle Wagner, Ph.D.

Credit Designation
The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Nurses may claim up to 2.5 contact hours for this session.

Pharmacy Credit
ACPE Universal Activity Number (UAN) is 0052-9999-12-2320-L04-P and provides 2.5 contact hours.

ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Professionals in Epilepsy Care Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Core Competencies: Medical Knowledge, Professionalism, System-Based Practice, Compassionate Patient Care, and Interpersonal and Communication Skills

Acknowledgment
This program is supported by an educational grant from Sunovion Pharmaceuticals, Inc.

2:00 p.m. – 2:30 p.m.
Clinical and Basic Science Keynotes
Convention Center – Ballroom 6C, Upper Level

Basic and Clinical Science Research Recognition Award Recipients each give a 15-minute keynote and will be presented at beginning of Translational Research Symposium.
Overview
Research. This symposium will inform the audience about recent advances in translational, basic research that directly bear on NIH benchmarks and that could potentially change/improve patient care. Advances in genetics, EEG recordings and analysis, potential cell based therapies, and understanding the relationship between epilepsy and autism will be presented.

Relationship to the Epilepsy Benchmarks. The presentations are aligned with the following benchmarks: Identify new treatments or therapies to prevent, interrupt, or reverse the development of epilepsy; develop and test at least one animal model of epilepsy and an associated condition; develop and test biological and other markers that pinpoint the locations of brain networks associated with the development of epilepsy.

Medical Treatment. Medical treatment will be advanced as genetic underpinnings of epilepsy are understood and new treatment modalities, such as cell transplants and diet therapies, are explored. Furthermore, identification and characterization of electrical biomarkers via advances in EEG technologies will lead to better understanding of epilepsy phenotypes and improved care.

Learning Objectives
- Recognize genetic epilepsies and understand the presumptive mechanisms that underlie conditions such as astatic myoclonic epilepsy and that may contribute to comorbidities such as autism. When managing such patients, address both the mechanism of the epilepsy and the expected comorbidities.
- Review data concerning cell based therapies in models of intractable epilepsy that may provide new insights into novel approaches for correcting network dysfunction in epilepsy.
- Use state-of-the-art EEG technologies to improve seizure classification and localization.

Target Audience
Intermediate and Advanced (see page 107 for details)

Program
Co-Chairs: Daniel H. Lowenstein, M.D. and Karen S. Wilcox, Ph.D.

2:30 p.m. Introduction and Overview
Daniel H. Lowenstein, M.D.

2:40 p.m. Role of CNTNAP2 in Epilepsy, Neuronal Migration Abnormalities, and Core Autism-related Deficits
Olga Peñagarikano, Ph.D.

3:05 p.m. Using Multi-electrode Array Recordings to Detect Unrecognized Electrical Events in Epilepsy
Catherine Schevon, M.D., Ph.D.

3:25 p.m. Embryonic MGE Cells as a Treatment for Epilepsy
Scott C. Baraban, Ph.D.

3:50 p.m. Glucose Transporter 1 Deficiency as a Treatable Cause of Myoclonic Astatic Epilepsy
Saul Mulllen, M.D.

4:10 p.m. Conclusions
Karen S. Wilcox, Ph.D.

Credit Designation
The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Nurses may claim up to 2.5 contact hours for this session.

Pharmacy Credit
ACPE Universal Activity Number (UAN) is 0052-9999-12-2321-L04-P and provides 2.5 contact hours.

ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Translational Research Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Core Competencies: Medical Knowledge

6:15 p.m. – 7:45 p.m.
Special Interest Group Meetings
Location listed under each session

PNES
Convention Center – Room 9, Upper Level
Coordinators: John J. Barry, M.D. and Markus Reuber, M.D., Ph.D.
Speakers: Nicole Roberts, Sigita Plioplys, M.D., Julia Doss, Psy.D.

The PNES SIG will be separated into two parts. In the first section, the focus will be on recent findings from a series of studies exploring the neurobiological and cognitive underpinnings of PNES. This will be discussed by Dr. Nicole Roberts. In the second segment, Drs. Sigita Plioplys and Julia Doss will discuss important clinical questions and difficulties in managing children with PNES and their families. They will also provide new research evidence from an ongoing prospective multi-site study on risk factors in pediatric PNES. Active input from the audience will be welcomed.

Sleep in Epilepsy – Mechanisms and Consequences of Interrupted Sleep by Epilepsy
Convention Center – Room 10, Upper Level
Coordinator: Mark S. Quigg, M.D.
Speakers: Carl Bazil, M.D., Ph.D., Erik St. Louis, M.D., Rama Maganti, M.D., Selim R. Benbadis, M.D.

This year’s SIG will concentrate on impact of interrupted sleep of the patient with epilepsy and talks will include: (1) The effects of epilepsy on underlying genetic mechanisms of the biological clock. Evidence of seizure effects on basic clock mechanisms will be presented. (2) The effects of anticonvulsant medications on sleep parameters. Patients with epilepsy have disturbed sleep, and certain anticonvulsant medications have particular effects on sleep regulation. (3) The effects of the epileptic state and accompanying seizures on sleep. Recent studies in patients after VNS placement and after epilepsy surgery show physiologic lesions that affect epilepsy also affect sleep.

6:15 p.m. – 7:45 p.m.
Investigators’ Workshop
Convention Center – Room 11, Upper Level

fMRI Task Selection for Presurgical Mapping in Children: Goals and Challenges
Moderator: Madison Berl, Ph.D.
Speakers: Louise J. Croft, M.S., Leigh Sepeta, Ph.D., Simona Ghetti, Ph.D.
You’re invited to attend
Sunday, December 2
8:00 a.m. - 8:30 a.m.
San Diego Marriott Marquis & Marina –
Marina Ballroom, Level 3
Coffee will be available

AES ANNUAL BUSINESS MEETING

All AES members are encouraged
to attend this yearly meeting.
Scientific exhibits will be on display at this year’s annual meeting and will be located in Rooms 3, 4, and 5, directly across from the General Session Room, on the Upper Level of the San Diego Convention Center. These exhibits will provide meeting attendees an opportunity to update themselves on the latest research. Authors will be present throughout the exhibit.

### Sunday, December 2 • 8:00 a.m. - 11:00 a.m.

<table>
<thead>
<tr>
<th>Company</th>
<th>Room</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Visualase, Inc.</strong></td>
<td>3</td>
<td>Update on MRI-Guided Laser Ablation to Perform Minimally Invasive Neurosurgery</td>
</tr>
<tr>
<td><strong>Sunovion Pharmaceuticals, Inc.</strong></td>
<td>4</td>
<td>Eslicarbazepine Acetate: Developing a New Treatment for Epilepsy</td>
</tr>
<tr>
<td><strong>Lundbeck</strong></td>
<td>5</td>
<td>Research Updates for Antiepileptic Therapies Clobazam and Vigabatrin</td>
</tr>
</tbody>
</table>

### Sunday, December 2 • 2:00 p.m. - 5:00 p.m.

<table>
<thead>
<tr>
<th>Company</th>
<th>Room</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medtronic</strong></td>
<td>4</td>
<td>Medtronic Deep Brain Stimulation Therapy for Epilepsy: Research and Technology Update</td>
</tr>
</tbody>
</table>

### Monday, December 3 • 8:00 a.m. - 11:00 a.m.

<table>
<thead>
<tr>
<th>Company</th>
<th>Room</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NeuroPace</strong></td>
<td>4</td>
<td>The NeuroPace® RNS System: Experience with a Responsive Neurostimulation System for the Treatment of Partial Epilepsy</td>
</tr>
<tr>
<td><strong>UCB, Inc.</strong></td>
<td>5</td>
<td>VIMPAT® (lacosamide) C-V: Continuing UCB’s Long-Term Commitment to Epilepsy Management</td>
</tr>
<tr>
<td>Poster Session 1</td>
<td>11:45 a.m. - 6:00 p.m.</td>
<td>Convention Center – Hall B, Ground Level</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------------</td>
<td>----------------------------------------</td>
</tr>
</tbody>
</table>

> Authors Present: 11:45 a.m. - 1:45 p.m.
> Poster Walking Tours (see page 11 for details)

### Translational Research Mechanisms 1.001

**WITHDRAWN**


1. **003** Transient Prenatal Hypoxia-Iscemia In Rats Diminishes Ca3 Hippocampal Inhibitory Circuit Development/L. Jantzie, P. Getsey, C. Yeung, D. Fini, C. Wilson, F. Jensen and S. Robinson

1. **004** Increased Expression Of Pan-TRK Receptor Proteins In The Cortex Of An Adult Rat Model Of Irradiation-Induced Cortical Dysplasia/Z. Ying, A. Nemes and I. Najm

1. **005** Directly Simulated Synaptogenesis After Albumin Exposure: A Model For Posttraumatic Epileptogenesis/L. Wood, I. Weissberg, D. Milikovsky, A. Friedman and D. Kaufer


1. **007** Sodium Selenate Treatment Reduces Neurodegeneration And Behavioral Impairments In A Rat Model Of Post-Traumatic Injury Epilepsy/S. Shultz, P. Zheng, D. Wright, L. Johnston, C. Hovens, N. Jones and T. O’Brien

1. **008** Biphasic Roles Of Insulin And IGF-1 In Post-Traumatic Epileptogenesis In Organotypic Hippocampal Cultures/Y. Berdichevsky, H. Mullan, Y. Saponjian and K. Staley


1. **010** Which Receptor Systems Play A Role In Postictal Refractoriness After Cortical Epileptic Afterdischarges?/P Mares and H. Kubova

1. **011** Brain Alkalosis And Consequent Seizures After Neonatal Asphyxia Are Caused By Acid Efflux Across The Blood-Brain Barrier/M. Helmy, P Watkins, E. Ruusuvuori, J. Voipio, P. Kanold and K. Kaila


1. **013** Blocking Mechanism Of The AMPA Receptor Antagonist Perampanel/M. Rogawski, C. Chen, L. Matt and J. Hell

1. **014** Subunit-Specific Dephosphorylation Of The Putative AP2 Binding Sites Of The GABA<sub>A</sub> Receptor During Lithium Pilocarpine-Induced Status Epilepticus/S. Joshi, S. Chester, K. Hawk, K. Rajasekara and H. Goodkin

1. **015** Hippocampal Loss Reduces Calcium Entry Through N-Methyl-D-Aspartate And Ryanodine Receptor Activated Systems In Cultured Hippocampal Neurons/K. Phillips, L. Deshpande and R. De Lorenzo

**Models**

1. **016** Modeling The Effective Connectivity Of The Visual Network In Healthy And Photosensitive, Epileptic Baboons/S. Narayana, K. Li, A. Laird, C. Franklin, S. Kadam, M. Leland, J. Caron, M. Hanes, K. Knape, D. Xie and J. Williams

1. **018** Effectiveness Of SSRI’s Or A 5-HT<sub>7</sub> Agonist On Prevention Of Seizure-Induced Sudden Death In DBA/1 Mice/C. Faingold, X. Long and A. Sik

1. **019** Reversal Of Stress-Induced Seizure Severity Enhancement By Glucocorticoid Receptors Antagonism In A Genetic Model Of Audiogenic Epilepsy/E. Umeoka and N. Garcia-Cairasco

1. **020** In Vivo-EEG Reveals Subclinical Ischemic Seizures And Limited Efficacy Of Phenobarbital In Neonatal Mice/S. Kadam, S. Kang, S. Kim and M. Johnston

1. **021** MECP2 Phosphorylation At Ser421 Can Be Mediated Via Seizure-Induced Activation Of Ca2+ - Permeable AMPA Receptors In Developing Brain/S. Rakhade, E. Rosenberg, J. Lippman-Bell, C. Hilario-Gomez and F. Jensen

1. **022** Whole-Cell Brain Tissue Impedance Changes As A Function Of State-Of-Vigilance/ M. Sedigh-Sarvestani, G. Thuku, S. Weinstein and B. Gluckman

1. **023** Anticonvulsant Activity Of Intravenous And Intramuscular Allogeneic Stem Cells/O. Zolokowska, A. Dhir, G. Cooke, C. Wu, L. Zhu, H. Wulff and M. Rogawski

1. **024** Decreased Subcortical Arousal In Limbic Seizures: Brainstem Cholinergic And Thalamic Inhibition During Cortical Slow Oscillations/J. Motelow, A. Gammadavelli, V. Chu, A. Mishra, R. Sachdev, B. Sanganahalli, M. Furman, D. Englott, F. Hyde and H. Blumenfeld


1. **026** Persistent Cardiac Alterations Occur Early In A Model Of Acquired Epilepsy/Y. Lai and A. Anderson

1. **027** Subtle Seizures After TBI In A Unique Strain Of Kindling-Susceptible Rats: Electographic, Behavioral, And Phenotypic Features/C. Cech, M. Hanson, L. Teg, B. Mulvey, T. Langberg, E. Hutchinson, P. Rutteck and T. Sutula

1. **028** Neuroplastic Alterations After Status Epilepticus In Two Experimental Models Of Temporal Lobe Epilepsy/O. Castro, E. Buntic, V. Santos, S. Marroni, M. Scobar, H. Pimenta and N. Garcia-Cairasco

**Human Studies**

1. **030** SUDEP Tissue Donation Program (STOP): Collaborative Network In Support Of SUDEP Registry, Tissue Repository And Human Translational Research/A. Goldman

1. **031** Beta Coherence In Human Temporal Neocortical Microcircuits/ R. McGinn, C. Flores, V. Lukankin, I. Marwa, S. Sugumar, J. Dian, P. Carlen, L. Zhang and T. Valiante

1. **032** Younger Age At Surgery Is Associated With Impaired Electron Transport Chain Complex Function In Children With Focal Cortical Dysplasia/M. Miles, L. Miles, H. Greiner, F. Mangano, P. Horn, J. Leach, K. Lee, T. DeGraw and C. Hoppel

1. **033** Gap-Junction Is A Potential Target For Epileptic Therapy In Human Gelastic Seizures With Hypothalamic Hamartoma/J. Wu, S. Rice, J. Beggs and J. Kerrigan


1. **035** Differences In Endocrine Response To Stress In Temporal Lobe Epilepsy Patients With And Without Seizure Freedom/J. Szafiarski, J. Allendorfer, E. Nelson, H. Heyse and L. Mendoza

1.037 Evidence For A Peripheral Annulus Of Enhanced Inhibition From Human Electroencephalographic/J. Loeb, A. Mannani and R. Serafini

1.038 Gamma-Hydroxybutyric Acid Depolarization For Newborn Screening Of Succinic Semialdehyde Dehydrogenase Deficiency, A Metabolic Epilepsy/P. Pearl, S. Forni, K. Gibson, Y. Yu and L. Sweetman

1.039 Serial Examination Of Serum II-8, II-10 And II-1RA Levels Is Significant In Neonatal Seizures Induced By Hypoxic Ischemic Encephalopathy/ Y. Lee, Y. Youn, S. Kim, I. Sung, S. Chung, Y. Kim and J. Han


1.045 Tele-Epilepsy: Developing A Multi-Modal Device For Non-EEG, Extramural, Nocturnal Seizure Monitoring/J. van Andel, C. Ungureanu and G. Betkay


1.049 Parent Knowledge On Home Management Of Acute Seizures/ L. Gän, K. Nickels, E. Wirrell, K. Ilg and L. Wong-Kiessel

1.050 How Do Parents Learn About Epilepsy: Written Handouts Or Lived Experiences/ D. Terry, L. Hamiwka and M. Eversole

1.051 Moving Toward Best Practice Nursing Guidelines In The Care Of Intellectually Disabled Persons With Epilepsy/ T. Buckley

1.052 The Impact Of New-Onset Epilepsy In Older Adults: A Qualitative Study/W. Miller and J. Buelow

1.053 The Factors Associated With Quality Of Life In Caregivers Of Patients With Epilepsy/ Y. Lee and H. Yu

1.054 Seizures Make Me A Little Bit Lost: Children’s Descriptions Of Their Epilepsy/ J. Mulligan

1.055 Examining Learning And Academic Challenges In Pediatric Non-Epileptic Seizures/ J. Doss, S. Plioplys, I. Sen-Gupta, S. Schuele, M. Macken, R. Benini, M. Levesque, J. Gotman and M. Avoli

1.056 Periodic Lateralized Epileptiform Discharges (PLEDS) In Adult Inpatients Undergoing Continuous EEG (CEEG) Monitoring/ I. Sen-Gupta, S. Schuele, M. Macken, M. Kwasny and E. Gerard

1.057 EEG Misinterpretation And Misdiagnosis Of Epilepsy In Psychogenic Non-Epileptogenic Seizure Patients/ R. Lopez-Baquer and I. Pita


1.059 Psychosocial Education


1.061 Evolving For The Protection Of Seizure Patients On Home Video EEG Monitoring/ T. Arthur and F. Mangano


1.065 An Extensive European EEG Database For Analyses Of Long-Term Recordings/A. Schulze-Bonhage, M. LeVanQuyen, F. Sales, B. Schelter, M. Ihle and A. Dourado

1.066 Patterns Of Intercital Spikes And Of Associated High-Frequency Oscillations (80-500 Hz) During Epileptogenesis In An Animal Model Of Temporal Lobe Epilepsy/ P. Salami, R. Benini, M. Levesque, J. Gotman and M. Avoli

1.067 Ambulatory EEG Monitoring With Video In Adults; Yield And Clinical Utility/ E. Fertig, E. Feoli, M. Fleming, C. Lambrakis, O. Laban-Grant, S. Mesad, J. Politsky and M. Lancman

1.068 Evolution Of Seizures On Continuous Video EEG In Pediatric Abusive Head Trauma/ C. Keator, D. Arndt, N. Stence, B. O’Neill, A. Brooks-Kayal and K. Chapman

1.069 Clinical Utility Of Long-Term Video-EEG Monitoring In A Cohort Of Patients In A Large Referral Center In Peru/ J. Delgado Rios, L. Mija, L. Portilla, W. Zapata, W. De La Cruz and D. Chacon

1.070 Profits Of Nocturnal EEG-Polysonmography In Epilepsy Units/ M. Torres, L. Guzman, R. Cambron, M. Toledo, L. Serrn, M. Gonzalez, M. Quintana, E. Santamarina, A. Ferre, M. Jurado, X. Salas-Puig and O. Romero
**Other Clinical EEG**

1. **1.072 Status Epilepticus Versus Recurrent Seizures In Newborns With Hypoxic-Ischemic-Encephalopathy**
   Treated With Hypothermia And Monitored With Continuous Video-EEG/M. Balestri, I. Guidotti, S. Pro, L. Giaccone, I. Spera, L. Orli, D. Longo, A. Todeschini, F. Vigeveano, F. Ferrari and M. Cilio


**Computational Analysis & Modeling Of EEG**

1. **1.090 MEG Ability To Lateralize The Epileptogenic Zone And To Predict Surgical Outcome In Epilepsy Patients Who Required IEEG/S. Almubarak, A. Alexopoulos and R. Burgess**

2. **1.091 Use Of A Rhythm-Based Vs. Single Time-Slice Method For Analysis Of Seizure Onset During Magnetoencephalography/ R. Alkawadri, R. Burgess and A. Alexopoulos**


4. **1.093 The Value Of MEG As A Presurgical Evaluation Tool: Adult Nonlesional Neocortical Epilepsy/ W. Jeong, C. Chung and J. Kim**

5. **1.094 Focal High Frequency Oscillations During Childhood Absence Seizures/ J. Tenney, H. Fujiwara, N. Hemiazpin and D. Rose**

6. **1.095 Maximum Resection Of MEG Spike Sources Achieves Good Seizure Outcome In Intractable Epilepsy Patients With Tuberous Sclerosis Complex/T. Okanishi, A. Ochi and H. Otsubo**

7. **1.096 Somatosensory Responses In Patients With Intractable Epilepsy/ P. Klais and J. Mosher**


1.148 Effects Of Adjunctive Lacosamide On Mood In Adults With Partial Epilepsy/ S. Mazza, G. Marano and M. Mazza
1.149 Ketone Stabilization During Long Term Fasting In Children On A Ketogenic Diet/Y. Liu, H. Lowe, M. Zat, J. Kobayashi, V. Chan and E. Donner
1.150 Impact Of Peri-ictal Interventions On Respiratory Dysfunction, Postictal EEG Suppression And Postictal Immobility/M. Seyal, L. Bateman and C. Li

**Prognosis**

1.154 The Risk And Causes Of Death In Childhood-Onset Epilepsy: A 4-Study Collaboration/A. Berg, K. Nickele, E. Winrill, C. Rios, A. Geerts, P. Callenbach, W. Arts, P. Camfield and C. Camfield
1.155 Juvenile Myoclonic Epilepsy: Long-Term Seizure And Social Outcome After A Mean Follow-Up Of 39.1 Years/F. Schneider, J. Geithner, F. K. Nickels, E. Wirrell, C. Rios, 4-Study Collaboration/A. Berg, P. Camfield and C. Camfield

1.156 Early Developmental And School Problems Do Not Presage Poor Seizure Outcome In Children With Uncomplicated Epilepsy/S. Jawed and A. Berg
1.157 Electrocardiogram Ordering Practices For Patients Admitted To An Epilepsy Monitoring Unit/ K. Krishnamurthy and V. Krishnan
1.159 A Group Of Canadian Pediatricians Awareness Of SUDEP/E. Donner, T. Jeffs and N. Jette
1.160 Parents’ Perceptions Of Activity Restrictions In Children With Epilepsy: Role Of Child And Family Factors/N. King, K. Speechley and G. Zou
1.161 Most Children With Non-Syncronic, Focal Epilepsy Of Unknown Cause Have A Good Seizure And Social Outcome 30 Years Later: A Population-Based Study/R. Camfield and C. Camfield
1.163 Intercital 12-Lead Electrocardiography In Patients With Epileptic Seizures/V. Krishnan and K. Krishnamurthy

**Women’s Issues**

1.164 The Risk Of Seizure Recurrence After Child-Bearing/K. Haral, M. Matsura and M. Haral
1.165 The Effects Of Progesterone Versus Placebo Treatment On Quality Of Life In Women With Epilepsy/ C. Harden, A. Herzig, S. Schaffer, K. Fowler and B. Jobst
1.167 Caring For Women With Epilepsy: Does An EMR Help Us Follow Guidelines?/P. Penovich and J. Hanna

**Neuro Imaging**

1.168 Intercital Seizure Burden Alters White Matter Integrity In Temporal Lobe Epilepsy/K. Osipowicz, N. Pajor, A. Sharan, M. Sperling and J. Tracy
1.169 Voxel-Based Morphometric MRI Post-Processing In MRI-Negative Orbitofrontal Epilepsy Patients/ S. Jones, Z. Wang, A. Ristic, C. Wong, J. Gonzalez-Martinez, I. Najim and A. Alexopoulos
1.173 Reversible And Irreversible Cranial MRI Findings Associated With Status Epilepticus/A. Cartagena, G. Young, D. Lee and S. Mirsattari
1.174 Disrupted Anatomical White Matter Network In Left Mesial Temporal Lobe Epilepsy/M. Liu, Z. Chen, L. Concha, C. Beaulieu and D. Gross
1.175 FDG-PET Using Statistical Analysis Provides Good Surgical Candidate With Temporal Lobe Epilepsy/H. Sugano, M. Nakajima, T. Higo, Y. Iimura and H. Arai
1.179 More Extensive Abnormal White Matter Than Gray Matter In Children With Frontal Lobe Epilepsy/ E. Widjaja, A. Kis, C. Go, O. Snead and M. Smith

**Functional Imaging**

<table>
<thead>
<tr>
<th>Poster Session 1</th>
<th>Saturday December 1, 2012</th>
<th>Convention Center – Hall B, Ground Level</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1.183</strong> Localizing The Ictal Onset Zone With Data-Driven fMRI Analysis/ B. Hunyadi, S. Toussey, M. De Vos, S. Van Huffel and W. Van Paesschen</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.184</strong> Increased Neural Response To Stress In Temporal Lobe Epilepsy Patients Who Believe Stress Affects Their Seizure Control/J. Allendorfer, H. Heyse, E. Nelson, L. Mendoza and J. Szafiarski</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.185</strong> Abnormal Structural And Functional Connectivity In A Specific Thalamocortical Circuit In Juvenile Myoclonic Epilepsy/ J. O’Muircheartaigh, C. Vollmar, G. Barker, V. Kumari, M. Symms, P. Thompson, J. Duncan, M. Koepp and M. Richardson</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.188</strong> Correlation Of EEG/fMRI Bold Response With Postoperative Outcome In Focal Epilepsy/D. An, F. Fahoum, J. Hall, A. Olivier, J. Gotman and F. Dubue</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.189</strong> Comparison Between Task-Based And Resting-State Functional MRI For Language Lateralization/ N. Tanaka, H. Liu, N. Suzuki and S. Stufflebeam</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.190</strong> Motor Reorganization In Frontal Lobe Epilepsy/K. Woodward, I. Gaxiola, D. Mainprize, M. Grossi, B. Goodyear and P. Federico</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.192</strong> In-Vivo Metabotropic Glutamate Receptor Type 5 (mGlur5) Abnormalities In Patients With Focal Cortical Dysplasias/U. Dubois, J. Rowley, P. Rosa-Neto and E. Kobayashi</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.193</strong> Age-Related Morphological And Functional Maturation Of The Corpus Callosum: A Quantitative Study With MRI And Intraoperative Evoked Potentials In Patients With Epilepsy/T. Ono, H. Baba, K. Toda, S. Baba and K. Ono</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.194</strong> The Post-Operative Changes In Major White Matter Fibers For Children With Medically Intractable Focal Epilepsy: A Diffusion Tensor Imaging Study/H. Kim, A. Harrison, P. Kankirawatana, C. Rozzelle and J. Blount</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.196</strong> Evaluation Of Interictal EEG-fMRI Sensitivity And Specificity For Detection Of The Ictal Onset Zone In Refractory Focal Epilepsy/S. Toussey, P. Dupont, S. Sunaert and W. Van Paesschen</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.197</strong> Familial Patterns Of Bold Activation/R. Carney, R. Masterton, S. Berkovic and G. Jackson</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.198</strong> Mapping Epileptic Networks In Juvenile Myoclonic Epilepsy Using MEG And fMRI/S. Blumberger, H. Soltaian-Zadeh, Q. Jiang, K. Mason, V. Wasade, M. Spanaki, D. Burdette and Andrew Zillgitt</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cormorbidity (Somatic And Psychiatric) Medical Conditions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.200</strong> Unprovoked Comorbidities At Onset Of Unprovoked Seizures In Children – A Report From Stockholm Incidence Register Of Epilepsy (SIRE)/E. Andell Jason, T. Tomson, S. Carlsson, C. Adelow, T. Andersson, G. Jackson, J. Freeman, A. Harvey and J. Archer</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.201</strong> Does The Amygdala Play A Role In Weight Gain After Epilepsy Surgery? – A Tertiary Care Center Experience/V. Rajasekaran, T. Weimer, P. Parenti, G. Pawar and A. Palade</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.202</strong> Epilepsy Patients Should Receive DXA Screening/L. Lee, M. Wagner and B. Wu</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.204</strong> Assessing Health In Epilepsy Clinic/R. Doss, S. Mason and M. Hamberger</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.205</strong> Prevalence And Associates Of Recent Suicidal Ideation And Behavior In Treatment-Resistant Focal Epilepsy Without Recent Depression: The ASERT Study/A. Kanner, D. Hesdorffer, J. Pollard, M. Spanaki, G. Krauss, C. Harden, K. Posner and J. French</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.206</strong> Screening For Mental Health Symptoms In A Multidisciplinary Pediatric Epilepsy Clinic/K. McNally, J. Crameri, M. Clary and M. Hamberger</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.207</strong> Common Comorbidities In Women And Men With Epilepsy And The Relationship Between Number Of Comorbidities And Health Plan Paid Costs In 2010/A. Wilner, A. Soucy, B. Sharma, A. Krueger and A. Thompson</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.208</strong> Bright Light Therapy For Symptoms Of Depression And Anxiety In Epilepsy/S. Baxendale, J. O’Sullivan and D. Heaney</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.210</strong> Depression, Seizure Type And Polytherapy With AED Influence Subjective Memory In Women With Epilepsy/B. Jobst, C. Harden, R. Scott, K. Fowler, A. Herzog and For The Progesterone Study Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.211</strong> Attention Deficit Disorder Symptoms Rates And Impact In Adults With Self-Reported Epilepsy: Results From The National Epidemiological Survey Of Epilepsy/ A. Ettinger, R. Ottman, R. Lipton, J. Cramer and M. Reed</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.212</strong> Longitudinal Monitoring Of Depression In An Adult Epilepsy Clinic/R. Doss, S. Mason and M. Hamberger</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.213</strong> Association Of Anxiety Symptoms With Epilepsy Type And Seizure Localization/H. Munger Clary and M. Hamberger</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.215</strong> Screening For Mental Health Symptoms In A Multidisciplinary Pediatric Epilepsy Clinic/K. McNally, J. Crameri, M. Clary and M. Hamberger</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.216</strong> Impact Of A Screening Tool On Management Of Psychosocial Comorbidities In Persons With Epilepsy/f. Galler and B. Jobst</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.217</strong> Depression And Quality Of Life In Hispanic Immigrants And US Born Epilepsy Patients/M. Bonafina, M. Lancman, L. Myers, O. Laban, E. Feoli, E. Fergin and M. Lancman</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.218</strong> Multi-Center Treatment Trial Pilot For Psychogenic Nonepileptic Seizures/W. C. LaFrance, A. F. Webb, A. Blum, G. Keitner, J. Barry and J. Szafiarski</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
1.1253 Breastfeeding Is Compatible With The Ketogenic Diet And Efficacious In Treating Seizures In Infants/L. Thompson, M. Gustafson, H. Kayyali and A. Abdelmoity

1.1254 Long-Term Safety And Efficacy Of Everolimus In Patients With Subependymal Giant Cell Astrocytoma (SEGA) Associated With Tuberous Sclerosis Complex (TSC): 3-Year Update/D. Franz, M. Care, K. Holland-Boulay, K. Agrinola, C. Tudor, J. Lebrec, D. Lam and D. Krueger

1.1255 The Modified Atkins Diet For The Treatment Of Juvenile Myoclonic Epilepsy/E. Kossoff, B. Henry and M. Cervenka

1.1256 Leucine In Protective In Acute Seizure Tests/A. Hartman, P. Santos and M. Cervenka


1.1258 Rasmussen Encephalitis: 5-Year Follow-Up Under Immunoadsorbtions And Rituximab/B. Schmalbach and N. Lang

1.1259 The Cognitive Effects Of Long Term Administration Of Ketogenic Diet In Rats/P. Emmady and J. Harney

1.1259 Anticonvulsant Triheptanoin Results In Few Changes In Brain Metabolism/T. McDonald, M. Hadera, U. Sonnewald and K. Borges

1.1260 Effects Of Chronic Metformin Treatment And A 35% Triheptanoin Diet On Seizure Threshold Of Pilocarpine-Induced Epileptic Mice/ A. Fernandez, S. Willis, K. Borges and J. Stoll


1.1262 Outcome Of Epilepsy Surgery In Older Patients/J. Hwang, B. Enos, L. Cahan, J. Schweitzer, S. Chayasirisobhon, K. Earnest, B. Spurgeon, S. Gurbani, H. Sindhu and M. Lin


1.1264 Corpus Callosotomy Versus Corpus Callosotomy With Focal Cortical Dysplasia And Intractable Epilepsy/C. Herren, M. S. Honma and M. Mantle

1.1265 Cost Analysis Of Epilepsy Surgery In Pediatric Drug-Resistant Epilepsy/M. Oldham, J. Teavat, P. Horn, H. Greiner and S. Stampfieur


1.1268 Functional Hemispherectomy In Young Children With Cortical Dysplasia And Intractable Epilepsy/C. Herren, D. Sirsi, M. Khan, S. Khan, R. Said and S. Arnold

1.1269 Hypometabolism Offers Insight Into The Seizure-Onset Zone In Refractory Neocortical Epilepsy/L. Olson


1.1271 Early Experience With Minimally Invasive Epilepsy Surgery Using Laser Ablation In A Pediatric Cohort/I. Miller, J. Ragheb, S. Bhatia and A. Hyslop

1.1272 The Modified Atkins Diet For The Treatment Of Intractable Epilepsy/A. McEvoy and B. Diehl

1.1273 Real-Time MRI-Guided Stereotactic Laser Thermal Amygdalolhippocampotomy (STLAH) For Mesial Temporal Epilepsy/J. Willis, R. Gross, N. Laxpati, A. Saindane and S. Nour

1.1274 Epilepsy Surgery In The Elderly: The Kork Experience/B. Steinhoff, A. Staack and A. Wendling

1.1275 Outstanding DC Current Shift In The Post-Ictal Suppression Guided Ictalogenic Target/H. Hasegawa

1.1276 Anterior Language And Motor Network Connectivity Within The FrONTAL Lobe: An Extra-Operative Cortico-Cortical Evoked Potential Study/V. Wykes, A. Misericocchi, A. Lemisiou, J. Duncan, T. Wehner, A. McEvoy and B. Diehl


1.1279 Functional Hemispherectomy In Young Children With Cortical Dysplasia And Intractable Epilepsy/C. Herren, D. Sirsi, M. Khan, S. Khan, R. Said and S. Arnold

1.1280 Cost Analysis Of Epilepsy Surgery In Pediatric Drug-Resistant Epilepsy/M. Oldham, J. Teavat, P. Horn, H. Greiner and S. Stampfieur


1.1282 The Modified Atkins Diet For The Treatment Of Intractable Epilepsy/A. McEvoy and B. Diehl


1.1285 Functional Hemispherectomy In Young Children With Cortical Dysplasia And Intractable Epilepsy/C. Herren, D. Sirsi, M. Khan, S. Khan, R. Said and S. Arnold


1.1287 Early Experience With Minimally Invasive Epilepsy Surgery Using Laser Ablation In A Pediatric Cohort/I. Miller, J. Ragheb, S. Bhatia and A. Hyslop

1.1288 The Modified Atkins Diet For The Treatment Of Intractable Epilepsy/A. McEvoy and B. Diehl

1.1289 Cost Analysis Of Epilepsy Surgery In Pediatric Drug-Resistant Epilepsy/M. Oldham, J. Teavat, P. Horn, H. Greiner and S. Stampfieur

1.325 Long Term Follow-Up Of The Multiple-Hit Rat Model Of Symptomatic Infantile Spasms/
O. Akman, S. Briggs and A. Galanopoulou
1.326 Decreased Hippocampal Neurogenesis As A Long-Term Consequence Of Early-Life Status Epilepticus In Rats/H. Kubova, G. Tsenov and P. Mares
1.327 Progression Of EEG Pattern In Status Epilepticus Correlates With The Degree Of Neuronal Degeneration/K. Imerman, S. Marsh and D. Treiman
1.328 mTORC1 Inhibition Rescues Learning And Memory But Not Social Deficits Following Status Epilepticus/A. Carter, A. Brewster, J. Lugo, V. Pacil, W. Lee, Y. Qian, F. Vanegas and A. Anderson
1.329 Neuronal Degeneration Is Observed In Multiple Regions Outside The Hippocampus After Lithium Pilocarpine-Induced Status Epilepticus In The Immature Rat/E. Scholl, F. Dudek and J. Ekstrand
1.330 Long-Term Expression Of IL-1 Beta In The Rat Hippocampal Reactive Astrocytes After Kainic Acid-Induced Status Epilepticus/S. Sakuma, H. Otsubo, H. Shintaku and T. Yamano

In Vitro Studies
1.331 Severe Trauma Disrupts Cationic Gradients In Hippocampal Neurons Of The Developing Brain/ T. Balena and K. Staley

Epidemiology
1.332 Neurological, Cognitive And Neuroimaging Outcomes Within 10 Years After Childhood Status Epilepticus: A Population-Based Study/R. Chin, S. Pujar, R. Scott, M. Martinos, W. Chong and B. Neville
1.333 Cardiovascular Fitness And Future Risk Of Epilepsy: A Prospective Study/J. Nyberg, M. Åberg, K. Torén, H. Kuhn and E. Ben-Menachem
1.334 Defining Incident Cases Of Epilepsy In Administrative Data/ P. Bakaki, S. Koroukian, L. Jackson, J. Albert and K. Kaiboriboon
1.335 Why Do Seizures Recur In Seizure-Free Children? A 30 Year Population-Based Cohort Of Children With Epilepsy/K. Nickels, L. Wong-Kisiel and E. Wirrell
1.336 Incidence And Prevalence Of Epilepsy Among Poor Health & Low Income Americans: A Longitudinal Cohort Study (1992-2006)/ K. Kaiboriboon, P. Bakaki, S. Lhatoo and S. Koroukian

WITHDRAWN

Public Health
1.340 Barriers To Bone Health Counseling For Women With Epilepsy On Antiepileptic Drugs/J. Roth, C. Paniszyn, V. Gendron, C. Harini and A. Blum
1.341 The Quality Of Epilepsy Care: Are We On The Same Page?/A. Oh, D. Becker and H. Kim
1.343 Knowledge Of Physicians And Practice Parameters Pertaining To The Diagnosis And Drug Management Of Pediatric Epilepsy/C. Hovinga, K. Kime, N. Bower, J. Titus, F. Perkins and D. Clarke
1.344 Refractory Epilepsy In Pregnant Women/L. Aenlle-Matusz, S. Nadeau and J. Cibula
1.345 Epilepsy Related Accidents In A Saudi Cohort/S. Hanif, S. Sinha and K. Siddiqui
1.346 Medication Adherence In Epilepsy Patients After A Single Neurologist Visit In Rural India/ J. Bigelow, V. Singh and M. Singh
1.347 Direct Costs Of Lennox Gastaut Syndrome In A Highly Specialized Hospital/ G. Salmeron Gomez and M. Pizarro Castellanos
1.348 Quality Of EEG Recordings Obtained By Non-Specialist Technicians In Rural Hospital Settings Before And After A One-Day Intensive Training Course/K. Ziamba, M. Hoerth, J. Drazkowski, K. Noe, L. Helepololei, J. Muccioli, L. Tapsell, B. Mill and J. Sirven

History Of Epilepsy
1.349 The Portrayal Of Seizures And Epilepsy On YouTube/V. Wong, M. Stevenson and L. Selwa
1.350 Epilepsy And The Heart – A Historical Review 1827 – 1935/S. Singh, R. Sankaraneni and J. VanDerWerf
1.351 Francisco Goya And The Impenitent’s Seizure/E. Carrazana and M. Lopez
Now you can access and find what you need for your professional education on the AES website by establishing and using your own dashboard:

- Take self-assessment tests
- Index your favorite topic areas
- Cross-reference to Epilepsy Currents
- View archived Annual Meeting symposia
- Link to your record on Medical Education Evaluator
- Link to Professional Connection and start to participate in an online discussion

It’s all here...starting now!
Log in to the AES Epilepsy Institute at www.AESNET.org

AES members have free access to start their dashboard homepage for their individualized professional development. Non-members are welcome as well for an annual access fee.
Overview
Trauma and tumors are inextricably linked to epilepsy. Among people with newly diagnosed epilepsy of known cause, primary brain tumors or brain metastasis, and Traumatic Brain Injury (TBI) predominate. Chronic seizures are often the most cited problematic complication to either of these conditions. Both trauma and tumors are complicated by their heterogenous epileptogenic injuries and the spectrum of comorbid conditions. Primary care and specialty physicians alike — including oncologists, neurologists, epileptologists, emergency room physicians — all struggle with how to best manage epilepsy as it pertains to both trauma and tumors as numerous therapeutic strategies are available.

This year’s Annual Course will delve into tumor-based and posttraumatic epilepsy, two of the most common yet challenging symptomatic epilepsies faced on a daily basis, through a multidisciplinary approach. The course is divided into two sessions with the morning session devoted to tumor-based epilepsy and the afternoon to posttraumatic epilepsy. Each session will be framed by common clinical scenarios including adults and children and will be used to discuss how disparate mechanisms lead to epilepsy, how the conditions are diagnosed, the questionable role for antiepileptogenic management and how to best manage the conditions from both a medical and surgical vantage point. The goal of the course is to highlight clinical management while illuminating basic science and practice gaps. Each session will end with a summary and offer a potential algorithm for clinical management for epilepsy related to each condition.

Learning Objectives
► Utilize algorithms that describe how best to manage patients with epilepsy related to brain tumors including novel intraoperative monitoring techniques
► Use an evidence-based algorithm for management of the patient with posttraumatic epilepsy
► Perform risk analyses in making treatment decisions regarding prophylactic use of AED in patients with CNS tumors
► Manage patients with metastatic brain tumors with treatment options based on evidence-based best practice.

Target Audience
Basic, Intermediate and Advanced (see page 107 for details)

Program
Chair: Joseph I. Sirven, M.D.
8:45 a.m. Introduction Overview
Joseph I. Sirven, M.D.

Tumors
8:55 a.m. Case Presentation: Benign Tumor-based Epilepsy
Lily Wong-Kisiel, M.D.
9:00 a.m. Epidemiology and Semiology of Tumor-based Epilepsy
Charles J. Vecht, M.D.

Trauma
9:25 a.m. Panel Flash Session: Tumor-based Factors — Genetic Factors, Tumor Types, Peritumoral Morphological Changes
Lara E. Jehi, M.D., Steve S. Chung, M.D., Joon Uhm, M.D.
9:40 a.m. Prevention of Epilepsy in Tumors? Insights from Basic Science, Glutamate Receptors
Joon Uhm, M.D.
10:05 a.m. Break
10:20 a.m. Case Presentation: Refractory Epilepsy Related to Tumor-based Epilepsy
Jeffrey M. Poltisky, M.D., FRCP(C)
10:25 a.m. Surgical Issues in Managing Tumor-based Epilepsy: Resection Extent Outcomes / Timing of Surgery
Edward Chang, M.D.
10:50 a.m. Intraoperative Monitoring: Role in Epilepsy-based Tumor Surgery (Novel Techniques)
Aatif M. Husain, M.D.
11:15 a.m. Case Presentation: Epilepsy Related to a Malignant-based Tumor
William O. Tatum, IV, D.O.

11:20 a.m. Debate: Valproic Acid for Seizures Due to Tumors
Pro: Ideal Drug in Tumor-based Epilepsy Due to Antineoplastic Properties
Charles J. Vecht, M.D.
Con: Poor Choice of Drug Due to Adverse Effects and Teratogenic Potential
Kimford J. Meador, M.D.

11:50 a.m. Morning Summary — Algorithm and Treatment Summary
Jorge G. Burneo, M.D., M.S.P.H.

Noon - 2:00 pm. Break in Exhibit Hall (Lunch: Noon - 1:00 p.m.)

SUNDAY
4:25 p.m.  Non-epileptic Seizures and Trauma  
Martin Salinsky, M.D.

4:40 p.m.  Surgical Management of Post-traumatic Epilepsy: Complexities-Adhesions, Multiple Foci, Encephalomalacia  
Jeffrey P. Blount, M.D.

5:00 p.m.  Conclusion: Algorithm and Treatment Summary  
Joseph I. Sirven, M.D.

Credit Designation  
The American Epilepsy Society designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit  
Nurses may claim up to 6.0 contact hours for this session.

Pharmacy Credit  
ACPE Universal Activity Number (UAN) is 0052-9999-12-2322-L04-P and provides 8.0 contact hours.

ABPN Core Competencies  
The American Board of Psychiatry and Neurology has reviewed the Annual Course and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Core Competencies: Medical Knowledge, System-Based Practice, and Practice-Based Learning and Improvement

Acknowledgment  
This program is supported in part by an educational grant from UCB, Inc. and Novartis Pharmaceuticals Corporation

8:45 a.m. – 5:15 p.m.  
Investigators’ Workshops  
Location listed under each session  
Please complete program survey – see page 11

Overview  
These workshops, conducted informally and designed to encourage interaction, will address several important areas of rapidly-emerging knowledge in clinical and basic research in epilepsy. The workshops are intended to identify challenges in current research, propose methods to overcome those challenges, and encourage areas for future investigation.

The Basic Science Investigator Workshops will highlight a number of research areas that have been developing rapidly over the last year. Participants include both established and junior epilepsy investigators as well as researchers outside the epilepsy community who have specialized expertise that may be applied to epilepsy basic science. In addition, one of the workshops features presentations by junior investigators in cutting-edge areas of research.

The Clinical Investigators’ Workshops provide a series of working seminars in matters of active clinical investigation and controversy. Speakers present results from their ongoing research and place their findings in the context of current understanding. One of these workshops has been selected as a Translational Investigators’ Workshop. This two-hour session will present a particularly broad overview of basic and clinical research on an important problem in epilepsy.

Most of the workshops will run as concurrent sessions on Sunday, while two concurrent workshops, including the longer translational workshop, are scheduled for Saturday afternoon, with a single workshop on Monday afternoon. A separate Investigators’ Workshop Poster Session will occur starting at noon close to the IW Platform Sessions.

This year the Epilepsy Research Recognition Award recipients will present their keynote addresses prior to the Translational Research Symposium on Saturday afternoon, rather than during the investigators’ Workshops. Please plan on attending to celebrate AES researchers.

Target Audience  
Basic scientists, neurologists, neuroscientists, pharmacologists, neuropsychologists and neurosurgeons who are performing research in epilepsy

Program  
Investigators’ Workshops Chair: Nicholas P. Pooles, M.D., Ph.D.  
Clinical Investigators’ Workshop Chair: Hal Blumenfeld, M.D., Ph.D.

Morning Session I – 8:45 a.m. - 10:15 a.m.

1. Multimodal Neuroimaging to Direct Epilepsy Surgery  
Convention Center – Room 8, Upper Level  
Moderator: John S. Duncan, D.M., FRCP  
Speakers: Christian Vollmar, M.D., William E. Bingaman, M.D., Andrew W. McEvoy, M.D.

2. The Extracellular Matrix in Epilepsy  
Convention Center – Room 11, Upper Level  
Moderator: Brenda E. Porter, M.D., Ph.D.  
Speakers: Esther Baronov, MS, Chris Ikonomidou, M.D., Ph.D., Lorenzo Cingolani, Ph.D.

3. SUDEP Research Consortium: A New Collaborative Network to Discover Predictive Genes, Mechanisms and Biomarkers of SUDEP  
Convention Center – Room 10, Upper Level  
Moderators: Alica M. Goldman, M.D., Ph.D.  
Speakers: George B. Richerson, M.D., Ph.D., Lisa M. Bateman, M.D., Jeffrey L. Noebels, M.D., Ph.D.

Break: 10:15 a.m. - 10:30 a.m.

Morning Session II – 10:30 a.m. - Noon

4. Validation of Epilepsy Biomarkers in Humans: Goals, Successes, Challenges  
Convention Center – Room 8, Upper Level  
Moderators: Jeffrey A. Loeb, M.D., Ph.D.  
Speakers: Laura A. Jansen, M.D., Ph.D., Gilles Huberfeld, M.D., Ph.D., Jeffrey A. Loeb, M.D., Ph.D.

5. Swimming Toward a New Path for Drug Discovery in Epilepsy: An Open Discussion of Traditional and Emerging Strategies  
Convention Center – Room 11, Upper Level  
Moderator: F. Edward Dudek, Ph.D.  
Speakers: H. Steve White, Ph.D., Scott C. Baraban, Ph.D., Yevgeny Berdichevsky, Ph.D.

6. Searching for Lesions in “Nonlesional” Epilepsy  
Convention Center – Room 10, Upper Level  
Moderator: Neda Bernasconi, M.D., Ph.D.  
Speakers: Fernando Cendes, M.D., Ph.D., Andrea Bernasconi, M.D., Francine Chassoux, M.D.

 Noon - 2:00 p.m. Poster Session (Lunch)  
Convention Center – Ballroom 6A, Upper Level  
Note: Number below refers to poster assignment


3.004 The Receptor For Advanced Glycation End Products (RAGE) Is Overexpressed In Mesial Temporal Lobe/A. Vezzani, V. Iori, M. Carli, R. Vertemara, T. Ravizza, E. Aronica, M. Maroso

3.005 A Reorganized GABAergic Circuit In A Model Of Epilepsy/Z. Peng, C. S. Huang, Y. Catina, N. Zhang, C. R. Houser

3.006 Is The Loss Of Astrocytic Glutamate Reuptake In The Developing Cortex Epileptogenic/C. Dulla, L. Andresen, A. Taylor, E. Hanson, M. Freeman, D. Cantu
3.067 PT5 Neurotrophin Receptor Modulation And JAK/STAT Inhibition: Role In The Progression Of Epilepsy In The Pilocarpine Rat Model/ H. Grabenstatter, Y. CruzDelAngel, J. Carlsen, T. Yang, A. M. White, F. M. Longo, S. J. Russek, A. R. Brooks-Kayal
3.088 Formation And Regulation Of Heteromeric HCN Channels In Live Cells: Insights From TIRF/FRET Imaging/Y. Noam, L. Regev, A. Koh, N. Hoshi, T. Z. Baram
3.011 An Epilepsy-Causing Mutation In SCN1A Causes Gain-Of-Function In GABAergic Intemeurons/E. Velazquez, A. Escayg, A. Goldin
3.013 Reduced Cortical GABA-A Receptor Endocytosis In A Mouse Model Of Absence Epilepsy/M. J. Gallagher, C. Zhou
3.015 Seizures In Mice Overexpressing The Calcium Channel Receptor Alpha2-Delta/L. Faria, I. Parada, Z. D. Lou, B. Barres, D. A. Prince
3.016 Closed-Loop Optogenetic Control Of Spontaneous Seizures/ C. Armstrong, E. Krook-Magnuson, M. Oijala, I. Soltesz
3.003 GABA Receptor Mutant Mice With Absence Epilepsy Display Loss Of Inhibitory Tonic Currents/K. P. Mangan, S. Petrov, S. Johnson, M. V. Jones
3.092 Tyrosine Phosphorylation Of Voltage-Gated Sodium Channel B1 Regulates Neurite Outgrowth/J. Calhoun, L. Ison
3.032 Dysregulation Of Voltage-Gated Ion Channel Expression In A Mouse Model Of Cortical Dysplasia/L. H. Nguyen, A. L. Brewster, A. E. Anderson
3.033 MAP Kinase Inhibition As A New Therapeutic Target For Intercital Spiking In The Rat/D. Senator, D. T. Barkmeier, S. Dattlof, J. A. Loeb
3.036 Regional Expression Patterns Of Candidate Genes Linked To Landau-Kleffner Syndrome/L. V. Long, E. Powell
3.037 Cardiac, Respiratory, And Cortical Function After Electrically-Induced Seizures In Wild-Type And 5-HT Neuron Deficient Mice/ F. G. Buchanan, G. B. Richerson
3.074 Identification Of Potential Genes Of Absence Epilepsy By MALDI Imaging Using Two Bidirectionally Selected Mouse Lines/B. Martin, M. Lagarrigue, , T. Alexandrov, R. Lavigne, G. Dieuset, S. Baulac, C. Pineau
3.097 T-type Calcium Channels Facilitate Neuronal Hyper-Excitability In Epilepsy/M. K. Patel, D. Gryder, N. Hargus, J. Renger, V. Uebele, E. Perez-Reyes, E. Bertram, A. Nigam
3.175 Sub-surface, Femtosecond Laser Incisions As A Therapy For Partial Epilepsy/R. N. Fetcho, J. Nguyen, M. Zhao, N. Nishimura, T. H. Schwartz, C. B. Schaffer
3.192 Scalp Ripples Are Associated With Thalamic BOLD Changes/ F. Fahoum, F. Melani, L. P. Andrade-Valencia, F. Dubeau, J. Gotman
3.193 Patterns Of fMRI Hippocampal Lamellar Activation Induced By Perforant Path Stimulation/S. Jaime, T. D. Duong, J. E. Cavazos
3.194 Reduced Default Mode Network Connectivity In Idiopathic Generalized Epilepsy With Uncontrolled Seizures/B. P. Kay, M. W. DiFrancesco, , S. K. Holland, J. P. Szaflarski
3.196 Propagation Of Interictal Activity In Frontal Lobe Epilepsy: A MEG-DTI Study/E. M. Castillo, Z. Li, G. Von Allmen, J. I. Slater, A. C. Papanicolaou
3.321 Long-term mTOR Hyperactivation Leads To Social Behavior And Learning And Memory Deficits/E. Arbuckle, G. Smith, J. Morrison, C. Flouria, O. Okonkw, N. J. Lugo
3.337 Synchronous Firing In Two Populations Of Neurons In Human Epileptic Hypothalamic Hamartomas/P. N. Steinmetz, S. Wait, G. P. Lekovic, H. L. Rekate, J. F. Kriegman
3.338 Detection Of Human Herpersivirus-7 In 305 Patients With Intractable Epilepsy/J. Li, C. Huang, D. Zhou
3.341 Inflammatory And Neuroplastic Changes In The Hippocampus 24 Hours After Lateral Fluid Perfusion Injury/L. Shapiro, M. J. Ruch, S. Mukherjee, Z. Zeitouni

Afternoon Session I – 2:00 p.m. - 3:30 p.m.

7. What’s Next? Epilepsy Research at the Cutting Edge: A Young Investigators’ Workshop
Convention Center – Room 8, Upper Level
Moderator: Scott C. Baraban, Ph.D.

8. Dysfunctional Phosphorylation Signaling in Epilepsy
Convention Center – Room 11, Upper Level
Moderator: Anne E. Anderson, M.D.
Speakers: Amy Brewster, Ph.D., James Trimmer, Ph.D., Nicholas P. Poolos, M.D., Ph.D.

9. Massively Parallel Sequencing in Epilepsy
Convention Center – Room 10, Upper Level
Moderators: Samuel F. Berkovic, M.D., Peter de Jonghe, M.D.
Speakers: Elliott Sherr, M.D., Ph.D., Erin Heinzen, Pharm.D., Ph.D., Ingo Helbig, M.D.

Break: 3:30 p.m. - 3:45 p.m.

Afternoon Session II – 3:45 p.m. - 5:15 p.m.

10. Neocortical Focal Seizures in Etiologically Realistic Models of Acquired Epilepsy
Convention Center – Room 8, Upper Level
Moderator: Raimondo D’Ambrosio, Ph.D.
Speakers: Raimondo D’Ambrosio, Ph.D., Ramon Diaz-Arrastia, M.D., Ph.D., Harold Sontheimer, Ph.D.
11. Brain pH in the Generation and Suppression of Seizures
   Convention Center – Room 11, Upper Level
   Moderator: Kai Kaia, Ph.D.
   Speakers: Saul Mullen, M.B.B.S., Steven Petrov, Ph.D., Kai Kaia, Ph.D.

12. Comorbidity Between Epilepsy and Autism Spectrum Disorder:
    Challenges in the Diagnosis
   Convention Center – Room 10, Upper Level
   Moderator: Stéphane Auvin, M.D., Ph.D.
   Speakers: Rochelle Caplan, M.D., Anne T. Berg, Ph.D.,
             Elizabeth Thiele, M.D., Ph.D.

5:15 p.m. – 6:15 p.m.
ABPN Town Hall on Subspecialty Exam and MOC Requirements
Convention Center – Room 7, Upper Level

Attention Epilepsy Specialists - Are you confused about what you need to do to become certified as an Epileptologist? Come and hear about the requirements you are facing for sitting for the Subspecialty exam (starting October 2013) and for the Maintenance of Certification (MOC) cycle that will follow. Dr. Patricia K. Crumrine, AES member and Chair of the Board for the Epilepsy Subspecialty, under the American Board of Psychiatry and Neurology (ABPN) will speak to the upcoming requirements. Also the AES Council on Education (COE) Chairs will speak to what AES is launching to support your efforts to prepare for the exam and become involved in a MOC recertification program, starting with your own “life-long learning” dashboard and self-assessment in the AES Epilepsy Institute.

6:00 p.m. – 7:30 p.m.
> Mentoring Session for Junior Investigators
   Marriott – Point Loma, South Tower, Level 1
   Pre-application required

This program is targeted to fellows, postdoctoral researchers, instructors and assistant professor level junior faculty. Epilepsy professionals at the Associate Professor level will volunteer to serve as mentors. Accepted applicants will meet with their assigned mentors during this time.

7:30 p.m. – 9:00 p.m.
> Special Interest Group Meetings
   Location listed under each session

Epilepsy Surgery Failures
Convention Center – Room 7, Upper Level
Coordinator: Michael M. Haglund, M.D., Ph.D.
Speakers: TBA

The power of the SIG is the participants, but the moderator would also like to thank the brave souls who were willing to put up their difficult cases for debate and analysis. However, this year’s topic will be “Epilepsy Surgery Failures,” so no one will be immune and no case can have a “seizure-free” ending. If you have cases, please email Michael Haglund at michael.haglund@duke.edu. We welcome six or seven cases from around the country to discuss and debate.

Neurostimulation – Neuromodulation in 2012: Update on Basic Science and Clinical Development
Convention Center – Room 14, Mezzanine Level

Coordinators: Christopher M. DeGiorgio, M.D., Erika E. Fanselow, Ph.D.
Speakers: Erika Fanselow, Ph.D., Paul Boon, M.D., Ph.D., Selim Benbadis, M.D., Martha Morrell, M.D.

Neurostimulation for epilepsy continues to expand at an exponential rate, and interest is at a record level. This year, Erika Fanselow will lead our symposium with a look at emerging neuromodulation therapies on the horizon. Paul Boon will explore new and alternative approaches to vagus nerve stimulation now arriving in Europe. Selim Benbadis will lead a debate on the role of implantable VNS at surgical epilepsy centers, as there is great variability in the acceptance and utilization of implantable VNS. Martha Morrell will present new information about therapy optimization and new long-term data from subjects enrolled in the multicenter prospective study of responsive neurostimulation (RNS). We will close with the science of implantable seizure detection and forecasting systems.

Supported by Cyberonics, Inc.

Epilepsy Care in Private Practice Epilepsy Centers: Towards Building a Consortium
Convention Center – Room 10, Upper Level

Coordinators: Marcelo Lancman, M.D., Pavel Klein, M.D.
Speakers: Marcelo Lancman, M.D., Pavel Klein, M.D.

1. Business development and management
2. Clinical research: Independent research collaboration
3. Clinical Research: Pharmaceutical sponsored studies

The focus of the discussion will be establishing a consortium of private practice epilepsy centers which would facilitate exchange of experience, ideas and collaboration and, in the future, advocacy.

Quality, Safety and Value in Epilepsy
Convention Center – Room 9, Upper Level

Coordinator: Jeffrey W. Britton, M.D.
Speakers: Nathan B. Fountain, M.D., Jeffrey W. Britton, M.D.

Demonstration and measurement of quality, safety and value are becoming increasingly important in healthcare. Demands for metrics enabling evaluation of these factors are increasing from healthcare consumers, payors and regulatory bodies. It is expected that establishment of such metrics will stimulate efforts for improvement in the quality, efficiency and value of healthcare. In this SIG, ABPN Maintenance of Certification (MOC) will be reviewed. In addition, an analysis of the value of continuous EEG and therapeutic hypothermia will be presented. Finally, there will be a discussion on the evolving definition of quality in epilepsy care.

Women’s Issues in Epilepsy – Controversies in the Management of Women with Epilepsy
Convention Center – Room 11, Upper Level

Coordinators: Lisa M. Bateman, M.D., Mary L. Zupanc, M.D.
Speakers: Cynthia L. Harden, M.D., Page Pennell, M.D., Georgia Montouris, M.D.

This year’s SIG will focus on areas of controversy in the management of women with epilepsy. Case-based vignettes will be used to form the basis for interactive discussions with an expert speaker panel and audience participants.

registration is not required

8:00 p.m. – 10:00 p.m.
Social Networking Groups
Marriott – Oceanside, South Tower, Level 1

Informal gathering and networking for SIG participants. Space is limited so participants are welcome on a first-come, first-served basis. Roundtable topics to be covered this year will include the role of VNS at surgical centers.
Translational Research

2.001 Rapamycin Suppresses Hippocampal Microglia Induced By Status Epilepticus/A. Brewster, W. Lee, Y. Lai and A. Anderson

2.002 Dendate Granule Cell Mutations Dependent Plasticity Of Mosaic Fibers In Experimental Temporal Lobe Epilepsy/J. Parent, A. Althaus, H. Zhang, E. Messenger and H. Umemori

2.003 Dysregulation Of FMRP Following Early-Life Seizures In Rats And Humans/J. Lippman Bell, M. Lechpammer, S. Francomacaro, E. Rosenberg and F. Jensen


2.009 Human Studies

2.030 mRNA Blood Expression Patterns In New Onset Idiopathic Pediatric Epilepsy/H. Greiner, P. Horn, K. Holland, J. Collins, A. Hershey and T. Glauzer


2.033 Utility Of EEG PPR In Predicting Chronic AED Efficacy: A Double Blind Placebo Controlled Study Of LTG Vs. VPA In JME/P. Timmings and D. Kastelein-Nolst Trenite

2.034 Slow Oscillations Coordinate Functional Connectivity Between Retrosplenial Cortex And Medial Temporal Lobe: Implications For Seizure Propagation And Memory Problems In Patients With Temporal Lobe Epilepsy/A. Kaveh, B. Foster and J. Parvizi

2.035 Overexpression Of Adenosine Kinase In Cortical Lesions From Patients With Tuberous Sclerosis Complex And Cortical Dysplasia Type IIIA/J. Li, F. Zhai, Y. Chen and G. Luan

2.036 Difficulties With Recruitment Of Traumatically Brain Injured Patients For A Prospective Post-Traumatic Epilepsy Study/L. Al-Omaishi, N. Theodore, L. Treiman and D. Treiman

2.037 First Unprovoked Seizure While Driving/N. Hynick, B. Pohlmann-Eden and K. Legg

2.038 Functional Mapping Of The Posteromedial Cortex In Conscious Human Subjects Using Electrical Brain Stimulation/B. Foster and J. Parvizi
Neurophysiology

ICU EEG

2.049 Non-Convulsive Seizures And Non-Convulsive Status Epilepticus In A Neurological Intensive Care Unit: Risk Factors And Outcomes/ I. Laccheo, H. Sonmezturn, J. Barwick, R. Tomyoz, Y. Shi, M. Ringel, G. Dicarlo, B. Abou-Khalil and K. Haas

2.050 Real-Time Segmentation And Inference Of Metabolic State From Burst Suppression EEG Patterns/ M. B. Westerveld, S. Ching, M. Shafi, S. Cash and E. Brown

2.051 Electrographic Seizures Are Common In Infants With Abusive Head Trauma/D. Hasbani, A. Topjian, J. Huh, S. Friess, T. Kilbaugh, C. Christian, D. Dlugos and N. Abend

2.052 Density Spectral Array For Seizure Identification In Critically Ill Children/A. Pensinkul, L. Beslow, S. Kessler, A. Topjian, D. Dlugos and N. Abend

2.053 Value Analysis Of Continuous Versus Routine 20-40 Minute EEG In Patients Undergoing Therapeutic Hypothermia After Cardiac Arrest/ A. Crepeau, J. Fugate, A. Rabinstein, E. Wijdicks, R. White and J. Britton

2.054 The Yield Of CVEEG In Detecting Seizures In A Tertiary Hospital Setting/A. Zilkigt, V. Wasade, L. Schultz, S. Gaddam, B. Assaad, D. Burdette and M. Spanaki

2.055 Automated Detection Of Periodic Discharges In ICU Patients Through Analysis Of Scalp EEG/ J. Chien, S. LaRochet, J. Halford, J. Sackelers, K. Kelly and D. Shiau


2.057 Diagnostic Value Of Continuous EEG In The Treatment Of Sub-Arachnoid Hemorrhage-Induced Vasospasm/ J. Politzky, P. Rodgers and I. Ugorec


Other Clinical EEG

2.059 Ictal Onset: EEG Source Imaging In Pediatric Medically Refractory Epilepsy/R. Arya, D. Rose, K. Holland, H. Fujiiwara and F. Mangano

2.060 Use Of Colored Filters For Assessment Of The Inhibition Of Photoparoxysmal Responses In Children With Primary Generalized Epilepsy In The Outpatient Setting/ A. Faris, J. Higgins, N. Bhamani, S. Kozlik and L. Bello-Espinosa


2.062 Abnormal Mismatch Negativity For Pure-Tone Sounds In Frontal Lobe Epilepsy/A. Matsuda, M. Miyajima, K. Hara, S. Watanabe, Y. Hirose, K. Ohta, T. Maehara, M. Watanabe, H. Hara, M. Matsuura and E. Matsushima

2.063 Human Sleep Spindles Decrease In Frequency When They Coincide With K-Complexes In Patients With Epilepsy/ E. Papathanasiou and S. Papacostas

2.064 Continuous High Frequency Activity: A Peculiare EEG Pattern Related To Specific Brain Regions/ F. Melani, R. Zelmann, F. Mari and J. Gotman

2.065 Spikes With Distinct High Frequency Oscillations Identify Better The SOZ Than HF Power Changes During Spikes/J. Jacobs LeVan, C. Vogt, R. Zelmann, J. Gotman and K. Kobayashi

2.066 Predicting Success Of Vagus Nerve Stimulation (VNS) From Intertectal EEG/C. de Vos, W. van Drongelen, M. Kornman and M. van Putten

2.067 Clinical Yield Of Routine EEG In Adult Patients/A. Mortada, J. Jirsch, S. Ahmed and D. Gross


Brain Stimulation

2.069 Abnormal TMS/EEG Responses In Epilepsy/E. ter Braack, I. Silva Santos and M. Van Putten


2.071 Olfactory Hallucinations Elicited By Electrical Stimulation Via Subdural Electrodes: Effects Of Direct Stimulation Of Olfactory Bulb And Tract/G. Mehta

2.072 Emergence Of Neural Synchrony During Kindling/X. Ren


2.075 Low Frequency Electrical Stimulation Of White Matter Tracts In Intractable Mesial Temporal Lobe Epilepsy/M. Koubeissi, D. Durand, E. Wijdicks, R. White and J. Britton


December 2, 2012
Poster Session 2
8:00 a.m. - 6:00 p.m.
Convention Center – Hall B, Ground Level
Clinical Treatments


2.118 Vagal Nerve Stimulation: Effectiveness In Children With Dravet Syndrome/D. Sirsi and S. Arnold

2.119 Super-Refractory Status Epilepticus (SRSE): Our Experience At A Pediatric Academic Tertiary Care Center/L. Shah, C. Herren and R. Said

2.120 Ketamine Use In The Treatment Of Refractory Status Epilepticus/A. Synowiec, D. Singh, V. Yenugadhati, C. Schramke, J. Valeriano and K. Kelly

2.121 Successful Functional Hemispherectomy In Two Refractory Epileptic Patients With Cerebral Hemiatrophy And Predominant-Contralateral EEG Findings/R. Takayama, K. Imai, K. Baba, Y. Takahashi and Y. Inoue


2.124 Tumor Associated Epilepsy/ J. Juranek, M. Bhattacharjee and B. Weber


2.126 Alternative Therapy And Infection-Related And Conventional Characteristics Between CNS Infections After Temporal Lobe Epilepsy/M. Open Label Study/J. Janousek, G. Mathews, L. Goldman, A. Barber and P. Klein

2.127 Treatment After Acute Seizure In The Emergency Room/J. Ochoa and E. Gore

2.128 Effective Antiepileptic Drugs For Intractable Partial Epilepsies In Children And Young Adults Are Different Among Actual Seizure Syndromes/E. Nakagawa, H. Komaki, Y. Saito, T. Saito, A. Ishiyama, M. Sasaki and T. Otsuki

2.129 Vagus Nerve Stimulation As Treatment For Refractory Status Epilepticus/D. Oronhau, L. Bailey, A. Hernandez, S. Malik, J. Honeycutt and M. Perry

2.130 Long Term Follow-Up In The Outcomes Of A New Onset Seizure Clinic At A Tertiary Care Center/R. Samaraweerad and D. Ficker

2.131 Vagus Nerve Stimulation For The Treatment Of Epilepsy In Children: A Review Based On Epilepsy Syndrome And Seizure Type/D. Holder, M. Tamber and P. Adelson

2.132 Lacosamide Efficacy In Refractory Epilepsy: A Prospective Open Label Study/J. Janousek, G. Mathews, L. Goldman, A. Barber and P. Klein


2.134 Seizures In Newborns With Congenital Heart Disease/M. Aberastury, W. Silva, C. Puga, M. Vaccarezza, C. Maxit and G. Agosta


2.136 Seizure Frequency, Hippocampal Volumes And Memory Impairment In Patients With Mesial Temporal Lobe Epilepsy/D. Pacagnella, T. Lopes, C. Yasuda, F. Cappabianco, A. Coan, M. Vaccarezza, C. Maxit and G. Agosta

2.137 Surgical Treatments For MTLE And Seizure Frequency Can Interfere With Memory Performance/D. Fernandes, T. Lopes, C. Yasuda, B. Damasceno, E. Chizoni, H. Tedeschi, E. Oliveira and F. Cendes

2.138 NREM Sleep Stability Unaffected By Refractoriness Of Epilepsy: A Case-Controlled Cap Analysis Study On Refractory Versus Controlled Epilepsy/G. Shukla, A. Gupta, P. Zanzmera, R. Thomas, V. Srivastava and M. Behari

2.139 Epilepsy Related Death In SCN1A Mutation Positive Dravet Syndrome/A. Brunklaus, R. Ellis, A. Hernandez, S. Malik, J. Honeycutt and M. Perry

2.140 Predictors For Long-Term Seizure Outcomes In Juvenile Myoclonic Epilepsy: 25 – 63 Years Of Follow-Up/J. Geithner, F. Schneider, Z. Wang, R. Herzen, J. Berneiser, C. Kessler and U. Runge

2.141 Comparison Of Clinical Characteristics Of Diffusion Tensor Image In Major Neural Pathways Of Patients With Nonlesional Epilepsy/H. Y. Hsin and T. Harnod

2.142 Trajectories Of Health-Related Quality Of Life In Children With New-Onset Epilepsy/K. Speechley, M. Ferro, C. Camfield, S. Levin, M. Smith, S. Wiebe and G. Zou

2.143 Factor Structure Of The Child Health Questionnaire And Predictors Of Health-Related Quality Of Life In Children With New-Onset Epilepsy/M. Ferro and K. Speechley

Neuroimaging

2.144 Hippocampal And Its Adjacent Regional Atrophy In Mesial Temporal Lobe Epilepsy: Manual Vs. Automatic Segmentation/S. Lim, Y. Kim and Y. Shon

2.145 Cortical Complexity Is Increased In Patients With Cryptogenic Epilepsy/D. Schrader, S. Hong, N. Bernasconi and A. Bernasconi

2.146 Altered Global Structural Brain Networks In New-Onset Pediatric Epilepsy: Increased Segregation And Impaired Integration/K. Dabbs, A. Tabesh, Leonardo Bonilha, B. Herrmann, D. Hsu, C. Stafstrom and J. Lin


2.149 White Matter Pathways In Epileptic Patients/J. Lankford, J. Juranek, M. Bhattacharjee and G. Von Allmen

2.150 Potential Role Of Non-Neoplastic Mesial Temporal Cysts In Temporal Lobe Epilepsy/M. Haykal, C. Wushensky and B. Abou-Khalil

2.151 Surface Based Fractionation Of Cortical Thickness And Identification Of Diffusion Changes In The Epileptic Cortex/R. Munian Govindan, E. Asano, C. Juhasz, J. Sokol and H. Chugani


2.153 Safety Of MRIs Following Disconnection Of VNS Device From Implanted Leads/V. Woodard, J. Boggs and C. O’Donovan

2.154 The Probability Density Characteristic Of Diffusion Tensor Image In Major Neural Pathways Of Patients With Nonlesional Epilepsy/H. Y. Hsin and T. Harnod
**Functional Imaging**

2.155 Measure Of The Thalamic Apparent Diffusion Coefficient In Juvenile Myoclonic Epilepsy/W. Blasque, A. Braga, F. Bellantoni, M. Libardi, D. Kirchner and L. Betting

2.156 Neuroanatomical Abnormalities In Juvenile Myoclonic Epilepsy: A Voxel-Based Morphometry Study/A. Villagran, F. Weermann and B. Pohlmann-Eden


2.166 Decreased Regional Homogeneity, A Measure Of Local Functional Connectivity, In Intractable Focal Epilepsy/K. Weaver, J. Ojemann, A. Poliakov, N. Kleinhans, G. Pauley, T. Grabowski and E. Novotny

2.167 Graph Theoretical Analysis Of Spike And Wave Discharge In Patients With JME/K. Jung, G. Lee, C. Lee, Y. Koo and Y. Cho

2.168 Hippocampal Functioning In Children And Adults With Epilepsy/L. Sepeta, L. Zimmaro, M. Berl, B. Xu, A. D’Alfonso, W. Theodore and W. Gaillard

2.169 Using MEG To Develop A Passive Motor Mapping Protocol For Pediatric Epilepsy Patients/M. McManis, E. Darrow, A. Hernandez, S. Malik, S. Perry, A. Childers, R. Ross, E. Guevara and K. Mooneyham


2.171 Functional Magnetic Resonance Imaging In The Default Mode Network/D. Vaughan, H. Pardoe, R. Masterton and G. Jackson

2.180 A Method To Display MEG Results In 3 Dimensions/J. Paugh, M. McManis, A. Hernandez and S. Perry

**Other Emerging Techniques**

2.172 The Effect Of Clinical Factors On Listening And Reading Language fMRI Paradigms In Patients With Left Hemisphere Focal Epilepsy/K. Miller, M. Berl, L. Zimmaro, W. Theodore and W. Gaillard

2.173 Resting State Functional Connectivity Abnormalities Emerging From The Left Amygdala Are Related To Anxiety And Depression In Right But Not Left Mesial Temporal Lobe Epilepsy/G. Doucet, K. Osipowicz, A. Sharan, M. Sperling and J. Tracy


2.175 Cerebral Hemispherectomy: The Effects Of Repeat Pulse Of Intensive Therapy/S. de Bode


2.177 Thalamic Medial Dorsal Nucleus Atrophy In Medial Temporal Lobe Epilepsy: A VBM Meta-Analysis/D. Barron, P Fox, A. Laird, J. Robinson and P. Fox

2.178 Structural And Functional Connectivity Of Hippocampal Networks In Temporal Lobe Epilepsy/E. Erkurukboyacii, N. KemmotSU, H. Girard, C. Cheng, E. Tecoma, V. Irarqui and C. McDonald


2.181 Atypical Language Representation In Epilepsy Patients/D. Eliašhiv, J. Chung, S. Otis and N. Gage

2.182 Intraoperative 3T MRI With Diffusion Tensor Imaging (DTI) Sequences Improves The Extent Of Disconnection During Callosotomy And Modified Functional Hemispherectomy/J. Cook, P. Chen, M. Korostenskaia, J. Baumgartner and K. Lee

2.183 7 Tesla Magnetic Resonance Spectroscopy In The Assessment Of Patients With Normal 1.5 Tesla MRI Temporal Lobe Epilepsy/S. Nikolova, D. Steven, J. Penner, J. Berne and R. Bartha


**Comorbidity (Somatic And Psychiatric)**

2.185 Pre-Surgical Mood Disorder Is Associated With Worse Post-Surgical Seizure Outcome In Patients With Refractory Temporal Lobe Epilepsy And Mesial Temporal Sclerosis/F. Gomes, G. Filho, L. Mazetto, M. Marinho, I. Tavares, L. Caboco, E. Yacubian and R. Centeno

2.186 Social Relationships And Feeling Of Loneliness In Youth With Epilepsy: Results From A Population-Based Study/K. Alfstad, J. Clench-Aas and M. Lossius

2.187 Clinical And Demographics Characteristics Of A Brazilian Population With Psychogenic Non-Epileptic Seizures/R. Alessi and K. Valente

2.188 Evaluating The Yield And Referral Follow-Through Of Routine Behavioral And Psychological Screening In Epilepsy Care Settings/B. Fisher, C. Dezort and A. Berg


2.190 Adults Versus Teenagers With Psychogenic Non-Epileptic Spells (PNES): Time From Admission To First Event And Annual Presentation/J. Loplumlert, C. Munoz, T. Hirfanoglu, B. Zony, J. Freitas, S. Kosachunhan, L. Tran, S. Rao, M. Khan, T. Syed and E. P. Knight

2.191 An Exploratory Qualitative Analysis Of The Psychological Processes Underlying PNES/L. Macleod, A. McIntosh, S. Berkovic, J. Loplumlert, C. Munoz and T. Hirfanoglu

2.192 Does Hippocampal Sclerosis Correlate With Depression In Patients With Medically Refractory Epilepsy?/A. Velez, E. Gherman and C. Szabo
2.193 Cognitive Profile Of Persons With Temporal Lobe Epilepsy And Comorbid Depression In An Urban Community/A. Sotetanto, J. McGinley and S. Haut


2.195 Correlations Of PHQ-9 With NDDI-E In Epilepsy Patients: A Pilot Study/J. Rathore, G. Tesar, N. Obuchowski, R. Busch, D. Humbel and L. Jehi

2.196 Multifactorial Origin Of Intercital Behavior In Frontal And Temporal Lobe Epilepsy/C. Helmstaedter and J. Witt

2.197 What Is Specific About The Psychological Profile Of Pediatric Patients With PNES/PNEE/? M. Ransby, K. Frampton, K. Nash, A. Ho, M. Connolly and D. Kingdon

Antiepileptic Drugs

Cohort Studies

2.198 Sodium Valproate Is Associated With Parietal Lobe Cortical Thinning And Reduced Brain Volume/H. Pardoe, A. Berg and G. Jackson

2.199 Comparative Effectiveness Of Levetiracetam And Oxcarbazepine As First Drug Monotherapy For Children With Focal Epilepsy/S. Kessler and J. Wilson


2.202 Health Outcomes Associated With Sequential Monotherapy And Combination Therapy With Antiepileptic Drugs In Patients With Pafial Onset Seizures/J. Cavazos, A. Liporace, J. Byun, J. Lim, B. Park, J. Shin and J. Moon

2.203 Lacosamide And Decreased Mortality In Refractory Status Epilepticus: A Comparative Cohort Study/S. Rueegg, S. Marsch and P. Sutter

2.204 Intravenous Ketamine For Refractory Status Epilepticus: A Retrospective Multicenter Study From The Critical Care EEG Research Consortium/J. Sotetanto, J. McGinley and S. Haut

2.205 Impact Of Concomitant Use Of Antiepileptic Drugs And Statins On Risk Of Cardiovascular Events/S. Karve, D. Mitra, K. Rajagopalan, S. Blum, T. Grinnell and V. Bollu

2.206 Adjunctive Retigabine In Drug-Resistant Epilepsy/K. Kelly, L. Stephen, P. Parker and M. Brodie

2.207 Treatment Of Refractory Seizure Clusters And Status Epilepticus With Intravenous Lacosamide: Single Center Retrospective Study Comparing Two Initial Doses: 200 And 400 Mg/B. Legros, C. Depondt, M. Levy-Noguere, L. Nigot, N. Mavroudakis, G. Naeije and N. Gaspard

2.208 Prevalence Of Baseline Hyperosmosia And Association With Initial Antiepileptic Treatment Selection Among Epilepsy Patients/V. Bollu, S. Karve and D. Mitra


Drug Interaction

2.210 Effects Of Enzyme-Inducing AEDs On Lipid Control And Statin Use In Adult Patients With Epilepsy/T. Grabarczyk, B. Gidal, A. Schuna and A. Margolis

2.211 Evaluation Of Efficacy And Safety Of Perampanel In The Presence Of Concomitant CYP3A4-Inducing AEDs: Analyses From The Perampanel Phase 3 Clinical Trials/A. Laurenza, B. Gidal, Z. Hussein, H. Yang, R. Fain, D. Kumar and J. Ferry

2.212 Maintenance Of Valproate And Lamotrigine Efficacy During One Year In A Large Series Of Patients With Drop Attacks/M. Thome-Souza and K. Valente

Drug Side Effects

2.213 Aggression In LGS Patients Treated With Clobazam During The CONTAIN Trial/J. Paolicchi, J. Isojarvi and D. Lee

2.214 Effects Of New Generation Antiepileptic Drugs On Vascular Risk Factors In Newly Diagnosed Epilepsy Patients/ S. Patten, J. Kim and K. Kim

2.215 Somnolence And Sedation Were Transient Adverse Events For Most Patients Receiving Clobazam Therapy During The CONTAIN Study In LGS/B. Renfroe, J. Isojarvi and D. Lee

2.216 Fetal Antiepileptic Drug Exposure And Cerebral Lateralization At Age 6 Years/K. Meador, G. Baker, N. Browning, M. Cohen, R. Bromley, J. Clayton-Smith, M. Kalyanpur, K. Kanner, J. Liporace, P. Pennell, M. Privitera, R. May and D. Loring

2.217 Metabolic Syndrome In Adult Epileptic Patients With Valproic Acid Monotherapy/A. Rakin, T. Egli, T. Rajasalu, M. Lember, S. Köks and S. Haldre

2.218 Oxcarbazepine-Induced Hyponatremia/Y. Kim, S. Lee, K. Chu, J. Byun, J. Lim, B. Park, J. Shin and J. Moon

2.219 Paradoxical Seizures During Treatment With Rufinamide/P. Patel, M. Andriola and R. Spiegel

2.220 Bone Health In Epileptic Pediatric Patients At KFSH/D. Al- Baradie


2.222 Evaluation Of Body Composition With Bioelectrical Impedance Analysis In Epileptic Patients Treated With Valproate/S. Hiz, E. Bayram, Y. Topcu, P. Karakaya, M. Bayram and U. Yis

2.223 Treatment-Emergent Adverse Events By Age For Patients With LGS Treated With Clobazam During Phase II/III Trials/J. Isojarvi, D. Lee and J. Buchhalter

2.224 Cognitive Effects Of Lacosamide/D. Iff, M. Majoe and A. Aldenkamp

2.225 Utility Of A Specific Instrument To Evaluate Antiepileptic Drugs Toxicity/N. de Silva, P. Caballero Murguia, M. Morello, S. Kochen and P. Saadon

Other

2.226 Pharmacokinetics Of N-Demethylclobazam, The Active And Primary Metabolite Of Clobazam/D. Tolbert and I. Bekersky

2.227 Intravenous Lacosamide Is Safe And Effective In Treating Refractory Status Epilepticus In A Critically-Ill Population: A Large Retrospective Case Series/C. Newey and S. Hantus

2.228 Satisfaction With Epilepsy Treatment In Patients With Epilepsy: A Systematic Review/K. Fiest, J. Dykeman, X. Liu, S. Patten, N. Jette and S. Wiebe

2.229 Safety And Efficacy Of Oxcarbazepine In Neonates In The Neonatal Intensive Care Unit/K. James and K. Velayudam

2.230 Treating Status Epilepticus With Lacosamide: A Systematic Review/M. Villafuerte and J. Burneo

2.231 The Effects Of Topiramate And Vagal Nerve Stimulator On Seizure Control And Weight In People With Metabolic Syndrome In Adult Community: Factors Affecting Quality Of Life/C. de la Loge, S. Dimova, V. Bollu, S. Karve and D. Mitra

2.232 Clobazam As An Adjunctive Treatment In Seizures Associated With Lennox-Gastaut Syndrome: Effect On Reducing Seizure Frequency And Medication Burden In The Clinical Setting/G. Deck and G. Montouris

2.272 A Framework For Multimodal Data Representation In The Planning Of Subdural Grid Placement/ M. van ‘t Klooster, J. Veelenturf, G. Huiskamp and F. Leijten


2.274 EEG Findings After Epilepsy Surgery And Its Relation With Outcome/A. Besocke, D. Benech, S. Scalise, E. Cristiano, M. Abarastury, M. Garcia and W. Silva

2.275 Intracarotid Sodium Amobarbital Inactivates Hippocampal Structures/M. Otero, R. Roth, S. Guerin and B. Jobst


2.277 Pre- And Post-Op Activation Of The Motor Cortex In Epilepsy With Hemiparesis And Rolandic Ischemia/ R. Severino, A. Palmini, E. Paglioli, D. Crestani, J. Hoefel, R. Nunes and J. Costa

2.278 Evolution Up To 18 Years After Surgery For Temporal Epilepsy With Hippocampal Sclerosis: Impact Of Technique, Medication Management And Presurgical Variables/D. Crestani, A. Palmini, M. Hemp, E. Paglioli, R. Severino, E. Paglioli, J. Costa, N. Azambuja, M. Portuguese, V. Vlunisky and M. Nunes

Behavior / Neuropsychology / Language

Adult

2.279 Correlation Of Neuropsychological Functioning And PET Hypometabolism In Intractable Mesial Temporal Lobe Epilepsy: Exploring The Concept Of The “Functional Deficit Zone”/A. Knopman, C. Wong, R. Stevenson, J. Homewood, A. Mohamed, E. Somerville, L. Wen, S. Eberl, M. Fulham and A. Blesel

2.280 Quality Of Life And Perceived Social Support In Patients With Generalized Versus Temporal Lobe Epilepsy/J. Thon and M. Hamberger

2.281 Increasing Age And Stimulation Identified Naming Sites/M. Hamberger, A. Williams, G. McKhann and C. Schevon

2.282 Mesial Temporal Activation In Magnetic Source Imaging: Relationship To Word Recognition And Delayed Recall In A Receptive Language Paradigm/G. Risse, R. Doss and W. Zhang

2.283 Skills For Better Support: Developing Self-Regulation Skills Among Patients For Members To Improve The Quality Of Informal Help Provided To Adults With Epilepsy/S. Stoll, A. Gorelick, R. Derry, L. Selwa, R. Kelly and N. Clark

2.284 Prevalence And Predictors Of Mood Disorders, Anxiety Disorders, And Suicide Risk In Women With Epilepsy/P. Patel, N. Foldvary-Schaefer, L. Jehi, G. Tesar and A. Viguera

2.285 Concordance Of Neuropsychological Data With VEEG And Imaging In Presurgical Evaluation/Y. Cukier, S. Schaffer and C. Harden

2.286 The Utility Of The Meyers Neuropsychological System For Use With Spanish Speaking Presurgical Epilepsy Patients/Y. Leon, S. Benbadis and J. Parvizi

2.287 Gender Differences In Non-Epileptic Seizure Seizure Spectrum And Risk Factors/A. Thomas and K. Bujarski

2.288 Numbers And Words In Human Broca’s Area: Electrical Brain Stimulation And Electrocorticography Study/D. Banerjee, L. Demetri and J. Parvizi

2.289 Co-Existing Psychogenic Non-Epileptic Seizures And Epileptic Seizures In An Epilepsy Monitoring Unit: Population: Incidence And Relevance/D. Thomas and A. Krumholz

Pediatrics

2.290 High Gamma Mapping Of Cognitive Tasks With EEGG In Children/O. Rose, H. Fujimura, J. Wilson, H. Greiner, L. Rozikov, J. Buroker, R. Arya and F. Mangano

2.291 Physicians’ Perspectives In Utilizing Neuropsychological Services In Pediatric Patients With Epilepsy/ J. Titus, C. Hovinga, K. Kime, N. Bower, F. Perkins and D. Clarke


2.293 Magnetic Source Imaging And Language Outcome After Pediatric Epilepsy Surgery/E. Adams, F. Ritter and W. Zhang

2.294 The Impact Of Maternal Anxiety About Epilepsy On Restrictions In Childhood Activities/ K. Evankovich, R. Schultz and M. Chapiski

2.295 Arithmetic Skills In Children With Epilepsy: The Role Of Attention, Inhibition, And Medication/ L. Chapiski, K. Hopkins, C. Johnson and M. Hiscock

2.296 Home-Based Computerized Intervention For Working Memory In Pediatric Epilepsy/M. Berl, E. Fisher, L. Sepeta, L. Zimmato and T. Tschida

2.297 Biological Underpinnings Of Social Skill Deficits In Children With Epilepsy/R. Siddarth, J. Levitt, R. Ly, S. Aramburni, R. Sanker and R. Caplan

2.298 Hippocampus Integrity May Not Be Necessary For Semantic Memory: Evidences From Children With Temporal Lobe Sclerosis/ P. Rzezak, C. Guimarães, D. Fuentes, M. Guerreiro and K. Valente

All Ages


2.300 Temporal Cognitive Impairment Due To Hippocampal Intercitial Epileptiform Activity In Humans/ J. Kleen, P. Lenck-Santini, R. Scott, G. Holmes and B. Jobst

2.301 Comparison Of Pre- Versus Post-Surgical Cognitive Functioning In Patients With Hypothalamic Hamartoma And Refractory Epilepsy/J. Wethe, G. Prigatano, J. Gray, K. Chapple, H. Rékat and J. Kernigan


2.304 Typographic Legibility Factors Associated To Reading Epilepsy/ M. Cao-Celestino and I. Rodriguez-Leyva

2.305 Accuracy Of Patients’ Seizure Reporting During Video EEG Monitoring/C. Ezzeani, K. Detyniecki, A. Bauerschmidt, F. Winstanley, R. Duckrow, L. Hirsch and H. Blumenfeld


2.307 Same Place 11 Years Later: A Case Of Test-Retest Reliability Of Cortical Language Mapping/K. Bortnik, G. McKhann II and M. Hamberger
2.345 The Establishment Of Professional Epilepsy Practice, Called "Theatrical Epilepsy Practice," Where There Is No Full-Time Epilepsy Specialist In The Okinawa Island Area, Japan/M. Noha, I. Takumi, J. Kadekawa, E. Takara and A. Teramoto

Epidemiology
2.349 Prevalence Of Epilepsy And Socioeconomic Factors In South Carolina, 2006-2010/D. Wilson, G. Smith and A. Selassie
2.350 Children With Epilepsy And Academic Performance – Are We Doing Enough?/C. Prasad, B. Corbet and A. Prasad
2.351 Clinician Adherence To Practice Parameters On First Nonfebrile Seizure In Children/J. Avallone, A. Patel, N. Baumer, A. Sansevere, L. Doyle, N. Mehta, S. Choi, A. Pinto and T. Loddenkemper
2.353 Seizures At Stroke Presentation Versus Seizures During Hospitalization In Ischemic Strokes: Clinical Characteristics, Risk Factors And Impacts On Outcome/C. Huang, G. Saposnik, J. Fang and J. Burneo

Get Started:
• Go to http://connect.aesnet.org
• Click Login
• Enter your Member login ID# and Password
• Click Go

You can use AES Professional Connection to:
• Connect with colleagues
• Build your network
• Discuss current issues
• Volunteer for Committees
• Participate in Committee and SIG discussion groups
• Share documents
• And more!
7:00 a.m. – 8:30 a.m.
Patient Education for Clinicians
Convention Center – Room 7, Upper Level
Moderator: TBA

The Epilepsy Foundation and the Epilepsy Therapy Project offer numerous provider and patient resources both online and in hard copy that can help patients, their caregivers, and their physicians improve treatment and self-management of this condition. This session will discuss the tools and programs to assist with self-management, patient and physician web events and other programs and resources that are available at no cost through these organizations.

7:00 a.m. – 8:30 a.m.
> Special Interest Group Meetings
Location listed under each session

Ketogenic Diet
Convention Center – Room 9, Upper Level
Coordinators: Elizabeth A. Thiele, M.D., Ph.D., Susan A. Masino, Ph.D.
Speakers: Christina Bergqvist, M.D., Liu Lin Thio, M.D., Ph.D.
Kristina Fengolio-Simeone, Ph.D.

This SIG will be an opportunity to discuss emerging research and clinical perspectives regarding pediatric growth and hormonal changes. Topics include cellular and molecular mechanisms in the hypothalamus within the context of a ketogenic diet as well as the potential role of the hypothalamus in comorbidities such as sleep disorders. Regulating sleep/wake transitions is one of many functions of the hypothalamus, a target of seizure-genic foci via polysynaptic projections. Injury to nuclei within this region could contribute to sleep disorder comorbidities associated with epilepsy. Ketogenic diet-induced changes in hypothalamic regions may directly counteract these and other effects, and may contribute to ketogenic diet’s anticonvulsant and neuroprotective effects.

Neuroimaging – Molecular Imaging
Convention Center – Room 8, Upper Level
Coordinator: Matthias M. Koepp, M.D., Ph.D.
Speakers: TBA

Single Photon (SPET) or Positron Emission Tomography (PET) are vital components in early translation of preclinical evidence to understand the neuropharmacology of epilepsy and comorbidities and to inform development of new treatments. PET/SPET are unique in their ability to measure pharmacological and molecular targets, but the advances made in the last decade as critical tools for translational neurosciences, especially for drug discovery and development, have not translated fully into clinical practice. In the format of a data blitz, this year’s neuroimaging SIG will provide a platform for both clinical and pre-clinical molecular imaging studies presented in the main poster sessions.

Neuropsychology
Convention Center – Room 10, Upper Level
Coordinator: Philip S. Fastenau, Ph.D.
Speakers: Philip S. Fastenau, Ph.D., Bruce P. Hermann, Ph.D., Jana E. Jones, Ph.D., Christoph Helmstaedter, Ph.D., Dipl. Psych., Ingrid E. Tuxhorn, M.B. ChB, M.D., Frank M. C. Besag, M.D., FRCP, FRCPsych, FRCPCH, Pierre-Pascal Lenck-Santini, Ph.D.

Transient cognitive impairment (TCI) refers to disruptions of cognitive functioning associated with interictal epileptiform discharges (IEDs). This has been a subject of steady interest for almost 60 years. TCI has been examined and tested using several methodological approaches, including correlations between IEDs and cognitive performance among people with epilepsy, similar studies in attention-deficit/hyperactivity disorder (ADHD), measuring changes in cognition and behavior following pharmacological interventions to suppress discharges, animal models, and clinical correlations within select epileptic syndromes. In the Neuropsychology SIG, a multidisciplinary group of speakers will discuss some of the major lines of evidence for TCI and discuss the implications for ameliorating cognitive dysfunction in people with epilepsy.

Status Epilepticus – Novel Directions in Refractory Status Epilepticus
Convention Center – Room 11, Upper Level
Coordinators: Tobias Loddenkemper, M.D., Susan T. Herman, M.D.
Speakers: Lawrence J. Hirsch, M.D., Alexander Rotenberg, M.D., Ph.D., Ronan Kilbride, M.D.

Status epilepticus is a life-threatening condition necessitating immediate medical attention and treatment. Specifically, diagnosis, treatment and prognosis of patients with refractory status epilepticus may be difficult depending on the duration, etiology and the underlying condition of the patient. This year’s SIG will focus on refractory status epilepticus. Dr. Hirsch will provide an overview on definitions and available therapeutic options, Dr. Rotenberg will subsequently address mechanisms and novel diagnostic and treatment approaches with electrical and transcranial stimulation, and Dr. Kilbride will provide an update on outcomes in refractory status epilepticus. We are looking forward to another exciting discussion with ample opportunities for audience participation and interaction.

Military Epileptology
Convention Center – Room 10, Upper Level
Coordinator: Jonathan Halford, M.D.
Speakers: Martin Salinsky, M.D., Ryan Rieger, M.H.P.A.

During this SIG, Dr. Martin Salinsky will talk about psychogenic non-epileptic events in veterans. Ryan Rieger will speak about the development of the nationwide Epilepsy Consortium within the VA system. Researchers will explain about the PEARLS and UPLIFT research programs and how they may apply to the practice of epilepsy care.

Neonatal Seizures – Which Treatments Should Be Used for Which Patients?
Convention Center – Room 8, Upper Level
Coordinators: Adam Hartman, M.D., Renee A. Shellhaas, M.D.
Speakers: Raman Sankar, M.D., Ph.D., Ronit Pressler, M.D., Ph.D., Timothy Benke, M.D., Ph.D., Adam Hartman, M.D.

Discussion of the merits and drawbacks of different medicines and treatment approaches with electrical and transcranial stimulation, and tested using several methodological approaches, including correlations between IEDs and cognitive performance among people with epilepsy, similar studies in attention-deficit/hyperactivity disorder (ADHD), measuring changes in cognition and behavior following pharmacological interventions to suppress discharges, animal models, and clinical correlations within select epileptic syndromes. In the Neuropsychology SIG, a multidisciplinary group of speakers will discuss some of the major lines of evidence for TCI and discuss the implications for ameliorating cognitive dysfunction in people with epilepsy.
The Epilepsy Research Benchmarks were established by and for the epilepsy community to guide research toward cures, defined as no seizures and no side effects for people with epilepsy and the prevention of epilepsy in those at risk. The Benchmarks were originally developed in 2000 and updated in 2007, as outcomes of the first and second Curing Epilepsy conferences, and they reflect priorities shared by the NIH, extramural research scientists, epilepsy professional and patient organizations, and people with or affected by epilepsy. We look forward to hearing about progress across all areas of the Benchmarks during this year’s AES meeting, and we hope you will attend the Translational Research Symposium, which will highlight some of these advances (Saturday, December 1, 2:00 p.m. – 4:30 p.m.) Links between symposia and other benchmark topics are noted below.

Story C. Landis, Ph.D.  
Director, National Institute of Neurological Disorders and Stroke

Daniel H. Lowenstein, M.D.  
Chair, Epilepsy Research Benchmarks Stewards

Frances E. Jensen, M.D.  
2012 AES President

University of California, San Francisco

Perelman School of Medicine, University of Pennsylvania

Area I: Prevent Epilepsy and its Progression
Merritt Putnam (Genetics)

A. Identify as yet unrecognized causes of epilepsy (e.g., genetic, autoimmune and infectious).
B. Identify underlying mechanisms of epileptogenesis.
C. Identify biomarkers for epileptogenesis.
D. Identify approaches to prevent epilepsy or its progression.
E. Develop new animal models to study epileptogenesis.
F. Test the efficacy of prevention strategies.

Area II: Develop New Therapeutic Strategies and Optimize Current Approaches to Cure Epilepsy

A. Identify basic mechanisms of seizure generation (ictogenesis) that will lead to the development of cures.
B. Develop tools that facilitate the identification and validation of a cure.
C. Optimize existing therapies and develop new therapies and technologies for curing epilepsy.

Area III: Prevent, Limit, and Reverse the Comorbidities Associated with Epilepsy and Its Treatment

A. Identify and characterize the full range and age specificity of comorbidities in people with epilepsy.
B. Identify predictors and underlying mechanisms that contribute to comorbidities.
C. Determine the optimal treatments for the neuropsychiatric and cognitive comorbidities in people with epilepsy.
D. Prevent or limit other adverse consequences occurring in people with epilepsy.
E. Develop effective methods for diagnosis, treatment and prevention of non-epileptic seizures (NES).

Curing the Epilepsies 2013: Pathways Forward
April 17-19, 2013
NIH Campus, Bethesda, MD

Join investigators and others with an interest in the epilepsies to learn about the latest research developments and to discuss future directions toward cures. A main outcome of the conference will be an update to the Epilepsy Research Benchmarks. Conference Co-Chairs:

Anne T. Berg, M.D.
Northwestern University
Feinberg School of Medicine

Samuel F. Berkovic, M.D.
University of Melbourne

Kevin J. Staley, M.D.
Harvard Medical School

Massachusetts General Hospital

Sponsored by NINDS, in collaboration with: AES, Citizens United for Research in Epilepsy, Epilepsy Foundation, Epilepsy Therapy Project, Finding a Cure for Epilepsy and Seizures, International League Against Epilepsy, National Association of Epilepsy Centers, Tuberous Sclerosis Alliance, and Vision 2020

NINDS Request for Information (RFI)
www.ninds.nih.gov/2013epilepsiesRFI

NINDS welcomes your input on progress made along the Epilepsy Research Benchmarks and on new or unmet scientific opportunities for the years to come. Responses to the RFI will be discussed at the 2013 Curing the Epilepsies Conference.

Please review the 2007 Epilepsy Research Benchmarks Progress Report online and submit your ideas!
Neuropharmacology – Obtaining Extramural Funding for Clinical Pharmacologic Studies in Epilepsy

**Convention Center – Room 11, Upper Level**

**Coordinators:** Scott Mintzer, M.D., Jeannine Conway, Pharm.D.

**Speakers:** Angela Birnbaum, Ph.D., Tracy Glauser, M.D., David Treiman, M.D.

This year’s Neuropharmacology SIG session will focus on practical advice for early- and mid-career clinicians looking to pursue funding for clinical research relating to antiepilepsy drugs. Many have experience working with industry-funded projects but may not know how to translate that to competitive extramural sources. Finding and earning funding for clinical research in epilepsy is challenging particularly at the beginning of an individual’s career. Writing grants tailored to the funding agency is essential, including clear specific aims and a budget that clearly fits the proposal. Our session speakers will provide brief presentations on selecting a funding agency, trials design and statistical analysis (or how to work with a biostatistician), and how to create a budget. Additionally, a speaker will provide insight into the study section role and tips for successful applications and common pitfalls to avoid. There will be time for discussion and questions around the topics. We look forward to an engaging session.

**Pregnancy Registry Outcomes – Global Pregnancy Registry Outcomes**

**Convention Center – Room 9, Upper Level**

**Coordinators:** Autumn Klein, M.D., Ph.D., Elizabeth Gerard, M.D.

**Speakers:** Torbjorn Tomson, M.D., Ph.D. (EURAP), Kimford J. Meador, M.D. (NEAD), Lewis Holmes, M.D. (North American Pregnancy Registry), Sanjeev V. Thomas, M.D., D.M. (India), Terence J. O’Brien, M.D., FRACP, John Craig, M.D.

This SIG updates the work being done around the globe to gather information on pregnancy outcomes in women with epilepsy, with emphasis on antiepilepsy drug–associated effects. Both published and non-published data is discussed.

**Overview**

Addressing the rapidly changing area of the genetics of epilepsy, this symposium will provide a scientific road map for epilepsy clinicians and scientists from gene discovery through therapeutic impact. The symposium will address gene discovery (how mutations / duplications / deletions are identified in populations and in individuals in the clinic); how we determine the functional impact of genetic changes; understanding genetic variability (how the same mutation causes such different phenotypes); genetic information impacts; and a personal and scientific perspective on epilepsy genetics.

**Learning Objectives**

- Recognize and evaluate patients with possible genetic epilepsies for mutations based on current understanding of the genetics of epilepsy
- Manage patients with presumed genetic epilepsy with medication or other treatments based on genetic information
- Provide patients with current information and appropriate counseling regarding genetic epilepsies and their specific syndrome.

**Target Audience**

Intermediate and Advanced (see page 107 for details)
Genetics – Targeted Therapies in Epilepsy

Convention Center – Room 7, Upper Level

Coordinators: Bruce J. Gluckman, Ph.D., Steven J. Schiff, M.D., Ph.D.
Speakers: Greg Gehardt, Paul E. Phillips, Ph.D., Alberto Morales-Villagran, Ph.D., Justin Ingram, Ph.D.

Neurological activity and seizure dynamics are typically observed from a combination of behavior and electrical measures of neural activity in the brain. But we know at the single neuron level that signaling is primarily mediated depending on speaker availability and topic preference. (Note that this description may change at the end of each presentation.

MEG / MSI – Getting Focused With MEG-EEG: The Origin, Propagation or Destination?

Convention Center – Room 15, Mezzanine Level

Coordinators: Anto I. Bagic, M.D., Ph.D., Jerry J. Shih, M.D.
Speakers: Hans Luders, M.D., Ph.D., Patrick Chauvel, M.D., Ph.D., Richard Burgess, M.D., Ph.D.

This year’s MEG SIG will tackle one of the fundamental issues for clinical MEG practice in epilepsy: Are we distinguishing between the true origin of a particular interictal (and ictal) activity and propagated activity or even secondary focus? The program will include three or four featured speakers who will follow a brief presentation and speaker introduction by the coordinator. Presentations will include EEG aspects of the topic, MEG aspects of the topic, and how to combine MEG and EEG effectively while trying to address this cardinal issue. The audience will have five minutes for questions at the end of each presentation.

Neuroendocrinology – Role of Hormones in Epileptogenesis

Convention Center – Room 14, Mezzanine Level

Coordinators: D. Samba Reddy, Ph.D., R.Ph., Jana Velikova, M.D., Ph.D.
Speakers: Massimo Avoli, M.D., Ph.D. (Neurosteroids and epileptogenesis), D. Samba Reddy, Ph.D., R.Ph. (Progesterone and epileptogenesis), Helen E. Scharfman, Ph.D. (Estrogens and epileptogenesis), Libor Velisek, Ph.D. (Glucocorticoids and epileptogenesis)

This SIG will be focused on the emerging evidence of hormonal influence on epileptogenesis, which is a process by which a brain becomes progressively epileptic due to an initial precipitating event of diverse origin such as brain injury, stroke, infections, or prolonged seizures. The mechanisms underlying the development of epilepsy are not very well understood. There is an intense search for drugs that truly prevent the development of epilepsy in people at risk. Steroid hormones play an important role in women with epilepsy. Progesterone, estrogens and neurosteroids have been shown to affect seizure activity in animal models and in clinical studies. However, the impact of hormones on epileptogenesis has not been investigated widely. There is emerging new evidence that progesterone, neurosteroids and endogenous hormones may play a role in regulating epileptogenesis. It is hoped that this SIG discussion may generate new insight on the disease-modifying potential of hormones in epileptogenesis.

4:00 p.m. – 5:30 p.m.

Pediatric Epilepsy Highlights Session

Convention Center – Ballroom 6A, Upper Level

Note: Number below refers to poster assignment

This session will showcase selected scientific abstracts focused on topics in clinical care and research in pediatric epilepsy. Authors will present a six-minute overview of their work. In addition, posters will be on display with authors available in the back of the room from 5:00 p.m. – 5:30 p.m.

1.137 Effect Of Antiepileptic Drugs On Vitamin D Levels In Children/ K. Taylor

1.153 A Double-Blinded, Randomized, Head-To-Head Trial Of Levetiracetam Vs. Sulthiame In Benign Epilepsy With Centrotemporal Spikes/L. Borggraefe

1.154 The Risk And Causes Of Death In Childhood-Onset Epilepsy: A 4-Study Collaboration/A. Berg

1.185 Abnormal Structural And Functional Connectivity In A Specific Thalamocortical Circuit In Juvenile Myoclonic Epilepsy/ J. O’Murcheartaigh

1.223 Efficacy And Safety Of Diazepam Auto-Injection For The Management Of Patients With Epilepsy Who Require Intermittent Medical Intervention Provided By Family Or Caregivers To Control Episodes Of Acute Reptitive Seizures/B. Abou-Khalil

1.247 Treatment Of Infantile Spasms With Very High Dose Prednisolone Before High Dose ACTH/S. Hussain

1.277 Cost Analysis Of Epilepsy Surgery In Pediatric Drug-Resistant Epilepsy/M. Oldham

1.280 Functional Lesionectomy: A Minimally Resective Strategy Effective In Children With MRI-Negative, Intractable Epilepsy/A. Hyslop

1.322 De Novo Gain Of Function KCNT1 Channel Mutations Cause Seizures And Developmental Delay In Malignant Migrating Partial Seizures Of Infancy/G. Barcia

1.332* Neurological, Cognitive And Neuroimaging Outcomes Within 10 Years After Childhood Status Epilepticus: A Population-Based Study/ R. Chin

*Dreifuss Honor – Abstract 1.332 has been selected from all submitted abstracts in honor of Dr. Fritz Dreifuss. The Fritz Dreifuss Epilepsy Fund: Honoring the leadership and passion Dr. Dreifuss brought to the care of his patients, research and the mentoring of young physicians.
There will be three concurrent sessions consisting of selected key scientific abstracts. Authors will present a ten-minute overview of their work followed by a five-minute Q & A.

**Overview**
The epidemiological relationship between Febrile Status Epilepticus (FSE) and Temporal Lobe Epilepsy (TLE) has been known for decades. However, there are major gaps in our knowledge regarding these relationships, preventing us from changing our diagnostic practices and care. Questions include: What is the true probability of developing TLE after FSE? Are there predictive markers for those at risk? Is FSE simply a marker of individuals who are destined to develop TLE, or does FSE contribute to the risk of developing TLE? If FSE does contribute to epileptogenesis, then does this happen only in the setting of a predisposed brain? These questions will be addressed within the symposium, using clinical examples and clinical studies as well as data from animal models. They will help guide clinicians in (a) diagnosing FSE; (b) discussing the significance of FSE with patients and families; (c) managing FSE and febrile seizures (FS) in individuals with a history of FSE.

**Learning Objectives**
- Manage FS/FSE based on knowledge regarding the relationship of FSE duration and the probability of developing TLE after FSE
- Obtain MRIs on children with FSE that allow evaluation of hippocampal volume and T2 measures (indicators of risk for future TLE).

**Target Audience**
Basic, Intermediate and Advanced (see page 107 for details)

**Program**
Chairs: Shlomo Shinnar, M.D., Ph.D., Tallie Z. Baram, M.D., Ph.D.

6:30 p.m.  Introduction and Overview
Shlomo Shinnar, M.D., Ph.D.

6:45 p.m.  What FEBSTAT Tells Us About Febrile Status Epilepticus (FSE) and TLE
Shlomo Shinnar, M.D., Ph.D.

7:25 p.m.  How Might Febrile Status Epilepticus Lead to TLE?
Tallie Z. Baram, M.D., Ph.D.

8:05 p.m.  Biomarkers for FSE-Induced TLE
James O. McNamara, M.D.

8:45 p.m.  Conclusions
Tallie Z. Baram, M.D., Ph.D.

**Credit Designation**
The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nursing Credit**
Nurses may claim up to 2.5 contact hours for this session.

**Pharmacy Credit**
ACPE Universal Activity Number (UAN) is 0052-9999-12-2324 L04-P and provides 2.5 contact hours.

**ABPN Core Competencies**
The American Board of Psychiatry and Neurology has reviewed the Pediatric State of the Art Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Core Competencies: Medical Knowledge, Professionalism, System-Based Practice, Compassionate Patient Care, and Interpersonal and Communication Skills
Monday December 3, 2012  Platform Sessions 4:00 p.m. - 6:15 p.m.

➤ A. Translational Research  
**Convention Center – Room 8, Upper Level**

Moderators: Jana Veliskova, Ph.D., Kristina Simeone, Ph.D.

A.01 Maternal Folic Acid Exposure During Gestation Increases Seizure Susceptibility In Offspring/Michael Colicos, F. Girotto, L. Scott, Y. Avchalamov, J. Harris, R. Tobias, C. Drummond-Main, L. Bello-Espinosa, J. Rho, J. Davidsen, C. Teskey

A.02 A Mouse Model Of Early Onset Epileptic Encephalopathy Reveals A Cellular Defect And Suggests A Targeted Therapeutic Intervention/B. Leav, C. Reid, K. Richards, V. Wimmer, J. Low, E. Thomas, E. Hill, H. Lerche, I. Scheffer, S. Berkovic, S. Petrou

A.03 WIN55, 212 Attenuates NMDA But Not Kainate Intra-Hippocampal Seizures Via mGluR1[6] And CB1 Receptors In Development/L. Friedman, V. Rudenko


A.07 Homeostatic Synaptic Compensation Following Interneuron Loss And Rescue By MGE Progenitor Cell Transplantation In Epileptic DLX1-/ Mice/M. Howard, J. Rubenstein, S. Baraban

A.08 The Preclinical Anticonvulsant Profile Of The Novel Investigational Drug Tonabersat/S. Erood, H. White, P. Blower, M. Halvorsen

A.09 Solute Carrier Transporters In Pharmacoresistant Epilepsy: An Integrative In Silico And Ex Vivo Analysis/N. Mirza, G. Vasieva, R. Appleton, S. Burn, D. de Plessis, J. Farah, V. Jasan, R. Mohanraj, G. Sills, A. Marson, M. Pirmohamed

➤ B. Neuroimaging  
**Convention Center – Room 9, Upper Level**

Moderators: Ruben Kuzniecky, M.D., JerrySZlafszyn, M.D., Ph.D.

B.01 Smaller Subcortical Volumes In Patients With Idiopathic Generalized Epilepsy And Their First Degree Relatives Using FIRST Analysis/F. Chowdhury, J. O’Murchtraigh, G. Barker, M. Richardson

B.02 Reduction Of Structural Hub Regions In New-Onset Pediatric Epilepsy/L. Bonilha, J. Lin, A. Tabesh, K. Dabbas, D. Heu, C. Scafstrom, B. Herrmann

B.03 Hippocampal Abnormality In Community-Based Non Refractory Focal Epilepsy: A Quantitative 12 And Volume Study/G. Jackson, H. Parode, S. Schuele, R. Fulbright, A. Berg

B.04 Are Prolonged Febrile Seizures Associated With Long-Term Changes In Hippocampus? A Quantitative Hippocampal Volumetric Analysis/S. Pujar, M. Martinos, B. Neville, C. Clark, R. Scott, R. Chin

B.05 Multiregional Network Of MRI Structural And Functional Connectivity Changes In Left TLE/ V. Morgan, M. Holmes, X. Yang, B. Landman, Z. Ding, H. Kang, H. Sonmezutuk, B. Abou-Khalil


➤ C. Clinical Epilepsy  
**Convention Center – Room 10, Upper Level**

Moderators: Kimford Meador, M.D., Tobias Loddenkemper, M.D.


C.02 Are High Frequency Oscillations Associated With Altered Functional Network Characteristics/E. van Diessen, J. Hanemaaijer, J. Jacobs, R. Zelmann, F. Jansen, C. Stam, J. Gotman, M. Zijlmans

C.03 High-Frequency Activity And Theta Coupling During Partial Epileptic Seizures/C. Jouny, U. Malinowska, M. Cervenka, G. Bergey

C.04 Correlation Of Osteoporosis Development And Chronic Cerebral Hyperactivity In Epilepsy/B. Wu, L. Lee, J. Grimes, A. Ndumire, M. Wagner

C.05 Do Antidepressants Have An Impact In Seizure Frequency And Psychiatric Symptoms In Patients With Epilepsy/R. Ribot, B. Ouyang, A. Kanner

C.06 Preventing Depression In Epilepsy: Project UPLIFT/N. Thompson, A. Patel, L. Selwa, C. Begley, R. Fraser, E. Johnson, S. Stoll (selected for Goldberg Kaufman Honor*)

C.07 Long-Term Post-Operative Seizure Outcome After Resective Surgery For Epilepsy/V. Wasade, R. Tahir, L. Schultz, B. Smith, K. Elieovich, J. Schwab, M. Spanaki

C.08 Electrocoercitography Of Face And Place Specificity During Visual Naming/C. Conner, C. Kadipasaoglu, T. Pieters, N. Tandon

C.09 Relative Risks Of Spontaneous Fetal Loss In Untreated Versus Untreated Pregnancies In Women With Epilepsy: Initial Analysis Of The Epilepsy Birth Control Registry/A. Herzog, A. Davis, W. Hauser, K. Cahill, K. Fewer, A. Saorta, H. Mandel

* Goldberg Kaufman Honor – Platform C.06 has been selected from all submitted abstracts in honor of Rebecca Goldberg Kaufman. The Rebecca Goldberg Kaufman Ethical Neuropsychiatry Award Fund: Raising the consciousness of the importance of psychiatry in epilepsy care.
0303 Functional Re-Wiring Of Hippocampal Neurons During Post-Traumatic Epileptogenesis/K. Lillis and K. Staley

0304 The Receptor For Advanced Glycation End Products (RAGE) Is Overexpressed In Mesial Temporal Lobe Epilepsy (MTLE) And Contributes To Experimental Seizures And Epileptogenesis/A. Vezzani, V. Iori, M. Carli, R. Vertemara, T. Ravizza, E. Aronica and M. Maroso

0305 A Reorganized GABAergic Circuit In A Model Of Epilepsy: Evidence From CRE-Dependent Labeling In A Somatostatin-CRE Mouse/Z. Peng, C. Huang, Y. Cetina, N. Zhang and C. Hauser

0306 Is The Loss Of Astrocytic Glutamate Reuptake In The Developing Cortex Epileptogenic?/D. Zhou, L. Andresen, A. Taylor, E. Hanson, M. Freeman and D. Cantu

0307 P75 Neurotrophin Receptor Modulation And JAK/STAT Inhibition: Role In The Progression Of Epilepsy In The Pilocarpine Rat Model/ H. Grabenstatter, Y. CruzDelAngel, J. Carlsen, T. Yang, A. White, H. Grabenstatter, Y. CruzDelAngel, J. Carlsen, T. Yang, A. White, M. Salzberg and T. O'Brien

0313 Reduced Cortical GABA-A Receptor Endocytosis In A Mouse Model Of Absence Epilepsy/ M. Gallagher and C. Zhou

0314 Epileptogenesis In TSC: Contribution From GABA_A Receptor Mediated Excitation?/ H. Sun, J. Goto, B. Kosaras, P. Klein, D. Kwiatkowski and F. Jensen

0315 Seizures In Mice Overexpressing The Calcium Channel Receptor Alpha2-Delta1/L. Fania, I. Parada, Z. Lou, B. Barnes and D. Prince

0316 Closed-Loop Optogenetic Control Of Spontaneous Seizures/ C. Armstrong, E. Krook-Magnuson, M. Ojala and I. Soltész


0318 Hypothalamic Aser A Receptor Kinetic Properties To Enhance Postsynaptic Inhibition And To Modify Drug Actions/D. Naylor

0319 Involvement Of Neuronal Phosphotyrosine Signal Adaptor N-SHC In Kainic Acid-Induced Epileptiform Activity/S. Baba

0320 Rapamycin Has Paradoxical Effects On S6 Phosphorylation In Rats With And Without Seizures/ L. Zeng, J. Dong, M. Wong and L. Chen

0321 Progressive Anticonvulsant Resistance During Post-Traumatic Epileptogenesis In Vitro/V. Dhala, Y. Berdichevsky, Y. Saponjian, M. Mail and K. Staley

0322 Unexpected Neuroprotective Effects Of Reactive Oxygen Species In The Central Nervous System: The Role Of The Neurotrophin Receptor, TRKB/Y. Huang and J. McNamara


0329 Tyrosine Phosphorylation Of Voltage-Gated Sodium Channel β1 Regulates Neurite Outgrowth/J. Calhoun and L. Isom

0330 Perventricular Nodular Heterotopia C-FOS Activation In Organotypic Hippocampal Slice Cultures/E. Doisy, J. Wenzel, D. Nguyen and P. Schwarzkozin

0331 TRPC3-Mediated Hyperexcitability And Epileptiform Activity In Experimental Cortical Dysplasia/F. Zhou and S. Roper

0332 Dysregulation Of Voltage-Gated Ion Channel Expression In A Mouse Model Of Cortical Dysplasia/ L. Nguyen, A. Brewster and A. Anderson

0333 Map Kinase Inhibition As A New Therapeutic Target For Intercital Spiking In The Rat/D. Senador, D. Bokmeier, S. Dattloff and J. Loeb

0334 Spontaneous Temporal Lobe Seizures In A Prenatal Freeze Lesion Rat Model/ A. Yamaoda, W. Sun, T. Uehara, K. Takase, H. Shigeto, S. Suzuki, Y. Ohyagi and J. Kira


0336 Regional Expression Patterns Of Candidate Genes Linked To Landau-Kleffner Syndrome/L. Long and E. Powell

0337 Cardiac, Respiratory, And Cortical Function After Electrically-Induced Seizures In Wild-Type And 5-HT Neuron Deficient Mice/ G. Buchanan and G. Richerson


0339 The Effect Of Focal Interictal Spikes During Development On Short-Term Synaptic Plasticity In The Prefrontal Cortex/A. Hernan, J. Barry, R. Scott and G. Holmes

0340 Modeling Electro cortical Source Dynamics Of Intracranial EEG Data In Epilepsy/Z. Acar, T. Mullen, G. Groppe, A. Mehta, G. Worrell and T. Uehara

0341 Evaluation Of Epileptogenesis In Two Different Types Of Status Epilepticus Induced By Electrical Stimulation Of Amygdala/V. Santos, C. Citielli, O. Castro, A. Fernandes, F. Del Vecchio and N. Garcia-Cairasco
3.042 Improving The Development Of Promising Drug Candidates: Preclinical Solutions Developed In Chronic Models Of Epilepsy/ M. Langlois, C. Bouysier, V. Duveau, C. Dumont and C. Roudard
3.044 Looking For Complexity In Epileptogenic Circuits: Can We Build A Common Framework For Computational Models?/J. Tejada, K. Costa, P. Bertitti, A. Roque and N. Garcia-Cairasco

Human Studies

3.045 From Rats To Men: A Virtual Water-Maze Task Shows Cognitive Impairments In Patients With Epilepsy/+T. Titiz, G. Holmes, R. Scott and P. Lenck-Santini
3.046 Evidence Of Increased Neuroinflammation In Human Tuberous Sclerosis Complex: Potential Implications For Neurological Dysfunction/P. Dilsiz, V. Ruppe, H. Weiner, C. Shoshkes Reiss, S. Najjar; J. French, O. Devinsky and D. Talos
3.049 Epilepsy And The Immune System “Is There Antibody There?”/ S. Wright, C.M. Jol-van der Zijde, M. D van Tol, R. Waters, B. Lang, G. Brouwer and A. Vincent
3.050 Linear Pairwise Granger Causality Identifies Ictal Propagation In Patients With Partial Epilepsy/ E. Andrade and Z. Liu
3.051 Differential Recording Of High Frequency Oscillations By Adjacent Micro And Macro Contacts In The Human Hippocampus/B. Esmaeili, V. DeStefano, V. Raghu, W. Wang, A. Popescu, G. Shearing, A. Bagic and R. Richardson
3.052 Altered NMDA And AMPA Receptor Subunit Expression In Cortical Tissue From Autism Spectrum Disorders And Treatment-Resistant Temporal Lobe Epilepsy/ A. Salih, P. Dilsiz, L. Frecska-Horvath, V. Ruppe, C. Shoshkes Reiss, C. Carlson, W. Doyle, Q. Devinsky and D. Talos

3.054 Impaired Expression Of Antiquitin (ALDH7A1) In Radial Glia And Cortical Astrocytes Is Associated With Neuronal Migration Defects In Pyridoxine-Dependent Epilepsy/S. Gospe, R. Hever, W. Roden and L. Jansen
3.055 Clustering Seizures Within And Between Patients Using Hierarchical Bayesian Models/O. Wulun, E. Marsh, B. Porter and B. Litt

Devices, Technologies, Stem Cells

3.057 Validation And Optimization Of Developing Microelectrode Array By An Acute Ex-Vivo Brain Neural Recording System/C. Huang, Y. Hsin, M. Chen, C. Chang, J. Chiou and T. Harnod
3.058 Side Effects Of Vagus Nerve Stimulation During Physical Exercise/O. Mulders, G. de Vos, I. Vosman, M. Driesse and M. van Putten
3.061 Design Of Application Specific Integrated Circuits For RF Powered Neural Recording, And Closed-Loop Electrical Or Optical Stimulation/ S. Lee, K. Qing, J. Joseph, O. Gall, A. Shah, H. Sharma and P. Irazoqui
3.062 Xenotransplantation Of Porcine Fetal Neuronal Stem Cells (PNSCS) In Epilepsy – A Feasibility Study In An Acute Seizure Rat Model/ B. Backofen-Wehrhahn, B. Petersen, S. Broer, M. Gernert, H. Niemann and W. Loscher
3.063 Possible Effect Of Low Current On Transcranial Focal Stimulation Via Tripolar Concentric Ring Electrodes On Behavioral Seizure Activity Induced By Pentyleneetetrazole In Rats/ W. Besio, O. Makeyev and X. Liu

Biomarkers

3.065 Effect Of Valproic Acid And MTHFR C677T Polymorphisms On Plasma Homocysteine Concentrations: Implications For Vascular Disease/A. Prasad, L. Cheng, D. Freeman, F. Mahmoud and M. Rieder
3.067 Functional Connectivity In Intracranial EEG Predicts Surgical Outcome In Intractable Temporal Lobe Epilepsy/A. Antony, I. Burgess, L. Jelé and R. Galan
3.068 Assessment Of Status Epilepticus Severity Using EEG Parameters/A. White, H. Gräbenstätter, J. Carlsten, A. Brooks-Kayal and D. Hinds
3.071 AEDs Reduce The Upper Photosensitivity Limit More Than The Lower Photosensitivity Limit In Photosensitive Patients: Implications For The Design Of The Photosensitivity Model/O. Dasteleijn-Nolst Trenite and R. Reed
3.074 Identification Of Potential Genes Of Absence Epilepsy By MALDI Imaging Using Two Bidirectionally Selected Mouse Lines/B. Martin, M. Lagarrigue, T. Alexandrov, R. Lavigne, G. Dieuset, S. Baulac and M. Portier
3.075 De Novo Generalized Periodic Discharges In Association With Pentobarbital And Propofol Withdrawal/A. Bhattachar D. Chowdary, A. Bhatt, A. Popescu and A. Abou-Khalil

Neurophysiology

ICU EEG

3.076 Micro and Macro Contacts In The Human Hippocampus/A. Bouysier, V. DeStefano, V. Raghu, W. Wang, A. Popescu, G. Shearing, A. Bagic and R. Richardson
3.077 Altered NMDA And AMPA Receptor Subunit Expression In Cortical Tissue From Autism Spectrum Disorders And Treatment-Resistant Temporal Lobe Epilepsy/ A. Salih, P. Dilsiz, L. Frecska-Horvath, V. Ruppe, C. Shoshkes Reiss, C. Carlson, W. Doyle, Q. Devinsky and D. Talos
3.078 Impaired Expression Of Antiquitin (ALDH7A1) In Radial Glia And Cortical Astrocytes Is Associated With Neuronal Migration Defects In Pyridoxine-Dependent Epilepsy/S. Gospe, R. Hever, W. Roden and L. Jansen

Monday December 3, 2012
Convention Center – Hall B, Ground Level
8:00 a.m. – 3:00 p.m.
3.076 Lateralized Rhythmic Delta Activity (LRDAI) On EEG In The Critically Ill Has The Same Significance As PLEDS/L. Hirsch, L. Manganas, N. Rampal, O. Petroff and N. Gaspard
3.077 Prognostic Implications Of Electroencephalogram (EEG) Patterns In Post Anoxic Hypothermic Patients/ S. Gowda, V. Gonzalez-Montoya, L. Kerntsky and L. Morton
3.078 Deterioration In The EEG Following Rewarming In Cardiac Arrest Patients After Mild Therapeutic Hypothermia/A. Shrestha, T. Larabee, L. Frey, K. Polovitz and J. Campbell
3.079 The Ten Minute EEG Using Subdermal Electrodes In The ICU/K. Abou Khaled and S. Farhat
3.082 Nonmetabolic Triphasic Waves And Frontal Rhythmic Slow Activity In Prognosis Of Subarachnoid Hemorrhage/T. Burghardt, W. Mohamed, A. Solaiman, M. Basha and A. Shah
Other Clinical EEG
3.084 Polarized And Lens Color Effects On Photoparoxysmal Response/ E. Kobylarz, M. Otero, S. Rydjeski and R. H. Liong
3.085 Electrocencephalographic Changes And Seizure Outcome Of PRES/Z. Sha, B. Moran, A. McKinney and T. Henry
3.086 How Accurately Can Dense Array EEG Estimate Intercital Spike Source?/M. Yamazaki, M. Terrill, A. Fujimoto, T. Yamamoto and D. Tucker
3.087 The Relationship Between Seizure Onset Zone And Ictal Tachycardia: An Intracranial EEG Study/M. Stefanidou, C. Carlson and D. Friedman
3.088 Ictal EEG Recording In Neonatal Pathology/H. Yamamoto and A. Okumura
3.089 Reorganization Of The Background EEG Underlies Stimulation Induced After Discharge/ G. Kalamangalam
3.091 Drug-Induced EEG Pattern Predicts Effectiveness Of Ketamine In Treating Refractory Status Epilepticus/ A. Aqaila, A. Shah and M. Basha
3.092 24h In-Home EEG After First Seizure In Adults/M. van Putten and J. Askamp
3.093 Forensic Implications Of Ictal Or Pre-ictal Grabbing Behaviors/ M. Spitz, M. Friedman, L. Frey, C. Drees and S. Pearson
3.094 Epileptiform Encephalopathy As A Result Of Psychotropic Medications/T. Beltran Paspard, H. Shin and N. Chahn
3.095 Novel EEG Pattern Associated With Transient Reduction Of Cerebral Blood Flow In Moya Moya Disease (MMD)/S. Lena, M. Boulos, J. Han, D. Mikulis, M. Tymianski, C. Jaigobin and R. Wennberg
Animal Studies
3.096 CELF4 Regulates A Vast Set Of mRNAs, Including Many Associated With Synaptic Function And Homeostatic Plasticity/J. Wagnon, M. Briese, W. Sun, C. Mahaffey, Y. Li, T. Cunk, G. Rot, D. Lin, J. Ule and W. Frankel
3.097 T-Type Calcium Channels Facilitate Neuronal Hyper-Excitability In Epilepsy/M. Patel, D. Gryder, N. Hargus, J. Renger, V. Uebele, E. Perez-Reyes, E. Bertram and A. Nigam
3.098 Early Involvement Of The Contralateral Cortex As A Spatial Organizer Of The Intercital Spikes/D. Vitantonio, W. Xu, J. Wu and G. Motamedi
3.099 The Illusions Of Up-Down State In Epileptic Brain As An Indicator Of Epileptogenicity And Pathological Functional Connectivity In Epileptic Brain/A. Bragin, F. Kheiri, S. Benassi and J. Engel
3.100 Adaptive Wildtype GABAA Receptor Expression, Distribution And Mobility In GABBR3 Knock Out Mice/ J. Kang, O. Magvanjav, Q. Zhang, R. Macdonald and W. Shen
3.101 Pilocarpine Induced Status Epilepticus Modifies Inhibitory And Electrical Synapse To Dentate Fast-Spiking Basket Cells/J. Yu, A. Produttur, F. Elgammal and V. Santhakumar
3.102 Antiseizure Drugs Differentially Modulate Theta-Burst Induced Long-Term Potentiation In C57BL/6 Mice/ P. West, G. Saunders, G. Remigio and H. White
3.103 Computational Modeling Of A Drosophila Motoneuron For Studying Activity-Dependent Splicing Changes Of Sodium Channels That Promote Seizure/C. Gunay, R. Baines and A. Prinz
3.104 Progesterone Suppresses Entorhinal Cortical Epileptiform Activity In Vitro/E. Chow, M. Jeffrey, W. Burnham and L. Zhang
3.105 GABAAergic Control Of The HPA Axis And Seizure Susceptibility/ J. Maguire and M. Panesiti
3.106 Temporal Lobe Epileptiform Activity Following Systemic Administration Of 4-Aminopyridine In Rats/M. Lévesque, P. Salami, C. Behr and M. Avoli
Computational Analysis & Modeling Of EEG
3.109 Automated Detection Of High Frequency Oscillations Using The Damped-Oscillator Oscillator Detector: Correlation With Seizure-Onset Zone/D. Hsu, M. Hsu, B. Brinkmann and G. Worrell
3.110 Differentiating Inter-Ictal And Pre-ictal States: Impact Of Weighted And Directed Short- And Long-Range Interactions In Epileptic Brain Networks/ S. Porz, C. Elger and K. Lehnerzt
3.111 Quantitative EEG (QEEG) Analysis Of The Slow Wave Phase Of Spike And Wave Activity In Treated And Untreated Primary Generalized Epilepsy (PGE)/Z. Fallil and S. Pacia
3.112 Stochastic Behavior Of Phase Synchronization And Cross-Frequency Couplings In The Epileptogenic Zone On Different Days Measured With 256 Channel Intercital Scalp EEG/ M. Holmes and C. Ramen
3.114 Comparison Of Dipole Source Analysis With Intracranial Electroencephalogram For Localization Of The Epileptogenic Zone In Intractable Non-Lesional Epilepsy Patients/B. Mudigoudar, M. Quach, H. Tsai and S. Agadi
3.115 Automated Artifact Detection In Intracranial EEG/B. Brinkmann, V. Vasoli, J. Echauz, B. Litt and G. Worrell
3.116 Retrospective Subdural EEG Source Localization Of The Ictal Onset Zone In Pediatric Epilepsy Surgery/ D. Tarquinio, A. Salah-Eddin, M. Diaz, T. Stewart and P. Jayakar
Clinical Epilepsy
Classification And Syndromes

3.119 Auras In Generalized Epilepsy/
P. Dugan, O. Devinsky, R. Kuzniecky,
R. Fahlstrom and EPGP Investigators

3.120 The Relationship BetweenTemporal Lobe Epilepsy And Restless Legs Syndrome/J. Remi,
V. Thiel, A. de Marinis and M. Mikati

3.121 Infantile Spasms Without Hypsarrhythmia — West Syndrome Variant Or A Different Entity?S. Khan and D. Sirs

3.122 Semiconfusional Striatum Of Generalized Tonic Clonic Seizures And Post-Ictal Electrographic Findings/
C. Carlson, T. Berk, J. French,
R. Kuzniecky, P. Dugan, D. Gazzola and D. Friedman

3.123 Characteristics Of Epilepsy In Neurofibromatosis Type 1 And Association With Mesial Temporal Sclerosis/A. Pecoraro, W. Gallentine,
A. Bunnenberg and D. Tucker

3.124 Early-Onset Versus Typical Childhood Absence Epilepsy: A Retrospective Study Characterizing A Patient Cohort/E. Sell and E. Lewis

3.125 Analysis Of Pregabalin And Lacosamide Using The Post-Marketing Antiepileptic Drug/Device Survey/G. Morris

3.126 Late Onset Rasmussen’s Encephalitis: A Report Of 4 Cases/A. Hartshorn, C. Guardia III,
V. Thadanai, G. Holmes and B. Jobst

3.127 Incidence Of Status Epilepticus Is Increased In Patients With Parkinson’s Disease/B. Feddersen, J. Rémi, M. Einhellig,
C. Stoyke and S. Noachtar

3.128 Improving Seizure Classification Through Structured Interviews And Video Tutorials/J. Remi, V. Thiel, A. de Marrinis and S. Noachtar

3.129 Seizure Duration Differs In Focal Epilepsies/C. Stoyke, J. Remi,
M. Fritsch and S. Noachtar

Clinical Diagnosis

3.130 Functional Analysis Of Epileptic Spike At Focal Cortical Dysplasia With Spatial Filtering Analysis/M. Nakajima,
F. Takeuchi, Y. Ueda, K. Otsuka, T. Ito,
H. Shiraiishi, S. Nakane and K. Takahashi

3.131 Intracerebral EEG Monitoring With Video In Children; Yield And Clinical Utility/E. Segal, M. Lancman,
J. Politsky, O. Laban-Grant, S. Berry and E. Fertig

3.132 Valproate Encephalopathy Mimicking Progressive Myoclonus Epilepsy/D. Andrade

3.133 Ictal Swearing: A Case Series/V. Birca, T. Tayah,
J. Saint-Hilaire and D. Nguyen

3.134 Rasmussen Encephalitis Associated With Myasthenia Gravis/S. Kayani, S. Arnold, M. Dowling,
M. Khan and S. Iannaccone

3.135 Importance Of Intensive Video EEG Monitoring In The Evaluation Of Change In Seizure Semiology In Intractable Epilepsy Patients/B. Kirmami and D. Mungall

3.136 Clinical And Ictal Characteristics In Infants Less Than Two Years Of Age; EEG Correlation Via Long-Term Video EEG Monitoring/J. Lee, V. H. Kim, Y. Jang,
J. Lee and M. Lee

3.137 An Unusual Cause Of EPC/R. Fabris and J. Britton

3.138 The Importance Of Simultaneous ECoG Recording During Routine EEG/ F. Incorvia-Tonin and S. Saygi

3.139 Outcomes Of Long-Term Monitoring For Epilepsy Among Different Adult Age Groups/J. Laine,
A. Bhatt, Y. Shi and N. Azar

3.140 Epileptogenic EEG Patterns In Patients With Gioblastoma Multiforme/T. Wychowski, M. Berg and N. Mohle

3.141 EEG And MEG Spike Source Localization In Patients With Small Focal Cortical Dysplasia/H. Itabashi,
K. Jin, M. Iwasaki, E. Okamura,
A. Kanno, K. Kato, R. Kawashima and N. Nakasato

3.142 Voltage Gated Calcium Channel Antibodies Associated With Subacute Limbic Encephalitis And Seizures/
M. Oller-Cramsie, S. Hwang, N. Mihu,
C. Allen, R. Buchsbaum and H. Choi

3.143 Case Series Of Neuropsychiatric Syndrome With An Initial Diagnosis Of EEG/ J. Menon and E. Ramsay

3.144 Nocturnal Frontal Lobe Epilepsy Presenting As Excessive Daytime Sleepiness/J. Cheng,
D. Wallace, M. Lopez and E. Carranza

Clinical Treatments

3.145 Outcome Of Ketogenic Diet Experience At Kuwait/A. Al Taiwain,
N. Al Qaoud and L. Heberle Cindro

3.146 High Dose Magnesium In Treatment Of Refractory Epilepsy/R. Askamp and M. van Putten

3.147 Establishment Of Seoul National University Hospital Epilepsy Registry (SNUHER)/Y. Kim, S. Lee,
K. Chu, J. Byun, J. Lim, B. Park,
J. Shin and J. Moon

3.148 Safety And Efficacy Of High-Dose Diazepam For Treatment Of Electrical Status Epilepticus During Slow Wave Sleep/E. Gertsch,
K. Charron, R. S. Olson, K. Park,
K. Knupp and S. Koh

3.149 Reporting And Publication Of Randomized Trial Abstracts At The American Epilepsy Society Meeting/R. Das and K. Mehta

3.150 Reported Management Decisions In (Suspected) Epilepsy/ J. Askamp and M. van Putten

3.151 Case Report: Vagal Nerve Stimulation (VNS) And Late Onset Asystole/V. Olotu, R. Shankar,
N. Coles, H. Sullivan and C. Jory

3.152 Autism, Seizures And Epilepsy/E. Obrien, A. Francis,
C. Allen, K. Kelley and J. Hageman

3.153 High Dose Oral Steroid As Successful Initial Treatment For Infantile Spasms: Follow-Up Of Seven Cases/S. Adhami and C. Harini

3.154 Epilepsy Surgery In MRI-Negative Sound-Induced Startle Epilepsy/N. Riggins, P. Li, V. Li,
D. Farooq and A. Weinstock

3.155 Outcomes In Epilepsy Patients On High Dose Levitiracetem/K. Dempsey, L. Hirsch, C. Ezeani,
R. Buchsbaum and H. Choi

3.156 Episodic Autobiographical Dysfunction In Transient Epileptic Amnesia: Effectiveness Of Antiepileptic Drugs/T.Packard, M. Wagner and D. Bachman

3.157 Treatment Of Seizures In Schizencephaly May Improve Clinical Outcome/M. El-Hagrass, K. Werner

3.158 Seizure Prophylaxis In Benign Focal Epilepsy Of Childhood With Centroteemporal Spikes/T. Heard,
C. Harini, J. Girard, K. Boyer and M. Takeoka

3.159 Vagus Nerve Stimulation In Treatment-Resistant Epilepsy: Long-Term Outcome/J. Dean, R. Pavelock

3.160 Cerebral Hematoma And Spontaneous Obliteration Of Cerebral Angiomasis Sturge-Weber Syndrome/Y. Ikuma, M. Nakajima,
H. Sugano, T. Higo and H. Arai

3.161 Effectiveness Of Polytherapy Of VPA Plus LTG In Childhood Absence Epilepsy/J. Bin and T. Eom

3.162 Progression To Infantile Spasms In An Infant With Tuborous Sclerosis On Vsgabatin And Everilimus: A Case Report And Review Of Literature/S. Verma and C. Marcuccilli

3.163 Rasmussen’s Encephalitis: A Wobbling Glass, Half Full/Y. Eksioglu

3.164 Early Exposure To Carbamazepine, Oxcabazepine, Phenytoin, And Lamotrigine In Epilepsy With Myoclonic-Atonic Seizures Associated With Worse Outcome/S. Nangia, J. Millichap,
A. Berg and N. Turri

3.165 Postoperative Cognitive Performance And Seizure Control Are Similar After Selective Amygdalophipocampectomy Or Anterior Temporal Lobe Resection In Patients With MTLE And Hippocampal Sclerosis/J. Lopes, D. Fernandez, C. Yasuda,
E. Ghizoni, H. Tedeschi, E. Oliveira and F. Cendes

Prognosis

3.164 Early Exposure To Carbamazepine, Oxcarbazepine, Phenytoin, And Lamotrigine In Epilepsy With Myoclonic-Atonic Seizures Associated With Worse Outcome/S. Nangia, J. Millichap,
A. Berg and N. Turri

3.165 Postoperative Cognitive Performance And Seizure Control Are Similar After Selective Amygdalophipocampectomy Or Anterior Temporal Lobe Resection In Patients With MTLE And Hippocampal Sclerosis/J. Lopes, D. Fernandez, C. Yasuda,
E. Ghizoni, H. Tedeschi, E. Oliveira and F. Cendes
3.166 Severity Of Epilepsy And Cognitive Functioning In Children With Epilepsy: A Prospective Study Of Family Factors As Mediators And Moderators/A. Lambrozos, W. Avison, G. Zou and K. Speakley
3.167 Prognosis In Partial Status Epilepticus/M. Kawai, B. McQueen and A. Verma
3.168 Mortality And Recovery From Refractory Status Epilepticus: A 7-Year Observation/R. Sutter, S. Hensch and S. Ruegg
3.169 Investigation For Increased Risk Of Seizures In Post-Surgical Roux-En-Y Gastroplasty Patients/P. Spritzer, M. Hoehr, J. Hentz, J. Madura and J. Drzakowski
3.171 Are Patients With Postictal Psychic Episodes At Increased Risk For Developing Psychiatric Comorbidities After Epilepsy Surgery?/S. Louis, M. Basha, S. Mittal, J. Lobe and A. Shah
3.172 Epidemiology, Aetiology And Treatment Outcomes Of Status Epilepticus In Lithuania/R. Mamenskiene, A. Jasionis and V. Budrys
3.173 The Clinical Characteristics Of Cryptogenic NORSE (New-Onset Refractory Status Epilepticus) Syndrome/B. Kim and S. Lee
3.174 Long Term Outcomes Of Infantile Spasms In Korea/J. Kim, J. Kang, Y. Lee, H. Kang, H. Kim and J. Lee

Neuroimaging Animal Studies
3.176 In Vivo Simultaneous Calcium And Intrinsic Signal Imaging Of 4-AP Ictal And Interictal Events Demonstrate Dynamic Neurovascular Coupling During Ictal But Not Intercital Events/H. Ma, S. Harris, M. Zhao and T. Schwartz
3.177 Optical Coherence Tomography Detects Cortical Optical Changes Associated With PTZ-Induced Seizure Activity/D. Binder, M. Eberle, C. Reynolds, J. Zuo, Y. Wang, M. Hsu and B. Park
3.178 Multiphoton Imaging Of Neuronal Projections Deep Within The Intact Mouse Hippocampus/ B. Hosford, J. Krofon and S. Danzer

Structural Imaging
3.180 Imaging Gray Matter Microstructure In Vivo Predicts Neuropathology In Epilepsy/J. Juranek, M. Bhattacharjee, J. Lankford and G. Von Allmen
3.181 The Complementary Role Of MRI Post-Processing And EEG In First Seizure And New Onset Epilepsy/C. Crocker, M. Schmidt, K. Legg, M. Blanchard and B. Pohlmann-Eden
3.182 Voxel-Based MRI Post-Processing In MRI Negative Refractory Epilepsies With Pathologically Confirmed Focal Cortical Dysplasia: Pilot Data On 20 Patients And 20 Controls/Z. Jaisani, I. Wang, S. Song, I. Najm and A. Alexopoulos
3.183 Quantifying The Contribution Of Thalamic Volume And White Matter Microstructure To Regional Cortical Thinning In Mesial Temporal Lobe Epilepsy (MTLE)/H. Girard, N. Kemmotsu, N. Kuckuboyaci, E. Tecoma, V. Iragui and C. McDonald
3.184 Seizure-Onset Age And Drug-Resistance Are Predictors Of White Matter Changes In Patients With MRI-Negative Epilepsy/S. Peng, Y. Hsin and T. Harnod
3.188 Grey And White Matter Brain Volumes And Intelligence: Differences Across Epilepsy Syndromes/ D. Jackson, K. Dabb's, J. Jones, D. Hsu, C. Szarfstorm, M. Seidenberg and B. Herrman
3.190 Correlative Disintegration In White Matter And Cortical Volume Loss Of Deep Gray Matter In Patients With Juvenile Myoclonic Epilepsy/ S. Kim, Y. Shon, S. Lim, Y. Kim and W. Kim
3.191 Is There A Causal Link Between Tumefactive Virchow-Robin (VR) Spaces And Epilepsy?/ B. Bhatia, B. Sitwat and K. Petropoulou

Functional Imaging
3.192 Scalp Ripples Are Associated With Thalamic Bold Changes/F. Fahoum, F. Melani, L. Andreade-Valencia, F. Dubeau and J. Gotman
3.193 Patterns Of fMRI Hippocampal Lamellar Activity Associated With Perforant Path Stimulation In The Kainic Acid Rat Model Of Epilepsy/ S. Jaime, T. Duong and J. Cavazos
3.194 Reduced Default Mode Network Connectivity In Idiopathic Generalized Epilepsy With Uncontrolled Seizures/B. Kay, M. DiFrancesco, S. Holland and J. Szafarski
3.196 Propagation Of Interictal Activity In Frontal Lobe Epilepsy: A MEG-DTI Study/E. Castillo, Z. Li, G. Von Allmen, J. Slater and A. Papanicolaou
3.197 1H-Magnetic Resonance Spectroscopy In The Assessment Of Epileptic Malformations Of Cortical Development/J. Buneo, S. Nikolova and R. Berntson
3.198 EEG-fMRI Study In Epileptic Patients With Periventricular Nodular Heterotopia/J. Koo Kang, E. Lee, S. Oh and H. Park
3.199 Is SISCOM (Subtraction Ictal SPECT Co-Registered To MRI) Helpful To The Successful Surgery In Inseional Extra-temporal Epilepsy/? P. Song, E. Joo, D. Seo, D. Koo and S. Hong
3.201 Attenuated And Augmented Emotional Face Processing Networks In Temporal Lobe Epilepsy/B. Fling, J. Riley and J. Lin
3.202 Language Activity In Epileptic Patients Represented By Magnetoencephalography Using Auditory Word Presentation/ N. Suzuki, N. Tanaka and S. Stufflebeam
Antiepileptic Drugs
Mechanisms of Action
3.207 Brivaracetam Has A Time- And Stimulation-Dependent Effect On Synaptic Transmission/X. Yang, S. Rothman and J. Dubinsky

Clinical Trials
3.223 A Retrospective Data Analysis Of Levetiracetam As Initial Monotherapy In Pediatric Epilepsy Patients/A. Hunnicutt, A. Morales, R. Blouin, E. Foster and M. Patel
3.224 Use Of Rescue Medications By LGS Patients Treated With Clobazam During The CONTAIN Trial/D. Lee, W. Rosenfeld and J. Isojarvi

Animal Studies


3.214 Initial Polytherapy For Status Epilepticus/C. Wasterlain, R. Baldwin, L. Suchomelova and J. Niquet

3.215 Effects Of The NKCC1-Inhibitor Bumetanide In The Kindling Model Of Temporal Lobe Epilepsy In Rats/M. Tzerer, K. Toellner, C. Brandt and W. Loescher

3.216 Synergistic Effects Of Perampanel Combined With Diazepam In The Lithium-Pilocarpine Rat Model Of Status Epilepticus/T. Hanada and K. Ido

3.217 Neuroprotective Effect Of Lacosamide On Hypoxic-Ischemic Brain Injury In Neonatal Rats/G. Ktn, J. Byeon, S. Eun and B. Eun

3.218 A Moderate-Throughput In Vitro Screen For Antiepileptogenic Compounds/Y. Saponjian, Y. Berdichevsky and K. Staley

3.219 Influence Of The First Line Treatment On The Prognosis Of Epilepsy In A Mouse Model Of Absence Epilepsy/A. Biraben, L. Javadin, F. Wendling and B. Martin

3.220 Allopregnanolone Treatment In A Rat Pediatrisk Status Epilepticus Model: Comparison With Diazepam/ C. Lossin, S. Shahangian and M. Rogawski

3.221 Perampanel Terminates Diazepam-Resistant Status Epilepticus In A Lithium-Pilocarpine Rat Model/K. Ido and T. Hanada

3.222 Effect Of Perampanel In Combination With AEDs In Amygdala Kindling Model/T. Wu and T. Hanada

Clinical Trials
3.223 A Retrospective Data Analysis Of Levetiracetam As Initial Monotherapy In Pediatric Epilepsy Patients/A. Hunnicutt, A. Morales, R. Blouin, E. Foster and M. Patel
3.224 Use Of Rescue Medications By LGS Patients Treated With Clobazam During The CONTAIN Trial/D. Lee, W. Rosenfeld and J. Isojarvi

3.225 Withdrawn


3.227 Experience Of Efficacy And Tolerability With Lacosamide As Monotherapy In Pediatric Patients With Partial Epilepsy/E. Barragan and M. Herrera


3.230 Synergistic Effects Of Perampanel Combined With Diazepam In The Lithium-Pilocarpine Rat Model Of Status Epilepticus/T. Hanada and K. Ido


3.232 Assessment Of Pharmaceutical Quality Of Brand And Generic Lamotrigine Tablets/S. Raman, S. Vaithianathan, J. Wong, T. Ting, W. Jiang, M. Kane and J. Polli

3.233 Establishing Maximum Tolerated Dose And Dose-Proportionality In Extended-Release Topiramate (USL255)/L. Lambrecht, T. Braun, W. Todd and M. Halvorsen

3.234 Evaluation Of Long-Term Treatment With Lacosamide For Partial-Onset Seizures In The Elderly/W. Rosenfeld, C. McShea and P. Doty

3.235 Response To Clobazam In VNS Vs. Non-VNS Patients: Post-Hoc Subgroup Analysis Of CONTAIN/ S. Benbadis, J. Isojarvi and D. Lee

3.236 Withdrawn


3.238 Pharmacokinetics Of USL261, A Novel Formulation Of Intranasal Midazolam/L. Bancke, H. Dworak and M. Halvorsen

3.239 Safety And Pharmacodynamics Of USL261, A Novel Formulation Of Intranasal Midazolam/H. Dworak, L. Bancke and M. Halvorsen

3.240 Clinical Outcome Of Levetiracetam For Epilepsy Patients/ T. Yamazoe, A. Fujimoto, H. Enoki, T. Yokota and T. Yamamoto


Cohort Studies
3.242 Rufinamide Dosing Patterns In Commercially-Insured Pediatric And Adult Patients/E. Silva, J. Margolis, Z. Wang, R. Copher and D. Labiner

3.244 Outcome Of Status Epilepticus In Patients Treated With Lacosamide/
N. Thakur, O. Laban-Grant, C. Lambrosikis,
S. Mesad, J. Politsky, E. Feoli, M. Evans,
S. JeanBaptiste-Berry, E. Segal,
E. Fertig and M. Lancman
3.245 Current Usage Of Perioperative Antiepileptic Drugs For Surgical Cases Of Supratentorial
Tumor/T. kunieda, Y. Arakawa, T. Kikuchi,
Y. Yamao, S. Shibata, R. Inano,
R. Matsumoto, A. Ikeda, N. Mikuni,
R. Takahashi and S. Miyamoto
3.246 Treating Epilepsy In Canada: An Observational Study Of Antiepileptic Drug Use/M. Freeman, D. Dhalla and
J. Alfonso Ross Terres
3.247 Clinical Effectiveness Of Eslicarbazepine Acetate (Zebinex) As An Add-On Therapy In Localization Related Epilepsy Over 12 Months/
D. Demodaran, J. Rigby, P. Cooper and
R. Mohanraj
3.248 Comparison Of Treatment Duration Of Antiepileptic Drug Combination Therapies Based On Mechanism Of Action In Partial Onset Seizures/Z. Wang, J. Mangolis,
R. Copher and J. Cavazos
3.249 New Antiepileptic Drugs In Newborns/C. Maxit, M. Aberastury, C. Vazquez Dusefante, I. Denzel,
M. Vaccarezza, W. Silva and G. Agosta
3.250 Early Efficacy With Adjunctive Lacosamide Treatment In Patients With Uncontrolled Partial Seizures: Analysis Of Mean Percentage Of Seizure-Free Days Per Week/C. McShea, M. Polinkovsky, S. Dimova,
P. Doty, M. DeBacker and S. Chung
3.251 Postmarketing Experience With Lacosamide As Add-On Therapy In Refractory Partial Onset Epilepsy In Slovakia/G. timarova, S. Mehesova and
E. Feketeova
3.252 Ornithine Decarboxylase And Self-Reported Side Effects Of Antiepileptic Drugs In Patients With Epilepsy At Tertiary Referral Center In Austria/E. Pataraia, R. Jung,
S. Bonelli-Nauer, K. Trimell and
S. Aull-Wattschinger
3.253 Efficacy And Tolerability Of Lacosamide In Nocturnal Seizures/B. Gonzalez Giraldez, S. Bellido Cuellar,
C. Aleran Marcollio and J. Gerratosa
3.254 Vitamin D Status In A Pediatric Outpatient Neurology Setting/J. Conry, J. Reese and D. Kassaye
3.255 Benefits Of Conversion From Immediate Release Lamotrigine To Extended Release Lamotrigine In Individuals With Drug-Resistant Epilepsy Or Adverse Effects/M. Osborn, P. Ramey and B. Abou-Khalil
3.256 Determining Minimal Important Change Thresholds For The Seizure Severity Questionnaire (SSQ) In Clinical Trials/J. Cramer, C. de la Loge,
Y. Brabant and S. Borgis
3.257 The Responsiveness Of Seizure Severity Questionnaire (SSQ) Items To Change In Seizure Frequency By Type/S. Borgs, C. de la Loge,
Y. Brabant and J. Cramer
3.258 Tolerability Of Overnight Switch From Oxcarbazepine To Eslicarbazepine Acetate/J. Höfler, J. Dobesberger,
M. Leitinger, C. Granbichler,
T. Moroder and E. Trinka
3.259 Valproate But Not Levetiracetam Alters Systemic Immune Parameters In Epileptic Patients/S. Guenther, S. Bauer,
M. Nowak, B. Tackenberg, W. Oertel,
F. Rosenow and H. Hamer
3.260 Cost-Utility Analysis Of Lacosamide Adjunctive Therapy In The Treatment Of Patients With Refractory Epilepsy In Canada/H. Benhaddi, C. Vicente and R. Tam
3.261 Equivalence Among Benzodiazepines Including Clonazepam: A Survey Of Epileptologists/N. Rincon Flores and S. Benbadis
3.262 Antiepileptic Drugs And Adherence: A Critical Review/A. Economos, J. Cheng and
e. Carrazena
3.263 Are Plasma Levels Of Lacosamide Of Any Value/? B. Pedersen and J. Rasmussen
3.264 Efficacy And Tolerability Of Adjunctive Eslicarbazepine Acetate In Adults With Drug-Resistant Focal Epilepsies In A Portuguese Epilepsy Center/A. Breia Neves and N. Ferreira
3.265 Recruiting Elderly Nursing Home Subjects For Antiepileptic Drug Studies/A. Birnbaum, J. Rarick, T. Pettus,
A. Breia Neves and N. Ferreira
3.266 Anterior Temporal Lobe Disconnection In Mesial Temporal Lobe Epilepsy/S. Abdul Qayyum, K. Siddiqui,
e. Khanal, A. Sabbagh, L. Soualim and
S. Sinha
3.267 Long-Term Outcome After Multiple Hippocammpal Transsection For Temporal Lobe Epilepsy/K. Usami,
K. Kawai, M. Kubota and N. Saito
3.268 Executive Functions Are Processed In The Area Of Anterior Nucleus Of Thalamus. An Intracranial Recording Study. Rector, M. Bockova,
J. Chladek, P. Jurak, J. Halamek,
J. Stillova, M. Balaz and J. Chrustina
3.269 Epilepsy Surgery In Patients With Epilepsy And Neurocysticercosis/ A. Escalaya, J. Cheng and
M. R. McLachlan, S. Mirsattari, D. Wehner,
B. Diehl, A. McEvoy and J. Duncan
3.270 Improved Outcomes With Earlier Surgery For Intractable Frontal Lobe Epilepsy/T. Simasathien,
S. Vadera, W. Bingaman and L. Jehi
3.271 Surgical Indication, Procedure And Postoperative Course Of Hippocammpal Transction/T. Uda and
M. Morino
3.272 Epilepsy Surgery In Patients With Malformations Of Cortical Development And Hippocammpal Abnormalities/G. Kuchukhidze,
S. K. Unterberger, J. Dobesberger,
G. Walser, E. Haberlandt,
F. Koppelstaetter, H. Maier, M. Ortler,
T. Czech, M. Feucht, G. Bauer and
E. Trinka
3.273 Improvement Of Outcome After Hippocammpal Surgery For Temporal Lobe Epilepsy/K. Usami
3.274 Postoperative Evolution/ J. Dobesberger, M. Nowak, B. Tackenberg, W. Oertel,
J. Dobesberger, M. Kirschner,
J. Mielke, T. McCarthy and I. Leppik
3.275 The Responsiveness Of Seizure Severity Questionnaire (SSQ) Items To Change In Seizure Frequency By Type/S. Borgs, C. de la Loge,
Y. Brabant and J. Cramer
3.276 Efficacy And Tolerability Of Lacosamide In Epilepsy Or Adverse Effects/P. Ramey, E. D. Segal,
E. Fertig and M. Lancman
3.277 Surgical Outcomes For Refractory Partial Epilepsy: A Review/ D. Vannan, E. Bubrick and B. Dworatzky
3.278 Surgical Treatment For Generalized Epilepsy: Experience From A Large Comprehensive Canadian Epilepsy Program/D. Steven, J. Burneo,
R. McLachlan, S. Mirsattani, D. Diosa,
A. Parrent, W. Blume, S. de Ribaupeire and
K. MacDougall
3.279 Efficacy Of Vagus Nerve Stimulation In Brain-Tumor Associated Intractable Epilepsy And The Importance Of Tumor Stability/K. Patel,
N. Moussazadeh, C. Gordon,
K. Hassnain, D. Labar, W. Doyle and
T. Schwartz
3.284 Safety And Vascular Consequences Of Operculo-Insular Cortectomy For Epilepsy/P. Finet, L. Crevier, D. Nguyen and A. Bouthillier


3.287 A Method To Co-Register Interoperatively Placed ECoG Grids With The Cortical Anatomy/D. Gupta, M. Adamo, A. Ritaccio and G. Schalk

3.288 Efficacy And Safety Of Vagal Nerve Stimulation For Intractable Epilepsy At Riyadh Military Hospital/S. Khan, A. Osman, K. Hussein, F. Al Qubati, S. Santos and D. Al Shammary


3.290 The Outcome Of 32 Vagus Nerve Stimulation Cases (VNS)/A. Fujimoto, T. Yamazoe, T. Yokota, H. Enoki, Y. Sasaki, M. Nishimura and T. Yamamoto

3.291 Cerebral Edema And Hemiation During Invasive EEG Monitoring May Be Associated With Good Outcome And Amelioration Of Seizures/J. Oster

Behavior / Neuropsychology / Language

3.292 Neuroticism And Executive Function In Drug Refractory Juvenile Myoclonic Epilepsy/R. Thomas, A. Marson, P. Smith, M. Rees, G. Baker and J. Walsh


3.294 Long-Term Effects Of Temporal Lobectomy On Accelerated Long-Term Forgetting In Mesial Temporal Lobe Epilepsy/C. Ozkara, L. Hanoglu, S. Gonenc, E. Ozmansur and M. Uzan

3.295 Gender, Subjective Memory, And Objective Memory Among Patients With Epilepsy/R. Trolinger, E. Feili, M. Lancman and M. Lancman

3.296 Prediction Of Cognitive Response By Model-Based Simulation Of Generative Verbal Fluency Scores After A Single Dose Of Topiramate In Healthy Volunteers/S. Marinoff, C. Ahmed, R. Brundage, S. Pakhomov, I. Leppik and A. Birnbaum

3.297 Driving And Epilepsy: Perspectives Of Patients With Epilepsy In Southwestern Nigeria/T. Sunmonu, M. Komolafe, O. Afolabi and O. Ogundin


3.300 Use Of Caffeine During Intra-Artinal Amobarbital Procedure (IAP)/L. Schrader, J. Horsfall and J. Stern


3.302 Unveiling The Mystery Of Déjà Vu/M. Brazdil, R. Marecek, T. Urbanek, T. Kasparek, M. Mikl, I. Rektor and A. Zeman

Pediatrics

3.303 Hippocampal Asymmetry And Memory Performance In Children Following Prolonged Febrile Seizures/M. Martinez, S. Pujan, R. Scott, R. Chin and M. de Haan

3.304 Childhood Absence Epilepsy: Correlation Between Seizure Frequency And Neuropsychological Profile/L. Bello-Espinosa, J. Rho, A. Datta, B. Minassian and M. Scantlebury

3.305 Age Of Seizure Onset Predicts Reduced Adaptive Functioning In Pediatric Epilepsy/A. Carbonell, M. Westerveld and C. Salinas

3.306 Associated Factors With Poor Adherence To Treatment In Adolescent Patients With Epilepsy/M. Gutierrez Cenizeros and E. Barragan Perez

3.307 Neurocognitive Trends In Bilingual Versus Monolingual Pediatric Epilepsy Patients/M. Connolly, A. Hanratty, G. Mucci, A. Martinez, M. Zupanc and J. Lin

3.308 Factors Of Emotional And Behavioral Problems In Pediatric Epilepsy/S. Eom, K. Oh and H. Kim

3.309 The Accurate Diagnosis And The Clinical Outcomes Of Nonepileptic Paroxysmal Events In Pediatric Patients/Y. Yoon Young, K. Hyo Jung, K. Heung Dong, L. Joon Soo, L. Young Mock and K. Hoon-Chul

3.310 Receptive And Expressive Language Functioning In Bilingual And Monolingual Pediatric Epilepsy Patients/G. Mucci, A. Hanratty, M. Connolly, A. Martinez, M. Zupanc and J. Lin

3.311 Significant Impact Of Behavioral Problems On Quality Of Life In Hispanic Urban Children With Epilepsy/A. Partikian, A. Sandoval, L. Hoang and S. Steward

Genetics


3.313 Chromosomal Microarray Is High Yield For Identifying Copy Number Variants In Epilepsy Patients/H. Olson, J. Avallone, Y. Shen, B. Wu and A. Poduri

3.314 Evidence For A Shared Genetic Susceptibility To Migraine And Epilepsy In The Epilepsy Phenome/Genome Project/M. Winawer, R. Connors and The EPSP Investigators

3.315 Bilateral Deletion Of The NRXN1 Gene Causing Autism, Developmental Delay, And Epilepsy In Fraternal Twins/J. Littman, C. Anderson, K. Carvalho, A. Legido and D. Khurana

3.316 Dravet Syndrome: Effect Of Different SCN1A Mutations In Seizure Control And Gait In Adults/D. Andrade, J. Rillstone, F. Coelho and B. Minassian


3.318 Novel Phenotypic Presentations Of Epilepsy Gene Mutations Uncovered Using Multiple Gene Sequencing/M. Ream, E. Davis, M. McDonald, N. Katsanis and M. Mikati


Animal Studies

3.321 Long-Term mTOR Hyperactivation Leads To Social Behavior And Learning And Memory Deficits/E. Arbuckle, G. Smith, J. Morrison, C. Floruta, O. Okonkwo and J. Lugo

3.322 Multiple Molecular Mechanisms For A Single GABAa Mutation In Epilepsy/T. Kim, A. Phillips, J. Low, S. Berkovic, B. Luscher, S. Petrov and C. Reid
Expanded this year, many of the participants will be offering mini-workshops dedicated to the education, awareness and research for people with epilepsy worldwide. All participants of AES including exhibitors are invited to attend the mini-workshops. The schedule will be posted daily outside the Center.

The Epilepsy Resource Center is a comprehensive one-stop resource for patients, researchers and clinicians specializing in the area of epilepsy.

Stop by the EPILEPSY RESOURCE CENTER at the Entrance of the Exhibit Hall!

2012 Epilepsy Resource Center — Participants —

- American Board of Clinical Neurophysiology, Inc. (ABCN)
- American Clinical MEG Society (ACMEGS)
- American Epilepsy Society
- ASET - The Neurodiagnostic Society
- Citizens United for Research in Epilepsy
- DClamp Software and IEEG Portal
- Dravet Syndrome Foundation
- Department of Veterans Affairs, Epilepsy Centers of Excellence
- Epilepsy Foundation
- Epilepsy Phenome/Genome Project
- Epilepsy Therapy Project
- HHV-6 Foundation
- Intractable Childhood Epilepsy Alliance ICE
- LGS (Lennox-Gastaut Syndrome) Foundation
- SeizureTracker.com
- SUDEP Aware
- The American Board of Registration of EEG and EP Technologies (ABRET)
- The Anita Kaufmann Foundation
- The Charlie Foundation
- Tuberous Sclerosis Alliance

and more...
Children's Hour – The Role of Inflammation in Epilepsy

Convention Center – Room 7, Upper Level

Coordinators: Mary B. Connelly, M.D., FRCP(C), Lieven Lagae, M.D., Ph.D.
Speakers: Annamaria Vezzani, Ph.D., Rima Nabbout, M.D., Ph.D., Sean J. Pittcock, M.D.

There is increasing evidence of the importance of inflammation in epilepsy, also in different childhood epilepsy syndromes. In this symposium, we will first focus on the fundamental inflammatory pathways, explaining their possible role in epilepsy. In the next step, a review of the clinical evidence of inflammatory processes in childhood epilepsy will be given. Finally, we will review the diagnosis and current anti-inflammatory treatment options in some childhood epilepsy syndromes.

Supported by Questcor Pharmaceuticals, Inc.

Frontal Lobe Epilepsy – The Effects of Seizures and AEDs on Frontal Lobe Function

Convention Center – Room 11, Upper Level

Coordinator: Fernando Condé, M.D., Ph.D.
Speakers: Kimford J. Meador, M.D., Christoph Helmstaedter, Ph.D., Matthias Koep, M.D., Ph.D.

We will examine recent data about the effects of seizures and AEDs on frontal lobe function and dysfunction both in generalized and localization-related epilepsies, and the relationships with quality of life and long-term outcome for cognition.

Temporal Lobe Club – Epilepsy Networks – Resting State fMRI Perspectives

Convention Center – Room 8, Upper Level

Coordinator: John M. Stern, M.D.
Speakers: John S. Duncan, D.M., Helmut Laufs, M.D., Zulfie Haneef, M.D., Graeme D. Jackson, M.D.

Epilepsy produces behavioral and cognitive changes that persist between seizures and may not be related to seizure occurrence. This has been investigated historically with psychological and psychiatric approaches. Current functional imaging techniques provide means to further the understanding of these aspects of epilepsy with a brain anatomy–based approach. The imaging results also may provide new insights into the anatomic networks underpinning forms of epilepsy, irrespective of seizures. The session will explore the results of resting state imaging of epilepsy with either focal-onset or generalized-onset seizures. Throughout the session, attention will be given to how the results may lead to new understanding of epilepsy localization, both during and between seizures.

Supported by Sunovian Pharmaceuticals, Inc.

Tuberous Sclerosis – Presurgical Epilepsy Evaluation and Utilization of Conventional and New Technologies

Convention Center – Room 10, Upper Level

Coordinators: Elizabeth A. Thiele, M.D., Ph.D., Martina Bebin, M.D.
Speakers: Michael Duchowny, M.D., Jeffrey Blount, M.D.

The TSC SIG this year will focus on TSC epilepsy surgery and the implementation of multimodalities in presurgical planning. Dr. Michael Duchowny from Miami Children's will discuss the presurgical epilepsy evaluation for TSC patients and the application and implementation of the various diagnostic tests in the surgical planning (MRI, PET, MEG, SPECT, EEG).

Dr. Jeffrey Blount, a pediatric neurosurgeon from Children’s Hospital of Alabama, will discuss the epilepsy surgical approach for TSC patients. A third speaker will discuss the significance of new EEG data acquisition techniques (i.e., HFOs) in seizure localization and surgical mapping and resection of tissue.

Supported by Lundbeck

Tumor-Induced Epilepsy

Convention Center – Room 9, Upper Level

Coordinators: Jeffrey M. Politsky, M.D., FRCP(C), Theodore H. Schwartz, M.D.
Speakers: Jeffrey Politsky, M.D., FRCP(C), Jeffrey Loeb, M.D., Ph.D., Edward Chang, M.D., Jorge Burneo, M.D., M.S.PH., Harald W. Sontheimer, Ph.D.

The focus of the 2012 Tumor-Induced Epilepsy SIG will be how to conduct meaningful and ethical research to advance our understanding of the field and our ability to care for brain tumor patients (with and without seizures). The 2012 SIG will include discussions on the following and related topics: anti-seizure drug trials; effects of various treatment modalities on tumor growth, recurrence, and epileptogenesis; ways to utilize resected tissue (e.g., established and new brain tissue banks); relationship of tumor development to neuronal network function (including epileptogenesis, functional and dysfunctional reorganization, and cognitive function); functional mapping and neuroimaging.

Practice Management Course

Convention Center – Room 3, Upper Level

Coordinator: Gregory L. Barkley, M.D.
Speakers: Gregory L. Barkley, M.D. and Jeffrey Buchhalter, M.D., Ph.D.

This course will give an annual update on ICD and CPT coding changes; discussion of what the election results mean for medical practice in 2013; and discussion regarding the likelihood of a fix to the SGR problem.

Scientific Symposium: Stereotactic Electroencephalography (sEEG) in the Pre-surgical Investigation of Refractory Focal Epilepsy

(1.5 CME Credits)

Convention Center – Ballroom 6C, Upper Level

Overview

A significant proportion of patients with refractory focal epilepsy who are being evaluated for resective surgery require invasive evaluations with subdural or depth electrode studies in order to better delineate the most likely epileptogenic zone. In most parts of the world that have the expertise and infrastructure to carry out intracranial electrode studies, the preferred method is subdural grid insertion with or without limited, non-stereotactic depth electrodes. A handful of centers in Europe and North America employ the use of stereotactically implanted, multiple-depth electrodes (stereotactic electroencephalography or sEEG), which have both advantages and potential limitations. Many centers have noted an increasing complexity of surgical cases presenting for presurgical evaluations, for example, patients who are MRI lesion negative, or who have dual or multiple epileptogenic pathways. Such patients may be studied best using sEEG. This symposium will address the rationale, technology, advantages, risks and outcomes of sEEG usage in intractable focal epilepsy.

8:30 a.m. – 10:00 a.m.

71
Learning Objectives

- Recognize the usefulness of sEEG as an invasive evaluation technique for defining the epileptogenic zone in select patients who are candidates for epilepsy surgery and develop appropriate capacity to perform such studies.
- Recognize the usefulness of sEEG as an invasive evaluation technique for defining eloquent cortex in select patients who are candidates for epilepsy surgery and develop the capacity for such studies.

Target Audience

Advanced (see page 107 for details)

Program

Co-Chairs: Hans O. Lüders, M.D., Ph.D. and Philippe Kahane, M.D., Ph.D.

8:30 p.m. Introduction and Overview
Hans O. Lüders, M.D., Ph.D.

8:35 p.m. Stereo-EEG Methodology: The European Approach
Giorgio LoRusso, M.D.

8:50 p.m. Stereo-EEG Methodology: The North American Approach
Jonathan P. Miller, M.D.

9:05 p.m. Depth Electrodes vs. Stereo-EEG vs. Subdural Electrodes: Relative Advantages and Disadvantages
Jorge A. Gonzalez-Martinez, M.D.

9:20 p.m. Mapping the Epileptogenic Zone with Stereo-EEG
Philippe Kahane, M.D., Ph.D.

9:35 p.m. Mapping the Eloquent Cortex with Stereo-EEG
Samden Lhatoo, M.D.

9:50 p.m. Round Table Discussion
Hans Lüders, M.D., Ph.D., Moderator

Credit Designation

The American Epilepsy Society designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Nurses may claim up to 1.5 contact hours for this session.

Pharmacy Credit

ACPE Universal Activity Number (UAN) is 0052-9999-12-2325-L04-P and provides 1.5 contact hours.

ABPN Core Competencies

The American Board of Psychiatry and Neurology has reviewed the Scientific Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Core Competencies: Medical Knowledge

Overview

Classification of the epilepsies is a dynamic concept that continues to undergo reevaluation, especially in light of advances in structural and functional neuro-imaging, genetics and neuro-immunology. This symposium, sponsored by the International League Against Epilepsy, will focus on the newly updated organization of the epilepsies, exploring the emerging concept of diagnostic specificity and how this relates to clinical practice. Controversies that have arisen regarding the specific aspects of classification, namely structural, genetic and immune, will be presented.

Learning Objectives

- Utilize the greater diagnostic specificity provided by the revised classification in managing patients and in doing research.
- Utilize newly described genetic and immunologic testing in order to provide greater specificity in diagnosing epilepsy and in managing patients.
- Utilize the revised classification to improve diagnostic specificity and coding accuracy for clinical epilepsy practice.

Target Audience

Basic, Intermediate and Advanced (see page 107 for details)

Program

Co-Chairs: Sheryl Haut, M.D., M.S. and Ingrid E. Scheffer, M.B.B.S., Ph.D.

8:30 a.m. Introduction and Overview
Sheryl Haut, M.D., M.S.

8:35 a.m. Update on the New Organization: Where Have the Modifications Taken Us?
Ingrid E. Scheffer, M.B.B.S., Ph.D.

8:45 a.m. Diagnostic Specificity: Applying This Concept to Every Patient
J. Helen Cross, M.B.Ch.B., Ph.D., FRCP, FRCPH

9:00 a.m. Controversies
- Genetic: How Do I Tell the Patient?
  Sameer Zuberi, M.B.Ch.B., FRCP, FRCPH
- Structural: Genetic or Acquired?
  James Barkovich, M.D.
- Immune: Which Patients Should Be Tested?
  Christian Bien, M.D.
- Coding: Will This Make a Difference to My Practice?
  Donna C. Bergen, M.D.

9:55 a.m. Conclusions
Ingrid E. Scheffer, M.B.B.S., Ph.D.

Credit Designation

The American Epilepsy Society designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Nurses may claim up to 1.5 contact hours for this session.

Pharmacy Credit

ACPE Universal Activity Number (UAN) is 0052-9999-12-2326-L04-P and provides 1.5 contact hours.

ABPN Core Competencies

The American Board of Psychiatry and Neurology has reviewed the North American Commission Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Core Competencies: Medical Knowledge, System-Based Practice and Practice-Based Learning and Improvement
Basic EEG in Epilepsy: Fundamentals and Interpretation
Convention Center – Room 4, Upper Level
Moderator: Greg Cascino, M.D.

The routine EEG recording remains essential in the care and management of individuals with seizures and suspected epilepsy. EEG findings may be of prognostic importance and be used to assess the efficacy of treatment. Use of appropriate EEG methodology and recognition of artifact and benign variant patterns are essential for satisfactory clinical studies. This workshop will review basic methodologies of EEG for the evaluation and treatment of pediatric and adult patients with seizure disorders. This will include use of appropriate EEG techniques and fundamentals of EEG recordings. Recognition of benign variant alterations and ictal-interictal epileptogenic discharges will be addressed. The presentations will also discuss the importance of EEG to identify characteristics of specific epilepsies and epileptic syndromes.

Intracranial Electrode Studies: How Do You Choose a Technique for Optimum Localization?
Convention Center – Room 5A, Upper Level
Moderator: Dennis Spencer, M.D.

Over the past thirty years, resection for medically intractable epilepsy has become a standard treatment option. However, in many instances successful surgery is not possible without defining the potential respective volume by intracranial electrophysiology. This workshop will look at three centers with different solutions to intracranial studies. Common problematic cases will be presented and each of the three surgeons will provide a rationale for their solution to a standard study.

Neuroradiology: Optimal Use of Neuroimaging in Diagnosing and Treating Epilepsy
Convention Center – Room 5B, Upper Level
Moderator: Michael Sperling, M.D.

Neuroimaging is an essential tool in the diagnosis and treatment of epilepsy. This workshop will review the techniques used to diagnose epilepsy, emphasizing both basic MRI customized for epilepsy and advanced neuroimaging techniques. We will review a rational approach to the use of neuroimaging, highlight specific techniques that enhance diagnostic ability, along with newer fMRI and other functional imaging methods. Interpretation of scans and various findings will be reviewed in this practical session.

Genetics: The Usefulness of Genetics In Patient Care
Convention Center – Room 9, Upper Level
Moderator: Christina Gurnett, M.D., Ph.D.

Knowledge of genetics is becoming increasingly important for the diagnosis and treatment of patients with epilepsy. In this skills workshop, we will discuss the following questions: Do you need to test for HLA genetic variants before starting carbamazepine or phenytoin? What is the role of chromosomal microarray analysis in idiopathic generalized epilepsies or in pediatric epileptic encephalopathies? What are the merits of single gene testing vs. gene panels vs. comprehensive genetic testing (i.e., exomes) for patients with epilepsy? How do you interpret the results of genetic testing?

Pediatric Epilepsy Surgery: Candidate Selection For What Outcome?
Convention Center – Room 10, Upper Level
Moderator: Gary Mathern, M.D.

The selection of candidates and anticipated outcomes for pediatric epilepsy surgery have evolved considerably over the past decade. This session is designed to address how the selection of pediatric epilepsy surgery patients is often different compared with older patients. This includes the finding that many children with localized lesions may show generalized semiology and/or EEG changes, and how developmental outcomes need to be included in the risk-benefit analysis. Speakers from three centers will present case studies and discuss additional cases from the audience.

Essentials of the Epilepsy Monitoring Unit: Basics for Setting up Video EEG and Related Services
Convention Center – Room 8, Upper Level
Moderator: R. Edward Hogan, M.D.

Technological advances have enhanced our capabilities for advanced neurodiagnostic testing for epilepsy, enabling acquisition of video-EEG and ictal SPECT studies for clinical diagnostic purposes. This skills workshop will review the basic indications and guidelines for establishing and maintaining an epilepsy monitoring unit, as well as basic safety issues in the EMU. The discussion will include practical information for setting up and maintenance of video-EEG equipment as well as issues in acquisition and processing of ictal / interictal SPECT studies.
**Poster Walking Tours** begin at the **Poster Information** table

**Exhibit Hall Hours:**
- Saturday, December 1 ...................... 11:45 a.m. - 6:00 p.m.
- Sunday, December 2 ....................... 10:00 a.m. - 4:00 p.m.
- Monday, December 3 ...................... 10:00 a.m. - 3:00 p.m.
<table>
<thead>
<tr>
<th>EXHIBITOR LOCATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ad-Tech Medical Instrument Corp</td>
</tr>
<tr>
<td>AED Pregnancy Registry</td>
</tr>
<tr>
<td>*American Board of Clinical Neurophysiology, Inc. (ABCN)</td>
</tr>
<tr>
<td>*The American Board of Registration of EEG and EP Technologies (ABRET)</td>
</tr>
<tr>
<td>*American Clinical MEG Society (ACMEGS)</td>
</tr>
<tr>
<td>*American Epilepsy Society</td>
</tr>
<tr>
<td>Analyze Direct</td>
</tr>
<tr>
<td>The Anita Kaufmann Foundation</td>
</tr>
<tr>
<td>*ASET – The Neurodiagnostic Society</td>
</tr>
<tr>
<td>Athena Diagnostics, Inc</td>
</tr>
<tr>
<td>BIOPAC Systems, Inc</td>
</tr>
<tr>
<td>Blackrock NeuroMed</td>
</tr>
<tr>
<td>Cadwell Laboratories, Inc</td>
</tr>
<tr>
<td>CareFusion</td>
</tr>
<tr>
<td>*The Charlie Foundation</td>
</tr>
<tr>
<td>Child Neurology Foundation (CNF)</td>
</tr>
<tr>
<td>*Citizens United for Research in Epilepsy (CURE)</td>
</tr>
<tr>
<td>Clever Sys, Inc</td>
</tr>
<tr>
<td>Compumedics USA, Inc</td>
</tr>
<tr>
<td>Cortech Solutions, Inc</td>
</tr>
<tr>
<td>Cyberonics, Inc</td>
</tr>
<tr>
<td>DClamp Software and IEEG-Portal</td>
</tr>
<tr>
<td>*Demos Medical Publishing</td>
</tr>
<tr>
<td>Department of Veterans Affairs, Epilepsy Centers of Excellence</td>
</tr>
<tr>
<td>*DigiTrace EEG Services</td>
</tr>
<tr>
<td>DIXI MEDICAL</td>
</tr>
<tr>
<td>*Dravet Syndrome Foundation</td>
</tr>
<tr>
<td>Eisai, Inc</td>
</tr>
<tr>
<td>Electrical Geodesics, Inc</td>
</tr>
<tr>
<td>ELEKTA Oy</td>
</tr>
<tr>
<td>Elsevier</td>
</tr>
<tr>
<td>emka TECHNOLOGIES Inc</td>
</tr>
<tr>
<td>Emory Genetics Laboratory</td>
</tr>
<tr>
<td>Epilepsy Foundation</td>
</tr>
<tr>
<td>Epilepsy Life Links</td>
</tr>
<tr>
<td>*Epilepsy Phenome/Genome Project</td>
</tr>
<tr>
<td>*Epilepsy Therapy Project</td>
</tr>
<tr>
<td>EUROMMUN US</td>
</tr>
<tr>
<td>Everidis Health Sciences</td>
</tr>
<tr>
<td>GeneDx</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Grass Technologies</td>
</tr>
<tr>
<td>*HHV-6 Foundation</td>
</tr>
<tr>
<td>HRA Healthcare Research &amp; Analytics</td>
</tr>
<tr>
<td>ILAE / IBE Congress Secretariat</td>
</tr>
<tr>
<td>Integra LifeSciences</td>
</tr>
<tr>
<td>*Intractable Childhood Epilepsy Alliance</td>
</tr>
<tr>
<td>John Libbey EUROTEXT</td>
</tr>
<tr>
<td>LGS (Lennox-Gastaut Syndrome) Foundation</td>
</tr>
<tr>
<td>Lifelines Neurodiagnostic Systems, LLC</td>
</tr>
<tr>
<td>Lippincott Williams &amp; Wilkins</td>
</tr>
<tr>
<td>Lundbeck US</td>
</tr>
<tr>
<td>Multi Channel Systems</td>
</tr>
<tr>
<td>National Association of Epilepsy Centers</td>
</tr>
<tr>
<td>National Institute of Neurological Disorders &amp; Stroke (NINDS)</td>
</tr>
<tr>
<td>Natus Medical Incorporated</td>
</tr>
<tr>
<td>Neuralynx Inc</td>
</tr>
<tr>
<td>Nihon Kohden America, Inc</td>
</tr>
<tr>
<td>Optima Neuroscience, Inc</td>
</tr>
<tr>
<td>Oxford University Press</td>
</tr>
<tr>
<td>Persyst Development Corporation</td>
</tr>
<tr>
<td>Pinnacle Technology, Inc</td>
</tr>
<tr>
<td>PMT Corporation</td>
</tr>
<tr>
<td>Questcor Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Rhythmlink International</td>
</tr>
<tr>
<td>Ripple LLC</td>
</tr>
<tr>
<td>*SeizureTracker.com</td>
</tr>
<tr>
<td>Smart Monitor Corp</td>
</tr>
<tr>
<td>*SUDEP Aware</td>
</tr>
<tr>
<td>Sunovion Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Supernus Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Transgenomic, Inc</td>
</tr>
<tr>
<td>Triangle BioSystems, Inc</td>
</tr>
<tr>
<td>*Tuberous Sclerosis Alliance</td>
</tr>
<tr>
<td>UCB, Inc</td>
</tr>
<tr>
<td>Upsher-Smith Laboratories, Inc</td>
</tr>
<tr>
<td>Visualase, Inc</td>
</tr>
<tr>
<td>Wiley-Blackwell</td>
</tr>
</tbody>
</table>

*Please see Epilepsy Resource Center participants on page 70.
**Saturday, December 1:**

**11:45 a.m.-6:00 p.m.**
Lunch: 11:45 a.m.-12:45 p.m.
Reception: 4:30 p.m.-6:00 p.m.
Prize Drawing: 5:00 p.m., Epilepsy Resource Center

**Exhibit Schedule**

**Sunday, December 2:**

10:00 a.m. – 4:00 p.m.
Lunch: Noon-1:00 p.m.
Coffee Break: 3:00 p.m.-3:30 p.m.
Prize Drawing: 3:15 p.m., Epilepsy Resource Center

**Monday, December 3:**

10:00 a.m.-3:00 p.m.
Lunch: Noon-1:30 p.m.
Coffee Break: 2:30 p.m.-3:00 p.m.
Prize Drawing & Grand Prize Drawing: 2:45 p.m., Epilepsy Resource Center

---

**Ad-Tech Medical Instrument Corp**
Booth #317
1901 William St
Racine, WI 53404
Phone: 262-634-1555
Fax: 262-634-5668
Email: lb@adtechmedical.com
Website: www.adtechmedical.com
Contact: Ms. Lisa Theama

For over 25 years, Epilepsy Centers have made Ad-Tech their choice for invasive electrodes for brain mapping and epilepsy monitoring. We offer a large variety of electrodes and accessories to meet you and your patients needs. Visit our booth to discover why Ad-Tech is your best choice.

**AED Pregnancy Registry**
Booth #441
121 Innerbelt Rd - Ste 220
Massachusetts General Hospital Somerville, MA 02143
Phone: 617-724-9550
Toll Free: 888-233-2334
Fax: 617-726-1911
Email: crsmith1@partners.org
Website: www.aedpregnancyregistry.org
Contact: Ms. Caitlin Smith

The AED Pregnancy Registry is dedicated to determine the safety of antiepileptic drugs that can be taken by women during pregnancy to treat disorders such as epilepsy, mood disorder, and chronic pain. The primary goal is to determine the frequency of major malformations in the infants exposed during pregnancy to AEDs. Please visit our booth for our latest information.

**American Board of Clinical Neurophysiology, Inc. (ABCN)**
Table #20
2509 W Iles Ave - Ste 102
Springfield, IL 62704
Phone: 217-726-7980
Fax: 217-726-7989
Email: abcn@att.net
Website: www.abcn.org
Contact: Ms. Janice Walbert

The American Board of Clinical Neurophysiology (ABCN) has a 65-year history of promoting excellence in Clinical Neurophysiology and offers examinations with added competency in Epilepsy Monitoring or Neurophysiologic Intraoperative Monitoring. A Generalist Track is also available. Stop by the booth for exam outlines and Practice Exam order forms.

**The American Board of Registration of EEG and EP Technologies (ABRET)**
Table #1
2509 W Iles Ave - Ste 102
Springfield, IL 62704
Phone: 217-726-7980
Fax: 217-726-7989
Email: abreteo@att.net
Website: www.abret.org
Contact: Ms. Janice Walbert

The American Board of Registration of Electroencephalographic and Evoked Potential Technologists (ABRET) is the credentialing board for Neurodiagnostic Technologists (EEG, EP, NIOM, LTM) and offers laboratory accreditation programs, LAB-EEG, LAB-NIOM, and LAB-LTM. Stop by our booth for assistance recruiting technologists and to learn about laboratory accreditation.

**American Clinical MEG Society (ACMEGS)**
Table #18
One Regency Drive R.O. Box 30
Bloomfield, CT 06002
Phone: 860-243-3977
Fax: 860-286-0787
Email: hburns@ssmgct.com
Website: www.acmegs.org
Contact: Haley Burns

ACMEGS is a non-profit professional medical association that represents clinical MEG centers in America. ACMEGS sets national standards for MEG use and advocates for individuals who would benefit from MEG through the education of medical providers, policymakers and regulators about the recommended standards of care. Our goal is to make MEG accessible to all patients.

**American Epilepsy Society**
Table #7
342 N Main St
West Hartford, CT 06117
Phone: 860-586-7505
Fax: 860-586-7550
Email: info@aesnet.org
Contact: Ms. Kathy Hucks

The American Epilepsy Society promotes research and education for professionals dedicated to the prevention, treatment and cure of epilepsy. Stop by the Epilepsy Resource Center for information on membership publications and research funding.

**Analyze Direct**
Booth #715
7380 W 161st St
Overland Park, KS 66205
Phone: 913-338-2577
Fax: 913-338-2554
Email: stuart@analyzedirect.com
Website: www.analyzedirect.com
Contact: Ms. Stuart Jackson

AnalyzeSISCOM is a research application that uses a combination of SPECT and MRI to assess regional activation in the brain during epileptic seizure. Previously only available as part of the Analyze visualization and analysis software suite, a highly improved stand-alone SISCOM will be demonstrated at AES 2012.

**The Anita Kaufmann Foundation**
Table #3
1786 Lilbet Rd
Teanack, NJ 07666
Phone: 201-655-0420
Toll Free: 866-596-4973
Fax: 866-303-3219
Email: debra@akfus.org
Website: www.akfus.org
Contact: Ms. Debra Josephs

Our sole mission is to educate the public not to fear epilepsy and seizures. We are the global sponsors of PURPLE DAY, the largest grassroots epilepsy awareness initiative in the world. We provide seizure first aid training and material worldwide. We have just introduced a program to help US Veterans with traumatic brain injury with the VA’s Epilepsy Centers of Excellence.

**ASET – The Neurodiagnostic Society**
Table #8
402 E Bannister Rd - Ste A
Kansas City, MO 64131
Phone: 816-931-1120
Fax: 816-931-1145
Email: sarah@aset.org
Website: www.aset.org
Contact: Ms. Sarah Ecker

ASET – The Neurodiagnostic Society advances the neurodiagnostic profession by providing education and advocacy, creating greater awareness of the profession, and establishing standards and best practices to ensure quality patient care. ASET provides its members practical guidance and helps them stay abreast of the latest advances in the field.
by moving the patient into their own environment. Our patent-pending Q-Video Mobile Camera allows video capture of the patient anywhere they are, allowing you to see what triggers episodes in the real world.

**CareFusion**

**Booth #217**

**PO Box 44994**

**Madison, WI**

Phone: 608-829-8500

Toll Free: 800-356-0007

Fax: 608-869-8737

Email: julie.phillips@carefusion.com

Website: www.carefusion.com

Contact: Ms. Julie Phillips

**The Charlie Foundation**

**Table #12**

1325 Victoria Circle S

Elm Grove, WI 53122

Phone: 262-271-3479

Fax: 262-754-1389

Email: bkania@chw.org

Website: www.charliefoundation.org

Contact: Ms. Beth Zupec

The Charlie Foundation exists to educate the public about ketogenic diet therapies for the treatment of epilepsy and to train healthcare professionals in the implementation and management of these regimens. We collaborate with other epilepsy non-profit organizations to disseminate information and promote diet therapies worldwide.

**Child Neurology Foundation (CNF)**

**Booth #420**

2000 W 98th St

Bloomington, MN 55431

Phone: 851-645-4466

Fax: 851-881-6276

Email: jennifer.wright704@gmail.com

Website: www.childneurologyfoundation.org

Contact: Ms. Jennifer Wright

**Citizens United for Research in Epilepsy (CURE)**

**Table #15**

223 W. Erie St - Suite 2SW

Elm Grove, WI 53122

Phone: 262-271-3479

Fax: 262-754-1389

Email: julie@cureepilepsy.org

Website: www.cureepilepsy.org

Contact: Julie Milder

Citizens United for Research in Epilepsy is a nonprofit organization dedicated to finding a cure for epilepsy by raising funds for research and by increasing awareness of the prevalence and devastation of this disease.

**CleverSys, Inc.**

**Booth #138**

11425 Isaac Newton Square - Ste 202

Reston, VA 20190

Phone: 703-787-6946

Fax: 703-787-8567

Email: nzhang@cleversysinc.com

Website: www.cleversysinc.com

Contact: Ms. Nai Li Zhang

CleverSys Inc. is a bioinformatics software company, with patented Behavior Recognition Technology for automated animal behavioral research. In addition to our software packages we offer behavioral research equipment such as mazes, operant chambers, and environments that are optimized for video analysis. We now offer CRO services for behavioral studies.

**Compumedics USA, Inc.**

**Booth #525**

6605 W WT Harris Blvd - Ste F

Charlotte, NC 28269

Phone: 704-749-3200

Toll Free: 877-717-3975

Fax: 704-749-3299

Email: kathy.caplan@compumedicsusa.com

Website: www.compumedics.com.au

Contact: Ms. Kathy Caplan

Compumedics USA, Inc. provides solutions for epilepsy monitoring. NEUVO LTM and Grael EEG Systems with CURRY-SCAN 7 Neuroimaging Suite meet requirements for routine and ambulatory recordings as well as LTM / Neuro-ICU monitoring. Compumedics addresses ultra-high density and extended frequency-range recordings for HFO, source localization and source imaging. SEE MORE! DO MORE!

**Cortech Solutions, Inc.**

**Booth #705**

1409 Audubon Blvd - Ste B1

Wilmington, NC 28403

Phone: 910-362-1143

Fax: 910-362-1147

Email: blattimore@cortechsolutions.com

Website: www.cortechsolutions.com

Contact: Ms. Brenda Lattimore

EEG / ERP and source modeling are just the start! Our systems incorporate HR, HRV, EMG, GSR, EEG, respiration, eye tracking and more. All the most advanced labs are already using our systems except perhaps yours.

**Cyberonics, Inc.**

**Booth #617**

100 Cyberonics Blvd

Houston, TX 77058

Phone: 281-228-7365

Fax: 281-853-2686

Email: renee.adams@cyberonics.com

Website: www.cyberonics.com

Contact: Ms. Renee Adams

Cyberonics, Inc. is a leader in the neurostimulation market and continues to demonstrate this commitment to physicians and their patients by providing innovative and effective medical device solutions for epilepsy. VNS Therapy® is the only FDA-approved device for the treatment of refractory epilepsy, with more than 70,000 patients implanted worldwide.
40 company testing locations in 20 major U.S. metropolitan areas where physicians can refer their patients for ambulatory EEG testing. Together, these facilities provide more than 25,000 days of ambulatory EEG monitoring each year.

**DIXI MEDICAL**

**Booth #118**

4 chemin de Palente

25000 BESANCON France

Phone: +33 3 81 88 99 99

Fax: +33 3 81 88 99 99

Email: secretariat@diximicrotechniques.com

Website: www.diximedical.com

Contact: Mr. Jose Moya

Mr. Jose Moya, sales manager with over 30 years partnership with clinicians and Researchers for the development of DIXI MEDICAL electrodes and accessories for the surgical treatment of epilepsy, is the proficient person for responding to any query and providing appropriate devices to neurosurgeons’ requirements. He is eager to welcome you at booth #118.

**Dravet Syndrome Foundation**

**Table #14**

11 Nancy Dr

Monroe, CT 06468

Phone: 203-880-9456

Email: maryanne.m@dravetfoundation.org

Website: www.dravetfoundation.org

Contact: Ms. Mary Anne Meskis

Dravet Syndrome Foundation is a nonprofit organization whose mission is to aggressively raise research funds for Dravet Syndrome and related ion channel epilepsies; to increase awareness of these catastrophic conditions; and to provide support to affected individuals and families.

**Eisai, Inc.**

**Booth #125, 303**

100 Tice Blvd

Woodcliff Lake, NJ 07677

Phone: 201-748-2527

Fax: 201-748-3196

Email: shirley.hunt@eisai.com

Website: www.eisai.com/US

Contact: Ms. Shirley Hunt

Eisai Inc. is the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (HHC) company that discovers, develops and markets products throughout the world. Headquartered in Woodcliff Lake, New Jersey, Eisai’s key areas of commercial focus are neurology and oncology. For more information, please visit www.eisai.com/US.

**Emory Genetics Laboratory**

**Booth #131, 230**

1600 Millrace Drive - Ste 200

Eugene, OR 97403

Phone: 541-687-7962

Fax: 541-687-7963

Email: conferences@egi.com

Website: www.egi.com

Contact: Ms. Dee Dee Nunes

EGI brings next-generation clinical EEG systems, tools, and workflows to hospitals and clinics worldwide. EEG systems feature EGI’s Geodesic Sensor Net for rapid application and unprecedented comfort. Your choice of routine EEG systems or dense array systems for source estimation. Visit EGI’s booth to see this in action!

**ELEKTA Oy**

**Booth #117**

Sittsaarenkatu 18-20

00530 Helsinki, Finland

Phone: 358-975-6240-22

Fax: 358-975-6240-11

Email: riitta.pietila@elekta.com

Website: www.elekta.com

Contact: Ms. Riitta Pietilä

Eleksa is a leading publisher of health science publications, advancing medicine by delivering superior reference information and decision support tools to doctors, nurses, health practitioners and students. With an extensive media spectrum — print, online and handheld, we are able to supply the information you need in the most convenient format.

**Emka TECHNOLOGIES Inc.**

**Booth #239**

307 Annandale Rd - Ste 203

Falls Church, VA 22042

Phone: 703-237-9001

Fax: 703-237-9006

Email: emkatech@emkatech.com

Website: www.emkatech.com

Contact: Ms. Virginie Brechet

rodentPACK, a tetherless epilepsy monitoring system, offer the advantages of implantable telemetry at the cost of a tether-based setup. This wireless head-mounted device measures EEG, EMG, ECG, and activity from up to 40 single or group housed subjects. Optional software features sleep scoring, seizure detection, GLP capabilities, and synchronized video.

**Elsevier**

**Booth #703**

1800 John F Kennedy Blvd - Ste 1800

Four Penn Center

Philadelphia, PA 19103

Phone: 215-239-3491

Fax: 215-239-3494

Email: j.francis@elsevier.com

Website: www.elsevier.com

Contact: Mr. Jeffrey Francis

Elsevier is a leading publisher of health science publications, advancing medicine by delivering superior reference information and decision support tools to doctors, nurses, health practitioners and students. With an extensive media spectrum — print, online and handheld, we are able to supply the information you need in the most convenient format.

**DigiTrace EEG Services**

**Booth #315**

200 Corporate Pl - Ste 5B

Peabody, MA 01960

Phone: 978-536-7400

Fax: 978-535-9778

Email: stuthill@sleepmedinc.com

Website: www.sleepmedinc.com

Contact: Mr. Stuart Tuthill

DigiTrace EEG products and services are used by dozens of comprehensive epilepsy centers throughout the U.S. There are also over 100,000 days of ambulatory EEG monitoring performed annually by DigiTrace across the U.S., with over 25,000 days of ambulatory EEG monitoring performed annually by DigiTrace across the U.S., with over 25,000 days of ambulatory EEG monitoring performed annually by DigiTrace across the U.S., with over 25,000 days of ambulatory EEG monitoring performed annually by DigiTrace across the U.S., with over 25,000 days of ambulatory EEG monitoring performed annually by DigiTrace across the U.S., with over 25,000 days of ambulatory EEG monitoring performed annually by DigiTrace across the U.S.

**DigiTrace EEG Services**

**Booth #315**

200 Corporate Pl - Ste 5B

Peabody, MA 01960

Phone: 978-536-7400

Fax: 978-535-9778

Email: stuthill@sleepmedinc.com

Website: www.sleepmedinc.com

Contact: Mr. Stuart Tuthill

DigiTrace EEG products and services are used by dozens of comprehensive epilepsy centers throughout the U.S. There are also over 100,000 days of ambulatory EEG monitoring performed annually by DigiTrace across the U.S., with over 25,000 days of ambulatory EEG monitoring performed annually by DigiTrace across the U.S., with over 25,000 days of ambulatory EEG monitoring performed annually by DigiTrace across the U.S., with over 25,000 days of ambulatory EEG monitoring performed annually by DigiTrace across the U.S., with over 25,000 days of ambulatory EEG monitoring performed annually by DigiTrace across the U.S.
integrated and comprehensive testing for neurologically-related genetic disorders. EGL offers an epilepsy next-generation sequencing panel featuring more than 125 genes associated with the disorder:

**Epilepsy Foundation**

Booth #514, Table 17

8301 Professional Pk E

Landover, MD 20785

Phone: 301-459-3700

Fax: 301-918-2103

Email: gjones@efa.org

Website: www.epilepsyfoundation.org

Contact: Ms. Gigi Jones

**Epilepsy Life Links**

Booth #540

333 Westchester Ave - Ste 104

White Plains, NY 10604

Phone: 914-428-9213

Fax: 914-428-9282

Email: glee@epilepsygroup.com

Website: www.epilepsygroup.com

Contact: Ms. Gladys Lee

Epilepsy Life Links provides a comprehensive array of supports and opportunities for persons with epilepsy, including free educational programs for patients and healthcare providers taught by our epilepsy specialists, support groups for adults in both English and Spanish, wellness activities, social media, and participation in local and national epilepsy fundraisers.

**Epilepsy Phenome / Genoma Project**

Table #10

3243 Sterling Ave

Alameda, CA 94501

Phone: 415-519-8962

Email: info@epgp.org

Website: www.epgp.org

Contact: Kristen Schardein

**Epilepsy Therapy Project**

Table #19

10 N Pendleton St - Upper Level

PO Box 742

Middleburg, VA 20118

Phone: 540-687-8066

Email: dwille@everidis.com

Website: www.epilepsy.com

Contact: Ms. Kim Macher

Epilepsy Therapy Project (ETP), sponsor of epilepsy.com, is a 501(c)(3) non-profit organization whose mission is to accelerate new therapies for people with epilepsy and seizures. Founded by parents and doctors, ETP supports the commercialization of new therapies through direct grants and investments in promising academic and commercial projects.

**EUROIMMUN US**

Booth #439

1100 The American Rd

Morris Plains, NJ 07950

Phone: 973-856-1000

Toll Free: 800-913-2022

Fax: 973-856-1098

Email: l.popelka@euroimmun.us

Website: www.euroimmunus.com

Contact: Mrs. Lauren Popelka

EUROIMMUN produces reagents for medical laboratory diagnostics. In the foreground are test systems for the determination of various antibodies in patient serum in the diagnosis of autoimmune diseases, infectious diseases and allergies. Indirect immunofluorescense, microplate ELISA, various blot techniques and all molecular biology techniques.

**Everidis Health Sciences**

Booth #729

2900 Brannon Ave

St. Louis, MO 63139

Phone: 877-776-0101

Fax: 314-864-4839

Email: dwille@everidis.com

Website: www.everidis.com

Contact: Ms. Donna Wille

Everidis is an innovative health sciences company focused on developing unique approaches to address nutritional and metabolic deficiencies. We strive to translate peer-reviewed research on health and nutrition into products that are safe, therapeutic and healthful. We are committed to improving patient quality of life.

**GeneDx**

Booth #132

207 Perrry Parkway

Gaithersburg, MD 20877

Phone: 301-519-2100

Toll Free: 800-229-5227

Fax: 301-519-2882

Email: GeneDx@GeneDx.com

Website: www.genedx.com

Contact: Ms. Marianne Sansing

GeneDx offers testing for more than 350 rare Mendelian disorders using DNA sequencing and deletion/duplication analysis of the associated gene(s), and offers oligonucleotide microarray-based testing and next-generation sequencing based panels for inherited cardiac disorders, mitochondrial disorders, and neurodevelopmental disorders. Visit www.GeneDx.com to learn more.

**GlaxoSmithKline**

Booth #425, 723

7545 Hartman Industrial Way

Austell, GA 30168

Phone: 404-921-5173

Toll Free: 866-475-8222

Email: bbright@czarnowski.com

Website: www.gsk.com

Contact: Mr. Barak Bright

GlaxoSmithKline is a leading research-based pharmaceutical company with a powerful combination of skills to discover and deliver innovative medicines. We offer a number of program resources to support effective health management strategies and improve patient care. Please visit our exhibit to learn more about our products and resources.

**Grass Technologies**

Booth #433

600 E Greenwich Ave

West Warwick, RI 02893

Phone: 401-828-4000

Toll Free: 877-472-7779

Fax: 401-822-2430

Email: spollard@astromed.com

Website: www.grasstech.com

Contact: Ms. Tina Pollard

Grass Technologies offers a wide range of instrumentation for PSG, EEG, LTM, Neuromonitoring — from lab based to ambulatory recorders — at affordable prices. Systems feature the world renowned accuracy, dependability and performance of Grass amplifiers, and powerful software. We also offer the new S12X Cortical Stimulator.

**HHV-6 Foundation**

Table #19

1253 Coast Village Rd - Ste 105

Santa Barbara, CA 93108

Phone: 805-869-1174

Fax: 805-565-9731

Email: jill_chase@hhv-6foundation.org

Website: www.hhv-6foundation.org

Contact: Ms. Jill Chase

The HHV-6 Foundation is a non-profit institution that encourages further discovery and scientific exchange between investigators by maintaining a repository of reagents to facilitate research, holding conferences for scientific and clinical researchers, and offering pilot grants for promising research projects focusing on the underappreciated viruses HHV-6A and HHV-6B.

**HRA Healthcare Research & Analytics**

Booth #116

400 Landix Plaza

Parsippany, NJ 07054

Phone: 973-240-1204

Fax: 973-240-1200

Email: knielsen@hraresearch.com

Website: www.hraresearch.com

Contact: Kathy Nielsen

Our team of experienced interviewers will be distributing carefully developed questionnaires. We’ll be gathering the answers to vital marketing and clinical questions—answers that can affect the introduction of new products or the continuation of existing healthcare products and services.
The ILAE is the world’s preeminent association of physicians and other health professionals. Its mission is quality of care for those with epilepsy and other related seizure disorders. IBE, an international organization, aims to improve the quality of life of all with epilepsy, their families and caretakers. IBE develops and supports national epilepsy organizations worldwide.

Integra LifeSciences
Booth #210
313 Enterprise Dr
Plainsboro, NJ 08536
Phone: 609-275-0500
Toll Free: 800-762-1574
Fax: 609-799-3297
Email: jon.trout@integralife.com
Website: www.integralife.com
Contact: Mr. Jon Trout

Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers a vast portfolio of implants, devices, instruments and systems used in neurosurgery and neuro critical care.

Intractable Childhood Epilepsy Alliance
Table #11
464 Heritage Dr
Lewisville, NC 27023
Phone: 336-918-9440
Email: michellewelborn@gmail.com
Website: www.ic-epilepsy.org
Contact: Michelle Warren Welborn

John Libbey EUROTEXT
Booth #111
127 Avenue de la Republique
92120 Montrouge, France
Phone: 33-146-7306-79
Fax: 33-140-8409-99
Email: gilles.cahn@jele.com
Website: www.jle.com
Contact: Mr. Gilles Cahn

John Libbey EUROTEXT is the publisher of both world-renowned specialists and new authors in epilepsy. Through the journal Epileptic Disorders, its state-of-the-art website and moreover through book series like Current problems in Epilepsy, Progress in Epileptic Disorders, Topics in Epilepsy, Mariani Foundation Paediatric Neurology, etc. it provides a first class knowledge.

LGS (Lennox-Gastaut Syndrome) Foundation
Table #4
PO Box 6948
New York, NY 10150
Phone: 718-374-3800
Email: christina@lgsfoundation.org
Website: www.lgsfoundation.org
Contact: Ms. Christina San Inocencio

The LGS Foundation is a non-profit organization dedicated to providing information about Lennox-Gastaut Syndrome while raising funds to pursue research, services, and programs for individuals living with LGS, and their families.

Lifelines Neurodiagnostic Systems, LLC
Booth #721
611 Riggin Rd
Troy, IL 62294
Phone: 618-667-6445
Fax: 618-667-1982
Email: simon@lifelinesneuro.com
Website: www.lifelinesneuro.com
Contact: Mr. Simon Griffin

Lippincott Williams & Wilkins
Booth #707
4750 Matty Ct
La Mesa, CA 91941
Phone: 619-838-8398
Email: gary.f.white@wolterskluwer.com
Website: www.lww.com
Contact: Mr. Gary White

Lippincott Williams & Wilkins publishes medical books and journals.

Lundbeck US
Booth #325, 336
4 Parkway N - Ste 200
Deerfield, IL 60015
Phone: 847-282-1000
Fax: 847-282-1001
Email: mtre@lundbeck.com
Website: www.lundbeckus.com
Contact: Ms. Margaret Trempe

Headquartered in Deerfield, Illinois, with a portfolio specialty central nervous system (CNS) therapies and a robust pipeline of promising CNS compounds, Lundbeck is committed to providing innovative therapies that fulfill unmet medical needs of people with CNS disorders, including rare diseases, for which few, if any, effective treatments are available.

Multi Channel Systems
Booth #114
Aspenhauserstrasse 21
72770 Reutlingen, Germany
Phone: 631-393-6401
Fax: 631-393-6407
Email: margaret@alascience.com
Website: www.multichannelsystems.com
Contact: Ms. Margaret Badon

Multi Channel Systems develops precision scientific measuring instrumentation and equipment for research groups and for the pharmaceutical industry, in the field of electrophysiology. We provide solutions for extracellular recordings with microelectrode arrays in vitro and in vivo with the MEA-System and the ME-System as well as for electrical stimulation with the STG series.

National Association of Epilepsy Centers
Booth #517
600 Maryland Ave SW - Ste 835W
Washington, DC 20024
Phone: 202-484-1100
Email: jgray@dc-crd.com
Website: www.naec-epilepsy.org
Contact: Ms. Johanna Gray

The National Association of Epilepsy Centers is a non-profit 501(c)(3) trade association with a membership of more than 175 specialized epilepsy centers in the United States. With the goal of no seizures and no side effects, NAEC strives to make high quality healthcare available and affordable for epilepsy patients across the country.

National Institute of Neurological Disorders & Stroke (NINDS)
Booth #711
31 Center Dr, RMB607, MSC2540
Bethesda, MD 20892
Phone: 301-496-5751
Toll Free: 800-352-9424
Fax: 301-402-2186
Email: frazin@ninds.nih.gov
Website: www.ninds.nih.gov
Contact: Ms. Natalie Frazin

The National Institute of Neurological Disorders and Stroke (NINDS) supports basic, translational, and patient-oriented research on epilepsy prevention, diagnosis and treatment, including mechanisms underlying seizures and epileptogenesis, gene discovery and targeted therapeutics, epidemiology, psychosocial and behavioral consequences, and development of new therapies.

Natus Medical Incorporated
Booth #225
1501 Industrial Rd
San Carlos, CA 94070
Phone: 650-802-0400
Toll Free: 800-323-8326
Fax: 650-802-0401
Email: marcom@natus.com
Website: www.natus.com
Contact: Ms. Carol Stone

Natus Medical Incorporated, under the Xitek, Dantec, Bio-logic and Embla brands, designs, manufactures and distributes a wide range of neurology and sleep diagnostic systems and supplies. Natus Neurology product lines are designed to deliver the latest innovations in EEG, Epilepsy, ICU, Ambulatory, PSG, EMG and IDI.
Neuralynx Inc.
Booth #124
105 Commercial Dr
Bozeman, MT 59715
Phone: 406-585-4542
Fax: 406-585-9034
Email: shawn@neuralynx.com
Website: www.neuralynx.com
Contact: Mr. Shawn Olson

Nihon Kohden America, Inc.
Booth #231
90 Icon St
Foothill Ranch, CA 92610
Phone: 949-580-1555
Toll Free: 800-325-0283
Fax: 949-271-5319
Email: jeannie_callahan@nkusa.com
Website: www.nkusa.com
Contact: Ms. Jeannie Callahan


Optima Neuroscience, Inc.
Booth #128
11930 Research Circle
Alachua, FL 32615
Phone: 352-371-8281
Fax: 386-462-5365
Email: info@optimaneuro.com
Website: www.optimaneuro.com
Contact: Ms. Amanda Burks

Optima Neuroscience develops clinically useful software, systems and devices for the diagnosis and treatment of neurological disorders. The company’s first product, IdentiEvent® EEG Review Software with Seizure Detection, allows clinicians to quickly identify seizure activity with accuracy and confidence.

Oxford University Press
Booth #112
198 Madison Avenue
New York, NY 10016
Phone: 212-726-6000
Toll Free: 800-451-7556
Fax: 212-726-6494
Email: robin.hesselink@oup.com
Website: www.oup.com/us
Contact: Ms. Robin Hesselink

Featuring: Engel Seizures and Epilepsy 2nd ed.; Noebels et al. Jasper’s Basic Mechanisms of the Epilepsies; Reuber/Schachter Borderland of Epilepsy Revisited; Zeman et al Epilepsy and Memory; Caplan/Bursch How Many More Questions?; Powell/ Monteggia The Autisms; Coleman/Gilberg The Autisms; Bartsch The Clinical Neurobiology of the Hippocampus

Persyst Development Corporation
Booth #731
12625 High Bluff Drive Suite 213
San Diego, CA 92130
Phone: 858-461-4542-108
Fax: 858-461-4531
Email: ann.shambo@persyst.com
Website: www.persyst.com
Contact: Ann M. Shambo

For more than twenty years Persyst has produced the most trusted and innovative EEG analysis products. Today Persyst is the world’s leading supplier of seizure detection, spike detection, and quantitative analysis software to every leading EEG manufacturer for continuous EEG monitoring, ICM and ambulatory EEG.

Pinnacle Technology, Inc.
Booth #120
2721 Oregon St
Lawrence, KS 66046
Phone: 785-932-8866
Fax: 785-749-9214
Email: llane@pinnaclet.com
Website: www.pinnaclet.com
Contact: Ms. Linda Lane

Pinnacle Technology provides preclinical seizure research tools. New this year is Sirenia™ Seizure Pro, analysis software that finds, identifies, and marks seizure events. We have 3- and 4-channel EEG/EMG systems capable of adding biosensor channels to measure neurotransmitters including glutamate, glucose, lactate, and choline. Synchronized video recording also available.

PMT Corporation
Booth #415
1500 Park Rd PO Box 610
Chanhassen, MN 55317
Phone: 952-470-0868
Fax: 952-470-0865
Email: info@pmtcorp.com
Website: www.pmtcorp.com
Contact: Ms. Teri Dawson

PMT Corporation’s commitment to innovative products and customer satisfaction has made PMT a leader in epilepsy monitoring. PMT utilizes the finest quality materials in the manufacturing process of their Cortac Cortical Surface Electrodes and Depthalon Depth Electrodes. PMT’s nationwide direct sales force is available 24 hours a day.

Questcor Pharmaceuticals, Inc.
Booth #212, 414
26118 Research Rd
Hayward, CA 94545
Phone: 510-400-0700
Fax: 510-400-0799
Website: www.questcor.com
Contact: Ms. Maha Hermes

Questcor Pharmaceuticals is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor’s lead product is HP Acthar® Gel (repository corticotropin injection), a naturally-derived formulation of adrenocorticotropic hormone (ACTH) used in a variety of disorders, including monotherapy treatment of infantile spasms.

Rhythmlink International
Booth #518
PO BOX 2045
Columbia, SC 29202
Phone: 803-252-1222
Fax: 803-252-1111
Email: arosinski@rhythmlink.com
Website: www.rhythmlink.com
Contact: Ms. Amanda Rosinski

Rhythmlink International designs, manufactures and distributes a variety of accessories for epilepsy monitoring, intraoperative neuromonitoring, electroencephalography, evoked potentials, polysomnography and intensive care units. Founded by neurodiagnostic technicians and engineers, Rhythmlink strives for continuous innovation and superior quality in all of its products.

Ripple LLC
Booth #134
2015 S 1100 E
Salt Lake, UT 84106
Phone: 801-413-0139
Fax: 801-413-2874
Email: csalvato@rppl.com
Website: www.rppl.com
Contact: Mr. Chris Salvato

SeizureTracker.com
Table #5
7964 Conell Ct - Ste R
Lorton, VA 22079
Phone: 703-339-8448
Fax: 703-339-8430
Email: rob@seizuretracker.com
Website: www.seizuretracker.com
Contact: Mr. Robert Moss

SeizureTracker.com is dedicated to providing people living with epilepsy and their doctors with free comprehensive tools to help understand relationships between seizures and anti-epileptic treatments. The tools found at SeizureTracker.com allow patients to create personalized reports of logged seizures and treatments that can be easily shared with their medical team.

Smart Monitor Corp.
Booth #237
6203 San Ignacio Ave – Ste 112
San Jose, CA 95119
Phone: 408-754-1695
Fax: 408-754-8629
Email: Sheri.Becker@smart-monitor.com
Website: www.smart-monitor.com
Contact: Ms. Sheri Becker

Smart Monitor is an innovative, San Jose, California company specializing in intelligent monitoring solutions for the healthcare and wellness markets. Our flagship product, the SmartWatch, is a patent-protected, intelligent wristwatch that continuously monitors movements, alerts upon the onset of excessive, repetitive motion and stores the data for later analysis.
Transgenomic’s Clinical Laboratories division class clinical and research services. proprietary molecular technologies and world- cancer and inherited diseases through company advancing personalized medicine in Transgenomic, Inc. is a global biotechnology Contact: Ms. Becky Kreifels Website: labs.transgenomic.com Fax: 610-293-8099 12325 Emmet St Booth #338 Transgenomic, Inc. specializes in molecular diagnostics for cardiology, neurology, mitochondrial disorders, and oncology. Triangle BioSystems, Inc. Booth #130 2224 Page Rd - Ste 108 Durham, NC 27703 Phone: 919-361-2653 Fax: 919-344-3081 Email: jmonizio@trianglebiosystems.com Website: www.trianglebiosystems.com Triangle BioSystems is a developer of neurological research equipment for brain and nerve monitoring, recording and stimulation. This advanced neuro-technology hardware/software enables the acquisition of action potential signals (spikes) from individual brain cells, as well as low frequency field potential (LFP and EEG) signals in miniature tethered and wireless packages.


Sunovion Pharmaceuticals Inc.
Booth #937
84 Waterford Dr
Marlborough, MA 01752
Phone: 508-787-4279
Email: pmoriarty@sunovion.com
Website: www.sunovion.com
Contact: Mr. Chris Fanale
Sunovion is a leading pharmaceutical company dedicated to discovering, developing and commercializing products that advance the science of medicine in the CNS and respiratory disease areas to improve the lives of patients and their families. Sunovion is a subsidiary of Dainippon Sumitomo Pharma Co., Ltd. To learn more, visit www.sunovion.com.

Supernus Pharmaceuticals Inc.
Booth #203
1550 E Oude Dr
Rockville, MD 20850
Phone: 301-838-2500
Email: tconnor@supernus.com
Website: www.supernus.com
Contact: Mr. Tilton Conner
Supernus is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of epilepsy and other central nervous system (CNS) disorders. For further information please contact Tilton Conner at (301) 838-2500 or inquiries@supernus.com.

Transgenomic, Inc.
Booth #338
12325 Emmet St
Omaha, NE 68164
Phone: 810-293-8099
Fax: 610-293-8099
Email: bkreifels@transgenomic.com
Website: labs.transgenomic.com
Contact: Ms. Becky Kreifels
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cancer and inherited diseases through proprietary molecular technologies and world-class clinical and research services. Transgenomic’s Clinical Laboratories division

EXHIBITORS

SUDEP Aware
Table #13
Suite 350, 283 Danforth Ave
Toronto, ON M4K 1N2 Canada
Phone: 416-556-8770
Toll Free: 855-857-8337
Email: tcjeffs@sudepaware.org
Website: www.sudepaware.org
Contact: Ms. Tamzin Jeffs
A not-for-profit dedicated to: raising awareness – understanding of Sudden Unexpected Death in Epilepsy (SUDEP) to find its causes and prevention; providing a support line for families living with and bereaved by epilepsy; creating tools to aid SUDEP education and discussion; and assisting enhancement of SUDEP research. Visit table 13 to receive your USB of SUDEP info.

Sunovion Pharmaceuticals Inc.
Booth #937
84 Waterford Dr
Marlborough, MA 01752
Phone: 508-787-4279
Email: pmoriarty@sunovion.com
Website: www.sunovion.com
Contact: Mr. Chris Fanale
Sunovion is a leading pharmaceutical company dedicated to discovering, developing and commercializing products that advance the science of medicine in the CNS and respiratory disease areas to improve the lives of patients and their families. Sunovion is a subsidiary of Dainippon Sumitomo Pharma Co., Ltd. To learn more, visit www.sunovion.com.

Supernus Pharmaceuticals Inc.
Booth #203
1550 E Oude Dr
Rockville, MD 20850
Phone: 301-838-2500
Email: tconnor@supernus.com
Website: www.supernus.com
Contact: Mr. Tilton Conner
Supernus is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of epilepsy and other central nervous system (CNS) disorders. For further information please contact Tilton Conner at (301) 838-2500 or inquiries@supernus.com.

Transgenomic, Inc.
Booth #338
12325 Emmet St
Omaha, NE 68164
Phone: 810-293-8099
Fax: 610-293-8099
Email: bkreifels@transgenomic.com
Website: labs.transgenomic.com
Contact: Ms. Becky Kreifels
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cancer and inherited diseases through proprietary molecular technologies and world-class clinical and research services. Transgenomic’s Clinical Laboratories division specializes in molecular diagnostics for cardiology, neurology, mitochondrial disorders, and oncology. Triangle BioSystems, Inc. Booth #130 2224 Page Rd - Ste 108 Durham, NC 27703 Phone: 919-361-2653 Fax: 919-344-3081 Email: jmonizio@trianglebiosystems.com Website: www.trianglebiosystems.com Triangle BioSystems is a developer of neurological research equipment for brain and nerve monitoring, recording and stimulation. This advanced neuro-technology hardware/software enables the acquisition of action potential signals (spikes) from individual brain cells, as well as low frequency field potential (LFP and EEG) signals in miniature tethered and wireless packages.

Tuberous Sclerosis Alliance
Table #6
801 Roeder Rd - Ste 750 Silver Spring, MD 20910 Phone: 301-562-9850 Toll Free: 800-225-6872 Fax: 301-562-9870 Email: info@tsalliance.org Website: www.tsalliance.org Contact: Ms. Katie Smith
The Tuberous Sclerosis Alliance is the only national organization dedicated to finding a cure for tuberous sclerosis complex (TSC) while improving the lives of those affected. We work to stimulate and sponsor research; develop programs, services and resources; and increase awareness among professionals and the public.

UCB, Inc.
Booth #103
1950 Lake Park Dr Smyrna, GA 30080 Phone: 770-970-7500 Toll Free: 800-477-7877 Fax: 770-970-8917 Email: crystal.friend@ucb.com Website: www.ucb.com Contact: Ms. Betsy Andrews
At UCB, we have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe immunological diseases and central nervous system disorders. With 8,500 employees in 40 countries, we invest 24% of revenue in cutting-edge scientific research to meet unmet patient needs.

Visualase, Inc.
Booth #618
8058 El Rio St
Houston, TX 77054 Phone: 832-577-7773 Fax: 713-741-0122 Email: amarquette@visualaseinc.com Website: www.visualaseinc.com Contact: Mr. Andre Marquette
The Visualase Thermal Therapy System is an MRI-guided, minimally invasive laser ablation system, allows monitoring of the ablation in real time. The system is FDA-cleared for the ablation of soft tissue including use in neurosurgical procedures (see Visualaseinc.com for complete indication). Several US centers have performed >65 epileptogenic foci procedures.

Wiley-Blackwell
Booth #110
350 Main St
Malden, MA 02148
Phone: 781-388-8200 Toll Free: 800-216-2522 Fax: 781-388-8212 Email: cfealley@wiley.com Website: www.wiley.com/go/neuro Contact: Ms. Caitlyn Feeley
Wiley is the leading society publisher. We publish on behalf of more societies and membership associations than anybody else, and offer libraries and individuals 1,250 online journals, thousands of books and e-books, reviews, reference works, databases, and more. For more information, visit www.wiley.com, or our online resource: onlinelibrary.wiley.com.
Medvedev, A. 1.047
Mefford, H. 1.312, 3.317
Mégevand, P. 1.101
Meihkhanov, L. 1.114
Mehesová, S. 2.351
Mehta, A. 2.074, 3.040, 3.070
Mehta, K.K. 3.149
Mehta, N. 2.351
Mei, H. 2.047
Melani, F. 2.064, 3.192
Mello, C. 2.044
Mendoza, L. 1.035, 1.184, 2.204
Menon, U. 3.143
Menzler, K. 1.316
Mesad, L. 3.060, 1.115, 3.244
Messas, C.S. 2.170
Messenger, E.A. 2.002
Meurs, A. 2.044
Miceli, C. 3.277
Michel, C.M. 1.101
Michelucci, R. 3.048
Mickle, J.W. 3.265
Mihaylova, T. 1.043, 1.271
Mihályi, N. 2.343, 3.142
Mia, L. 1.070
Mikati, M. 1.124, 2.340, 3.123, 3.318
Mikláš, M. 3.032
Mikulíš, D. 3.095
Mikuni, N. A.06, 2.246, 3.245
Miles, L. 3.022, 3.328, 3.339
Miles, M. 3.328
Miles, M.V. 1.032
Milovský, D. 2.105
Mill, B.J. 1.348
Miller, L. 2.128, 2.260
Miller, L.O. 1.288
Miller, I. 1.287
Miller, J. 1.268, 2.075
Miller, J.W. 2.326
Miller, K. 2.172
Miller, M. 1.052
Milett, D. 1.300
Milich, J.J. 3.164
Minnassian, B. 1.317, 3.316
Mindruta, I. 2.104, 2.104
Minotti, L. 2.104
Miccinovíc, S. 1.116
Mirsattari, S. 1.173, 3.205, 3.274
Mirza, A. 3.019
Misericocchi, A. 1.276, 3.277
Mishra, A. 1.024, 2.018
Mistry, H. 2.032
Mitra, D. 2.205, 2.206
Mittal, S. 2.083, 3.171
Miyajima, M. 1.082, 2.062
Miyamoto, A. 1.06, 2.24, 2.245
Misla, L. 1.264
Modar, F. 3.185, 1.116
Mody, I. 3.346
Moeller, J. 1.133, 2.115
Mogul, D. 2.014
Mohamed, A. 2.279
Mohamed, L. 1.087
Mohamed, W. 3.082
Moghaddam, G. 1.089, 3.247
Moghbel, N. 3.140
Mojon-Afshari, F. 2.105
Monsivais, D. 1.290
Montano, N. 2.025
Montavon, A. 2.104
Montouris, G. 2.232, 3.241
Moon, J. 2.218, 3.147
Mooneney, K. 2.197
Moore-Hill, D. 3.198
Morgas, A. 3.223
Moran, B. 3.085
Moreira, C.H. 3.083
Moreira-Filho, C.A. 3.329
Moretto, M. 2.225
Moreno, L. 1.121
Moreno-Avellan, A.J. 1.047
Morgen, L. 1.121
Morgen, V.L. 2.004
Monire, M. 1.089, 3.279
Monta, M.E. 2.136
Moroder, T. 3.256
Moron, D. 2.116
Morris, G.L. 3.315
Morris, L. 1.002
Morris, S. 1.267
Morrison, J. 3.321
Morset, R. 2.102, 3.084
Mortada, A.A. 2.067
Mortati, K.A. 1.081
Morton, L.D. 3.077
Moseley, B.D. 1.076
Mosher, J.C. 1.06, 1.090, 1.096
Motamed, G. 3.098
Motolow, J.E. 1.024, 2.018
Moussazadeh, A. 1.103, 3.314
Muco, G.A. 3.307, 3.310
Mucciol, J. 1.348
Mudigoudar, B. 3.314
Mukherjee, H. 3.341
Mukherjee, S. 3.341
Mukherjee, T. 3.078
Mullan, H. 1.002
Mullan, B. B.06, 2.163
Mulders, D.M. 3.058
Mullan, M. 1.114
Mullen, B. 1.099
Muller, A. 3.315
Mullen, A. 1.082
Mullen, T. 3.040
Müller, A. 2.225
Müller, G.P. 3.066
Müller, K. 2.209
Müller, S.G. 1.170
Müller, H. 2.326
Mukherjee, S. 3.341
Mulders, D.M. 3.058
Mullan, B. 3.314
Mullan, H. 1.009
Mullan, S. 3.315
Zhang, Y. B.09, 2.302
Zhang, Y.H. 2.097
Zhao, G.D. 3.003
Zhao, M. 3.175, 3.176
Zheng, P. 1.007
Zhou, C. 3.013
Zhou, D. 2.113, 3.338
Zhou, F. 3.031

Zhou, J. 2.270
Zhou, S. 1.241, 3.241
Zhou, X. 2.346
Zhu, J. 1.233, 1.234, 1.239
Zhu, L. 1.023
Ziemba, K.S. 1.348
Zijlmans, G.J. 2.070
Zijlmans, M. C.02, 2.268

Zillgitt, A. 1.057, 2.054, 1.198
Zimmama, L.A. 2.168, 2.172, 2.296, 3.204
Zimmerman, R. 2.322
Zions, M. 3.026
Zolkowska, D. 1.023
Zony, E. 2.190
Zou, G.Y. 1.160, 2.142, 3.166

Zuurka, G. 2.320
Zuberi, S.M. 2.139
Zucchinri, S. 3.048
Zupanc, M. 3.307, 3.310
Zuña, Y.C. 2.221, 3.170

ABSTRACT AUTHOR INDEX
Leader Level

Special thanks to...

UCB, Inc.

for supporting:

- Exhibit
- Scientific Exhibit
- Program Book Ad
- Educational Grant – Annual Course and Epilepsy Specialist Symposium
- AES Fellows
- PAME Conference
- Annual Meeting App
Leader Level

Special thanks to...

Eisai, Inc.

for supporting:

- Exhibit
- Epilepsy Currents Ads
- Educational Grant – Annual Fundamentals Symposium
- AES Fellows
- AES Named Fellowship
- SIG
- Young Investigator Awards
- Nurse Awards
- PAME Conference

Eisai
Partner Level

Special thanks to...

Lundbeck

for supporting:

- Exhibit
- Scientific Exhibit
- Innovation Pavilion (3)
- Epilepsy Currents Ads
- AES Fellows
- SIGs (3)
- Educational Grant – Annual Fundamentals Symposium
- PAME Conference
Special thanks to...
Sunovion Pharmaceuticals, Inc.

for supporting:

- Exhibit
- Scientific Exhibit
- Educational Grant – Annual Fundamentals Symposium and Professionals in Epilepsy Care Symposium
- Lunch in Exhibit Hall (Saturday)
- Epi-PORT
- SIGs (2)
- PAME Conference
- Exhibit Hall Reception
- Poster Session Breakfast (Monday)
- Exhibit Hall Coffee Break (Sunday)
- Program Book Ad

Sunovion
Healthy bodies, healthy lives
Special thanks to...  

**Contributor Level**

**Nihon Kohden America, Inc.**

for supporting:
- Exhibit
- Program Book Ad (2)
- Epi-PORT
- Exhibit Hall Reception

**Contributor Level**

**Questcor Pharmaceuticals, Inc.**

for supporting:
- Exhibit
- SIG (2)
- Innovation Pavilion
- Program Book Ad
- PAME Conference

**Supporter Level**

**Special thanks to...**

**Supernus Pharmaceuticals, Inc.**

for supporting:

- Exhibit
- Program Book Ad (2)
- Epi-PORT
- Exhibit Hall Reception
Special thanks to...

Upsher-Smith

for supporting:
- Exhibit
- Coffee Break (Saturday)
- Hoyer Lecture
- Program Book Ad
- Virtual Bag Banner Ad

Special thanks to...

Cyberonics, Inc.

for supporting:
- Exhibit
- Educational Grant – Epilepsy Specialist Symposium
- PAME Conference

Special thanks to...

GlaxoSmithKline

for supporting:
- Exhibit

Special thanks to...

Novartis Pharmaceuticals Corporation

for supporting:
- Annual Course

Special thanks to...

Elekta

for supporting:
- Exhibit

Special thanks to...

Medtronic, Inc.

for supporting:
- Young Investigator Awards
- Scientific Exhibit
Patron Level

Special thanks to these companies for supporting...

Visualase
- Exhibit
- Scientific Exhibit

Ad Tech Medical Instrument Corp.
- Scientific Exhibit

Neuropace
- Scientific Exhibit

ILAE/IBE Congress
- Exhibit

Rhythm Link
- Exhibit

Blackrock Microsystems
- Exhibit

Epilepsy Foundation
- Exhibit

PMT Corporation
- Exhibit

Ripple LLC
- Exhibit

Neurolynx, Inc
- Exhibit
AES 66th Annual Meeting
The American Epilepsy Society (AES) is one of 108 Chapters of the International League Against Epilepsy (ILAE). The Annual Meeting of the American Epilepsy Society is the largest meeting and exhibition in the world of those who share the common scientific and clinical interests of epilepsy and clinical neurophysiology. Each year, 4,000+ attendees gather who are dedicated to improving the quality of life for those afflicted with epilepsy. This meeting will be the top forum to examine common concerns and to gain insight from leading authorities.

Mission Statement
The American Epilepsy Society promotes research and education for professionals dedicated to the prevention, treatment, and cure of epilepsy.

Target Audience
Basic: Those new to epilepsy treatment or whose background is limited, e.g., students, residents, general physicians, general neurologists and neurosurgeons, other professionals in epilepsy care, administrators.
Intermediate: Epilepsy fellows, epileptologists, epilepsy neurosurgeons, “mid-level” providers with experience in epilepsy care (e.g., advanced practice nurses, nurses, physician assistants), neuropsychologists, psychiatrists, basic and translational researchers.
Advanced: Symposium will address highly technical or complex topics (e.g., neurophysiology, advanced imaging techniques, advanced treatment modalities, including surgery).

Policy on Commercial Support and Conflict of Interest
The American Epilepsy Society maintains a policy on the use of commercial support, which ensures that all educational activities sponsored by the AES provide in-depth presentations that are fair, balanced, independent and scientifically rigorous. All faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to the activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentations. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. This information will also be made available through syllabus materials and faculty presentations.

Disclosure of Unlabeled / Unapproved Uses
This educational program may include references to the use of products for indications not approved by the FDA. These discussions are noted on the faculty’s disclosure forms as well as during their presentations. Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any other manufacturers of pharmaceuticals.

Abstracts
Abstracts from the 2012 Annual Meeting are available on the AES website and as an online supplement to Epilepsy Currents.

Accreditation
The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to offer continuing medical education for physicians.

Insurance, Liabilities
AES cannot be held responsible for any personal injury, loss, damage, accident to private property or additional expenses incurred as a result of delays or changes in air, rail, sea, road, or other services, strikes, sickness, weather, acts of terrorism and any other cause. All participants are encouraged to make their own arrangements for health and travel insurance.

Credit Designation
Physicians: The American Epilepsy Society designates this live activity for a maximum of 34.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistant: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 34.75 hours of Category 1 credit for completing this program.

Nurses: EDUPRO Resources LLC is an approved provider of continuing nursing education by Pennsylvania State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation, Provider number P208-8/08-11.

EDUPRO is also an approved provider by the California Board of Registered Nursing, Provider number CEP-14387.

Nurses who participate in selected AES programs can receive up to 34.75 contact hours. To successfully complete the activities, nurses will be required to complete evaluations for each session attended and to access the Medical Education Evaluator to claim credit.

Disclaimer: Accreditation refers to educational content only and does not imply endorsement of products by PSNA, ANCC, CBRN, or EDUPRO Resources LLC.

Pharmacists: Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Selected AES programs are approved for a total of 34.75 contact hours. To successfully complete the CPE activities, pharmacists will be required to complete evaluations for each program attended and to access the Medical Education Evaluator to claim credit.

International Credits: The American Medical Association has determined that non-U.S. licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 Credit™.

Maintenance of Certification
To assist physicians with Maintenance of Certification (MOC) requirements, all AES Annual Meeting education programs have been approved as part of a comprehensive lifelong learning program, which is mandated by the American Board of Medical Specialties (ABMS) as a necessary component of Maintenance of Certification.

CME / CE Certificates
The Medical Education Evaluator® is an online system that allows any attendee to self-manage the process of completing course evaluations, tracking credits and printing out the appropriate certificate for either AMA PRA Category 1 Credits™, CNE or ACPE pharmacy statement of credits.

Once you have accessed the Medical Education Evaluator® via the AES Website, you will be asked to enter your “myAES number” and password. The certificate(s) are saved to your personal account page, which is cumulative. You may print the certificate(s) in PDF format at any time.

To help support this process, attendees who want educational credits will be asked to pay:

Member Fees: $35 through January 18, 2013
$50 January 19 – February 28, 2013
Non-member Fees: $50 through January 18, 2013
$75 January 19 – February 28, 2013

The online Evaluator will be left open through February 28, 2013, so you must complete the evaluations and credit tracking by that date.

By completing this information online, attendees greatly assist the Council on Education and Annual Meeting Committee with important needs assessment data whereby the AES can further plan and address educational gaps to meet the needs of our learners.

A meeting attendance certificate will be available at the registration desk for international meeting attendees.

Handouts
Handouts for the educational symposia will be available via the virtualTotebag.

For instructions: Please refer to the flyer provided in your meeting bag or go to the AES website for details.

Questions? Please contact virtualTotebag Support Desk – 410.402.1028, option 1 John Colban – 410.402.1062 Email: support@virtualtotebag.com
**Audience Response System**
AES will be utilizing the Audience Response System (ARS) in all of the symposia. Faculty will have ARS questions throughout their presentations with multiple choice answers. To participate, you will use your cell phone to text your reply. When a question appears in a presentation, simply text your answer (a 5 or 6 digit code) to "22333." Standard text rates will apply. The ARS will allow for interactive audience participation as well as real time, immediate feedback to enhance the learning environment and ensure that we are meeting the learning objectives set forth by each symposium.

**Program Changes**
AES cannot assume liability for any changes in the program due to external or unforeseen circumstances.

**Commercial Exhibits (page 75)**
The Exhibit Hall is an integral part of the learning experience. Meeting participants will have an ideal opportunity to learn about the latest in pharmaceuticals, publications, scientific equipment, and technology relevant to the fields of epilepsy and neurophysiology. Please check the AES website for an updated listing of exhibiting companies and organizations. To ensure safety and security, no children, strollers, carriages, wheeled luggage or wheeled briefcases will be allowed in the Exhibit Hall during exhibit hours.

Saturday, December 1 ........................................... 11:45 a.m. - 6:00 p.m.
Sunday, December 2 ---------------------------------- 10:00 a.m. - 4:00 p.m.
Monday, December 3 ........................................... 10:00 a.m. - 3:00 p.m.

**Scientific Exhibits (page 29)**
AES has adopted and approved guidelines for industry-sponsored scientific exhibits at the Annual Meeting. Scientific Exhibits differ from traditional poster presentations in that a broad range of material can be presented as a collection of topics, such as results of various clinical trials, or a thematic presentation of one aspect of drug development. Scientific Exhibits will be displayed Sunday, December 2 and Monday, December 3. An application to register for a Scientific Exhibit was e-mailed to interested companies in May. Reservations will be reviewed and accepted on a first come, first served basis until space is sold out. Send inquiries of interest to Jolynn Amsden at jamsden@aesnet.org.

**Cyber Café (page 7)**
**Convention Center – Hall B, Ground Floor**

Open during Exhibit Hall hours
The Cyber Café will be available at the Convention Center with e-mail and Internet access. Check in with family members and colleagues, and conduct online research while attending the meeting. You will also be able to complete the course evaluations and obtain your CME certificate online.

**Language**
The official language of the Annual Meeting is English. Simultaneous translation is available in the Annual Course and NAC Symposium.

**Photography and Recording of Programs**
AES strictly prohibits all photography (flash, digital, or otherwise), audio and/or videotaping during the Annual Meeting. Equipment will be confiscated.

**Press Room**
**Convention Center – Room 1A, Upper Level**
AES offers meeting information and assistance for journalists reporting on epilepsy studies, educational presentations, and special reports at this meeting. The AES on-site Press Room staff works with journalists to develop stories, research facts and information, and connect with experts and presenters. The on-site Press Room is also available to sponsors and exhibitors for the display and distribution of relevant press releases and media kits. For more information, contact Peter Van Haverbeke 703-927-9639 or Natalie Judd 203-605-9515 natalie@bigvoicecomm.com.

Friday, November 30 ............................................. 11:00 a.m. - 6:30 p.m.
Saturday, December 1 ------------------------------- 7:30 a.m. - 6:30 p.m.
Sunday, December 2 ------------------------------- 7:30 a.m. - 6:30 p.m.
Monday, December 3 ------------------------------- 7:30 a.m. - 6:30 p.m.
Tuesday, December 4 ------------------------------- 7:30 a.m. - 2:30 p.m.

A series of media briefings on the following topics will be held in the press room from Saturday, December 1 through Monday December 3. Details will be posted in room 336 at the San Diego Convention Center and in advance on the AES website Press Room after December 1.

- Pediatric Medications and Interventions
- Seizure Suppression by Brain Cooling and by Light
- Maternal Health
- Barriers to Optimal Care
- Significant Misunderstanding about Epilepsy Drug/Surgical Management
- Laser Surgery Less Invasive, More Precise in Early Reports
- New and Developing OVS Therapies in Epilepsy
- Conquering Depression in Epilepsy and Family Function
- From Rats to Men

**Hotel Information**
**Early Departure Policy**
Guests who check out of the hotel prior to their scheduled departure date will be charged a penalty of one night’s room rate and tax.

**San Diego Marriott Marquis and Marina (Headquarters Hotel)**
333 West Harbor Drive, San Diego, CA 92101
Telephone: 619.234.1500

**Hilton San Diego Bayfront**
One Park Boulevard, San Diego, CA 92101
Telephone: 619.564.3333

**Manchester Grand Hyatt San Diego**
One Market Place, San Diego, CA 92101
Telephone: 619.232.1234

**Residence Inn Gaslamp San Diego**
356 6th Avenue, San Diego, CA 92101
Telephone: 619.487.1200

**Meeting Location**
**San Diego Convention Center**
111 West Harbor Drive, San Diego, CA 92101

**Business Centers**
Two full-service business centers are available at the following locations:

- FedEx Office (formerly FedEx Kinko’s): The FedEx Office business service center is conveniently located in the Hall D lobby on the ground floor of the San Diego Convention Center. On-site services include shipping, mailing, faxing, and photocopying. Visit https://printonline.fedexkinkos.com/ to place an order, or contact FedEx Office at the San Diego Convention Center by calling 619.525.5450.

- The UPS Store (#6200): The UPS Store Business Center is located on the Lobby Level of the Marriott’s south tower. Services include receiving shipments at the hotel, printing documents, or sending small or large packages. You may also submit documents online for printing and pick-up on-site. For details, please visit http://www2.theupsstorelocal.com/6200/ or call 619.230.8940.

**No Smoking Policy**
For the comfort and health of all attendees, smoking is not permitted at any AES functions. This includes educational sessions, meetings and all food functions. Both the Convention Center and the Marriott San Diego are smoke-free facilities. Also, smoking is not permitted in public buildings, restaurants or bars.

**Meeting Attire**
AES promotes casual business attire for the duration of the Annual Meeting. Consider bringing a light jacket or sweater with you since meeting room temperatures and personal comfort levels vary.
Information for International Travelers

Consulates and Embassies
All international embassies from other countries to the United States are located in Washington, D.C. There are a number of international embassy branch offices, called consulates, located in Los Angeles, CA. If your country does not have a consulate in Los Angeles, CA, call directory information in Washington, D.C. (phone: 202.555.1212) for the number of your national embassy.

Gratuites
Gratuites are not automatically added to the bill, except in some cases for large groups. Servers are usually given 15% to 20% of the bill. Taxi drivers usually receive 15% of the fare and doormen and porters are normally tipped $1 per bag.

Registration & Security
The American Epilepsy Society is committed to providing a secure meeting environment. A formal security plan is in place with the Security Department at the Convention Center. All meeting attendees will be required to produce government-issued photo identification prior to receiving their badge and registration materials. Appropriate badges must be worn at all times while in attendance at the meeting and are required for admittance to all meeting activities. Special security procedures are also in place for exhibition materials and all deliveries to the AES meeting.

Contact Information
American Epilepsy Society
342 North Main Street
West Hartford, CT 06117-2507
Phone: 860.586.7505
Meeting Fax: 860.586.7550
E-mail: info@aesnet.org
Website: www.AESNET.org

Safety and Security Information
The following security measures have been designed to further enhance your personal and professional safety.

- Pick up any Convention Center house phone located in the facility and dial 5490 or 619.525.5490 from any other phone. In addition, there are phones located throughout the facility that will connect you directly to the security department. Uniformed Convention Center employees have radios and are ready to assist you. Advise the dispatcher of the exact location within the Convention Center.
- We respectfully request that you do NOT call 911 directly.
- An EMT will be on duty in the Convention Center throughout the meeting.
- A government-issued photo identification is required to receive a badge and to replace a lost badge.
- Convention Center Security may randomly check packages and bags at the Convention Center entrances, meeting rooms and in the Exhibit Hall.
- You will be asked to always clearly display your name badge and to use only approved Convention Center entrances and exits.
- Appropriate badges will be required to enter all educational sessions, Poster Sessions, the Exhibit Hall and meetings. Due to safety and fire regulations, doors will be closed to all session rooms that fill to capacity.
- Throughout the meeting, you will notice security staff presence to monitor the safety of all participants.
- Do not leave unattended packages (i.e., briefcases, laptops, purses, etc.) in any area of the Convention Center or hotel.
- Please report any suspicious activity to security staff or to the AES registration desk staff.

General Safety Tips
- Remove your badge once you leave the meeting facilities.
- Carry important telephone numbers with you.
- Do not display or carry large amounts of cash.
- Walk in groups, especially at night.
- Lock your hotel room door.
- Always verify hotel room repair or service calls.
- Do not disclose your room number to anyone.
- Never give your personal information (credit card, room number, etc.) over the phone; instead, go to the front desk if the hotel calls with questions.

Speaker Ready Room and Photos

Location: Convention Center – Room 17A, Mezzanine Level

Speakers need to have photos taken for repurposing of symposia on the AES website. All faculty PowerPoint presentations have already been uploaded through the AES Faculty Development Room. All speakers must stop by to reconfirm their presentation with an audiovisual technician.

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, November 29</td>
<td>4:00 p.m. - 8:00 p.m.</td>
</tr>
<tr>
<td>Friday, November 30</td>
<td>8:00 a.m. - 6:00 p.m.</td>
</tr>
<tr>
<td>Saturday, December 1</td>
<td>8:00 a.m. - 6:00 p.m.</td>
</tr>
<tr>
<td>Sunday, December 2</td>
<td>8:00 a.m. - 6:00 p.m.</td>
</tr>
<tr>
<td>Monday, December 3</td>
<td>8:00 a.m. - 6:00 p.m.</td>
</tr>
<tr>
<td>Tuesday, December 4</td>
<td>8:00 a.m. - 11:00 a.m.</td>
</tr>
</tbody>
</table>
American Epilepsy Society 2012 Annual Meeting

Hotel

Downtown San Diego

1. San Diego Marriott Marquis & Marina
2. Hilton San Diego Bayfront Hotel
3. Manchester Grand Hyatt San Diego
4. Residence Inn San Diego Downtown/Gaslamp Quarter

Walking time (in minutes) from SUCC

<table>
<thead>
<tr>
<th>Hotel</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>San Diego Marriott Marquis &amp; Marina</td>
<td>1</td>
</tr>
<tr>
<td>Hilton San Diego Bayfront Hotel</td>
<td>1</td>
</tr>
<tr>
<td>Manchester Grand Hyatt San Diego</td>
<td>8</td>
</tr>
<tr>
<td>Residence Inn San Diego Downtown/Gaslamp Quarter</td>
<td>6</td>
</tr>
</tbody>
</table>
IN THE MAJORITY OF PATIENTS AT 2 WEEKS1,2

The power to stop infantile spasms

Acthar is proven to stop infantile spasms and eliminate hypsarrhythmia

- Significantly higher response rate compared to prednisone in a randomized clinical trial1,2
- Proven effective in both cryptogenic and symptomatic cases1,3
- Comprehensive support and rapid access to Acthar through the Acthar Support & Access Program (A.S.A.P.), 888-435-2284, and the Hospital Sample Vial Program

H.P. Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age.

Important Safety Information

Acthar should never be given intravenously. It is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency or adrenocortical hyperfunction or sensitivity to proteins of porcine origin. Acthar is contraindicated in children under 2 years of age with suspected congenital infections. Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar.

The adverse effects that may occur with Acthar are related primarily to its steroidogenic effects and are similar to corticosteroids. There may be increased susceptibility to new infection and increased risk of reactivation of latent infections. Adrenal insufficiency may occur after abrupt withdrawal of the drug following prolonged therapy. Cushing's syndrome, elevated blood pressure, salt and water retention, and hypokalemia may be seen. Masking of symptoms of other underlying disease/disorders may occur. There is a risk of gastrointestinal perforation and bleeding with increased risk of perforation in patients with certain GI disorders. Onset or worsening of euphoria, insomnia, irritability (especially in infants), mood swings, personality changes, depression, and psychosis may occur. Caution should be used when prescribing Acthar to patients with diabetes or myasthenia gravis. Prolonged use may produce cataracts, ocular infections or glaucoma. Use in patients with hypothyroidism or liver cirrhosis may result in an enhanced effect. There may be negative effects on growth and physical development and decreases in bone density.

Specific adverse reactions reported in infantile spasms clinical trials in infants and children under 2 years of age included: infection, hypertension, irritability, Cushingoid symptoms, constipation, diarrhea, vomiting, pyrexia, weight gain, increased appetite, decreased appetite, nasal congestion, acne, rash, and cardiac hypertrophy. Convulsions were also reported, but these may actually be occurring because some IS patients progress to other forms of seizures and IS sometimes mask other seizures, which become visible once the clinical spasms from IS resolve. Other adverse reactions in adults and children over 2 years of age included: abdominal distension, anxiety, asthma, chest discomfort, congestive heart failure, dizziness, dyspnea, erythema, fatigue, flushing, headache, hyperhidrosis, hypersensitivity or allergic reactions, injection site pain, muscle weakness, palpitations, peripheral edema, tachycardia, and weakness.

This is a summary only. For a complete list of indications, contraindications, warnings, precautions, and potential adverse reactions associated with H.P. Acthar Gel, please refer to the full Prescribing Information. A Medication Guide is also available for patients and caregivers of patients with IS.

Please see Brief Summary of Prescribing Information on the following page and refer to www.acthar.com.

Clinical Studies Experience

Postmarketing Experience

Adverse Reactions in Infants and Children Under 2 Years of Age

Adverse Reactions in Adults

HYPERSENSITIVITY REACTIONS

Gastrointestinal Perforation and Bleeding

Dosage and Administration

CARCINOMA AND LYMPHOMA

Adverse Reactions in Infants

Adverse Reactions in Children

Adverse Reactions in Adults

Treatment of Patients with Hypertension, Congestive Heart Failure, or Renal Insufficiency

Treatment of Patients with Hypertension

Treatment of Patients with Congestive Heart Failure

Treatment of Patients with Renal Insufficiency

Adverse Reactions with Chemoprophylaxis

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology

Preclinical Pharmacology
SUPERNUS HAS BEEN DEVELOPING ADVANCED DRUG DELIVERY SYSTEMS FOR MORE THAN 20 YEARS

Supernus Pharmaceuticals

A legacy of innovation, a portfolio of promise

OUR PROVEN EXTENDED RELEASE TECHNOLOGIES INCLUDE:

**Microtrol**: Multiparticulate Platform
Employs multiparticulates filled into capsules or compressed into tablets to deliver customized-release profiles, including immediate, extended, pulsed, and delayed

Benefits may include:
- More convenient or less frequent dosing
- Improved side effect profile for compounds with a narrow therapeutic window
- Enhanced patient compliance
- Sprinkle option for ease of administration

**Solutrol**: Matrix Delivery Platform
An innovative platform that enables delivery of poorly soluble, highly water-soluble, and pH-dependent compounds in a reproducible and complete manner

Benefits may include:
- Tablet presentation for challenging compounds
- More convenient or less frequent dosing
- Improved patient compliance

SUPERNUS TECHNOLOGIES HAVE BEEN USED TO DEVELOP SEVERAL ADVANCED THERAPIES, INCLUDING:

- **Adderall XR** (mixed salts of a single-entity amphetamine product) Extended-Release Capsules
- **Carbatrol** (carbamazepine) Extended-Release Capsules
- **Intuniv** (guanfacine) Extended-Release Tablets
- **Oracea** (doxycycline, USP) Capsules
- **Sanctura XR** (trospium chloride extended release tablets)


For more information visit www.supernus.com

Microtrol and Solutrol are registered trademarks of Supernus Pharmaceuticals, Inc.
Adderall XR, Carbatrol, and Intuniv are registered trademarks of and marketed by Shire LLC.
Oracea is a registered trademark of Galderma Laboratories, LP.
Sanctura XR is a registered trademark of Allergan, Inc.

©2012 Supernus Pharmaceuticals, Inc. All rights reserved. SPN.2012-0005